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ABSTRACT
Drug induced liver injury (DILI) is one of the main causes of 
patient morbidity and mortality, and is an important factor in drug 
attrition during development. DILI is commonly associated with 
exposure to therapeutic agents or the formation of reactive metabolites 
from hepatic metabolism. These may cause redox perturbation within 
the cells which can result in oxidative stress as well as protein 
modification. These events can lead to the activation or inhibition of 
cellular defence responses. Although there are defence mechanisms 
present to counter this, if the chemical challenge is overwhelming and 
the defence is breached, a switch from cell defence to cell death is 
favoured. Two families of transcription factors, in particular, are the 
focus of much interest in determining the role of transcriptional 
adaptation to stress, namely Nrf2 and NF-kappa B (NF-kB). Nrf2 
regulates the majority of cytoprotective genes and is regulated by its 
inhibitory protein. Keapl. NF-kB is the master regulator of cell immunity, 
inflammation, proliferation and survival. The main aim of the 
investigations described within this thesis are to investigate 1) the co­
regulation of the Keapl/Nrf2 and NF-kB pathways during cellular stress, 
2) the molecular mechanisms underlying Nrf2 activation, and also 3) the 
basal status of cysteine residues present in Keapl and how they serve as 
'sensors' to cellular stress.
The first investigation in this thesis was to investigate Nrf2 and 
NF-kB, whose simultaneous regulatory functions during cellular stress 
remains unclear. Both transcription factors were known to be sensitive 
to electrophilic stress and redox perturbation in mouse liver cells. 
Molecular probes such as; N-acetyl-p-benzoquinineimine (NAPQI), the 
reactive metabolite of paracetamol (APAP); dinitrochlorobenzene 
(DNCB), a model electrophile; and buthionine (S,R)-sulfoximine (BSO), an 
inhibitor of glutamate cysteine ligase were used to induce cellular stress. 
NAPQI, DNCB and BSO can all cause glutathione (GSH) depletion; 
however only NAPQI and DNCB can covalently bind proteins. All three 
chemicals induced Nrf2 nuclear accumulation, but NF-kB binding activity 
was only increased after BSO treatment. In fact, NF-kB binding activity 
decreased after exposure to NAPQI and DNCB. The employment of RNAi 
to manipulate Keapl (the inhibitor of Nrf2), Nrf2 itself and NF-KB-p65, 
was used to understand their roles in the response to drug stress. The 
RNAi depletion of Keapl led to reduced toxicity following exposure to 
DNCB and also the depletion of Nrf2 and NF-kB augmented toxicity. 
Interestingly, increased Nrf2 caused by Keapl depletion was reversed by 
co-depletion of NF-kB. We have demonstrated that Keapl/Nrf2 and NF-
i
kB respond differently to electrophiles which bind proteins covalently 
and also the redox perturbation associated with glutathione depletion. 
This suggests that cross-talk may enable NF-kB to partly influence Nrf2 
expression during cellular stress.
One of the current hypotheses to explain Nrf2 activation centres 
on the key modification of Keapl cysteine residues by chemical or 
oxidative stress. It has been suggested that Nrf2 activation can occur as 
a result of chemical modification of cysteine residues within Keapl, but 
also as a consequence of oxidative stress without concomitant chemical 
modification. In order to further elucidate the specific pre-requisites for 
Nrf2 activation, five molecules known to induce Nrf2 activation via 
cysteine modification and/or by GSH depletion were deployed. These 
five Nrf2-inducing molecules were chosen based on the following 
properties; (1) direct cysteine alkylation and GSH depletion - DNCB and 
lodoacetamide (IA); (2) direct cysteine alkylation but no GSH depletion - 
dexamethosone-21-mesylate (Dex-mes) and 15-deoxy-A-( 12,14)- 
prostaglandin J2 (ISd-PGJz); or (3) GSH depletion but no direct cysteine 
alkylation - BSO. A control molecule trimellitic anhydride (TMA) which 
does not modify cysteine or deplete GSH was also used. This study has 
demonstrated that Nrf2 can be activated (1) by DNCB and IA, (2) by Dex- 
mes and 15d-PGJ2, and (3) by BSO. TMA did not activate Nrf2. Therefore, 
these results have demonstrated that Nrf2 can be activated by either 
direct modification of Keapl, through a profound depletion of GSH alone 
or through a combination of both. Moreover, a toxicologically-relevant 
molecule such as TMA, that displays neither of these properties, is 
unlikely to induce Nrf2-dependent cell defence.
Following this, further investigations were planned to elucidate 
the Keapl cysteine basal status and also further explore the molecular 
mechanisms underlying how Keapl cysteine residues sense chemical or 
oxidative stress. An ectopic Keapl-expressing cell-based system and 
liquid chromatography electrospray ionisation tandem mass 
spectrometry (LC-ESI MS/MS) was used to analysis Keapl cysteine 
modifications. A high concentration of N-ethylmalemide (NEM) (50mM) 
over 2min was used to alkylate Keapl-V5 cysteine residues in HEK293T 
cells. The aim of this was to achieve the maximum coverage of Keapl-V5 
cysteines intracellularly within a short time frame without causing 
cellular damage. Interestingly, a proportion of the Keapl-V5 
overexpressed protein displays all of its cysteine residues modified by 
NEM. This suggests that all Keapl cysteine residues are available for 
modification by reactive chemicals, and can be found in a basally 
reduced state. Next, investigations were designed to determine if 
Keapl-V5 cysteine residues can undergo S-glutathionylation.
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Immunoprecipitated Keapl-V5 from HEK293T cells was resolved on non­
reducing and reducing gels following treatment with or without BSO and 
the subsequent addition of DMSO, IA and NEM. Gels were probed with 
anti-Keapl and anti-GSH antibodies. Under non-reducing conditions, S- 
glutathionylation on Keapl-V5 proteins was detected in the control, 
BSO, IA and NEM treated samples but under reducing conditions S- 
glutathionylation, a form of reversible oxidation, on Keapl-V5 was 
removed. This suggested that S-glutathionylation on Keapl-V5 can occur 
constitutively under basal conditions or as a form of oxidative 
modification under cellular stress. Therefore, a proportion of Keapl 
cysteines are found to be reduced basally and S-glutathionylation can 
occur under basal or stressed conditions. This further suggests that 
every Keapl cysteine residue can serve as a 'sensor' to detect 
electrophiles or reactive oxygen species during cellular stress which will 
ultimately lead to Nrf2 activation.
In order to further improve the investigation into the role played 
by Keapl cysteine modification in Nrf2 activation, the use of click- 
chemistry (CC) as a novel technique was tested. The common alkylating 
agents, IA and NEM, are incorporated with an alkyne group to form click 
compounds. These click compounds were tested in comparison with 
their parent compounds for their ability to induce Nrf2. Based on this 
study, NEM-Click and NEM were observed to have similar Nrf2-activating 
properties. However, when compared to IA and lA-click, NEM-click is 
more efficient in activating Nrf2 and causes less toxicity in cells. Hence, 
NEM-click and CC can be used as a novel approach for the analysis of the 
role of Keapl cysteine modification in Nrf2 activation.
To summarise, the results presented in this thesis have 
demonstrated that chemical and oxidative stresses have a differential 
effect on the Keapl/Nrf2 and NF-kB pathway. Moreover, we have 
described the existence of a crosstalk mechanism between both 
pathways. Furthermore, Nrf2 inducing molecules have been observed to 
be able to activate Nrf2 by direct modification of Keapl cysteine 
residues, depletion of cellular GSH without concomitant binding of 
Keapl cysteines or both. The results of this investigation have also 
shown that all the cysteines on a proportion of Keapl are reduced 
basally, and they are available for modification by chemical molecules or 
can be S-glutathionylated under basal and stressed conditions. For 
future work, it is important to further explore the crosstalk mechanism 
between both pathways, and to further elucidate the modifications of 
Keapl cysteine residues either by chemical binding or oxidation and how 
this results in the activation of Nrf2 using novel approaches such as 
NEM-click.
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1.1 INTRODUCTION
Adverse drug reactions (ADRs) are categorised as any 
detrimental effect outside the normal therapeutic use of a drug 
(Pirmohamed et al. 1998). They are one of the main causes of hospital 
admission (Pirmohamed et al. 2004), leading to morbidity and mortality 
among patients and play a significant role in drug attrition during 
development (Park et al. 2005a). Whilst many cell types may be 
damaged by off target effects of a drug molecule, the liver is clearly one 
of the most commonly affected organs. The main physiological role of 
the liver is to metabolise xeno- and endobiotics to aid their clearance. 
The main proteins involved in the metabolism of drugs are the 
cytochrome P450 (CYP450) enzymes which are found in abundance in 
the liver. These phase 1 enzymes can bio-inactivate drugs to form non­
reactive metabolites. However, they are also largely recognised for 
formation of chemically reactive metabolites (CRMs), which may be a 
prerequisite for certain toxicities seen in ADRs. Hence, the liver is the 
main site of drug metabolism making it a major target for liver-specific 
toxicity or drug-induced liver injury (DILI) (Park et al. 1995). The 
generation of CRMs has been observed with paracetamol (Hinson et al. 
1981), carbon tetrachloride (Recknagel et al. 1989), bromobenzene 
(Jollow et al. 1974) and furosemide (Williams et al. 2007) during 
hepatotoxicity and recent evidence, in the largest study of its kind, 
indicates the direct role of hepatic metabolism forming CRMs as a risk 
factor for hepatic adverse events (Lammert et al. 2010).
The impending ability for CRMs to bind to cellular proteins, alter 
their conformation and function, leading to drug-induced toxicity (Zhou 
et al. 2005) has been classified as "The Critical Protein Hypothesis". This 
hypothesis suggests that the covalent binding of liver proteins by CRMs, 
once glutathione (GSH), the most abundance intracellular non-protein
4
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thiol molecule is depleted, leads to liver injury (Park et at. 2005a). 
Hence, these alterations to hepatic cellular proteins may elicit a 
hepatocellular defence response by initiating protein expression. The 
liver can produce a number of responses capable of bio-inactivating 
CRMs. These cellular defence responses are involved in the restoration 
of homeostasis and include GSH and GSH-dependent enzymes, Phase I 
and II proteins, transcription factors and heat shock proteins [Fig 1.1 
illustrates this balance between defence (specifically for the defence 
elicited by the transcription factor Nrf2) and damage during exposure to 
paracetamol].
Whilst GSH and GSH-dependent enzymes form the vanguard of 
the cellular defence response against CRMs (DeLeve et at. 1991), phase I 
and II proteins also play a key role. Phase I enzymes catalyse oxidation, 
reduction and hydrolysis reactions to incorporate a functional group for 
subsequent Phase II conjugation reactions and elimination. The Phase I 
family is made up of the CYP450 superfamily, flavin-containing mono­
oxygenase system, dehydrogenases, esterases and NADPH-cytochrome 
P450 reductases. Phase II enzymes include anti-oxidant and 
detoxification proteins that are either ubiquitously expressed or 
inducible in cells (Prestera et al. 1993b). These facilitate the removal of 
CRM from the body by increasing their polarity enabling their 
elimination into bile or urine. There are several transcription factors 
which can respond to CRM formation within cells (Primiano et al. 1997). 
These include: the Cap'n'Collar (CNC) family consisting of nuclear factor- 
erythroid 2 (NF-E2)-related factors; Nrfl, Nrf2 and Nrf3 (Motohashi etal. 
2002), the Nuclear factor kappa-light-chain-enhancer-of activated B cells 
(NF-kB) family comprising of five members; p65 (Rel A), RelB, c-Rel, 
p50/pl05 (NF-kB1) and p52/pl00 (NF-kB2) (Hayden et al. 2004),
5
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activating protein (AP-1) which is made up of a family of homo- and 
hetero- dimers of Jun, Fos or activating transcription factor basic region 
leucine zipper (bZIP) proteins (Karin et al. 1997), and the heat shock 
protein (HSP) family which is expressed basally at low levels under 
physiological conditions and consists of the smalt HSPs (16-30), HSP40, 
HSP60, HSP70, HSP90 and HSP110 (Freeman et al. 1996; Kalmar et al. 
2009). Together, these factors act in concert to drive the transcription 
and translation of many cytoprotective genes to aid the detoxification of 
CRMs and the restoration of cellular and organ homeostasis.
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Chapter 1
1.2 ADVERSE DRUG REACTIONS AND DRUG-INDUCED LIVER INJURY
A major cause of patient morbidity and mortality is adverse drug 
reactions. In the United States, it has been estimated that ADRs 
contributed to about 100,000 deaths alone in 1994 (Lazarou etal. 1998). 
A recent study in Sweden showed that ADRs comprised the 7th most 
common cause of death (Wester et al. 2008). This observation is in line 
with other studies in the United States and Canada where it has been 
described as the 4th and 19th most common cause of deaths, respectively 
(Lazarou et al. 1998; Bains et al. 1999). A recent analysis of 18,820 
hospital admissions from two Merseyside hospitals in the UK, conducted 
from November 2001 to April 2002, showed that adverse drug reactions 
accounted for 1225 (6.5%) admissions. Twenty-eight people (2.3%) died 
directly from the reactions (Pirmohamed et al. 2004). Recently, a case 
study reported that 1 in 7 patients suffered from an ADR, and this was a 
significant cause of morbidity and increased hospital stay (Davies et al. 
2009). Therefore, ADRs are a significant cause of hospital admission and 
patient morbidity and mortality.
ADRs can be classified into five main types in accordance with 
their chemical and pharmacological characteristics (Table 1.1) (Park et 
al. 1998). ADRs can affect many parts of the body. However, the liver 
represents the primary target for drug-induced liver injury (DILI) due to 
its main physiological role in drug metabolism and CRM formation (Park 
et al. 1995). DILI accounts for a significant cause of patient morbidity 
and mortality (Lee et al. 2005). Furthermore, DILI accounts for more 
than 50% of acute liver failure (Ostapowicz et al. 2002; Lee 2003) and is 
one of the main causes of drug attrition within development. More than 
600 drugs have been shown to cause liver toxicity (Park et al. 2005a). 
Hence, the understanding of DILI is required to further improve drug
8
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safety and reduce the occurrence of DILI in patient populations (Holt et 
al. 2010).
Type of Reactions Characteristics Examples
A-Augmented 1. Predictable from drug 
pharmacology
2. Exaggeration of 
pharmacological effect
3. Dose-dependent
1. Hypotension with anti­
hypertensives drugs
2. Haemorrhage with anti­
coagulants drug
B-Bizzare (Idiosyncratic) 1. Not predictable from 
the drug pharmacology
2. Dependent on the 
individual metabolic or 
immunological factors 
which may contribute 
to susceptibility
3. Not dose-dependent
1. Hepatitis with 
halothane
2. Hypersensitivity with 
anti-convulsants
C-Chemical 1. Predicted or
rationalised from the 
chemical characteristic 
of the drug and its 
metabolite
1. Hepatotoxicitywith 
paracetamol
D-Delayed 1. Reactions arises years 
after treatment
1. Tumours from 
chemotherapeutic 
agents
2. Phocomelia with 
thalidomide
E-End-of-treatment 1. Reactions arises when 
treatment stops or drug 
withdrawn
1. Withdrawal seizures 
upon stopping 
phenytoin
2. Withdrawal syndrome 
upon stopping 
paroxetine
Table 1.1: Classification of ADRs. Types of ADRs, A-E, with their 
characteristics and examples. (Adapted from Park et al, 1998).
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1.3 PARACETAMOL HEPATOTOXICITY
Paracetamol (APAP) Is an easily available, over the counter 
analgesic and antipyretic drug. Its mechanism of action is thought to be 
through the inhibition of cyclooxygenase activity, leading to the 
reduction of pro-inflamatory prostaglandin synthesis (Hinz et al. 2008). 
However, a novel mechanism of action has been proposed that suggest 
thats active paracetamol metabolites have an analgesic and antipyetic 
effect indirectly through the cannabinoid receptors by activating 
transient receptor potential vanilloid 1 (Zygmunt et al. 2000; Ottani et 
al. 2006; Mallet et al. 2010). The consumption of paracetamol taken at 
therapeutic doses is safe, but it is associated with hepatotoxicity when 
taken in overdose (Lee 2004).
The cause of paracetamol-induced hepatotoxicity is through the 
direct result of the formation of a reactive metabolite, NAPQI (Hinson et 
al. 1981). The bioactivation and excretion of paracetamol is represented 
schematically in Fig 1.2. Therapeutic doses of paracetamol are 
metabolised and excreted, around 55% and 30% by UDP- 
glucuronosyltransferase (UGT) and sulphotransferase (ST), as the 
glucuronide and sulphate conjugates, respectively (Howie et al. 1977). 
However, the Phase I enzymes, CYP2E1, CYP3A4 and CYP1A2 can 
metabolise 5% of a therapeutic dose of APAP to NAPQI (Dahlin et al. 
1984; Raucy et al. 1989; Thummei et al. 1993). NAPQI is then rapidly 
detoxified by GSH or glutathione S-transferase (GST)-mediated 
conjugation with GSH and excreted in the urine as a cysteine or 
mercapturate product (Mitchell et al. 1973). During paracetamol 
overdose, sulphation by ST and glucuronidation by UGT rapidly become 
saturated and excess paracetamol will become bioactivated by CYP450 
(Bessems et al. 2001). The production of NAPQI will be quenched by GSH
10
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but when the GSH system becomes overwhelmed, NAPQI will 
accumulate within hepatoctyes. This could lead to NAPQI binding 
covalently to proteins which may result in the modification of their 
function and structure. The accumulation of NAPQI has been shown to 
modify and inhibit 17 proteins in the livers of rodents [for a review, see 
(Park et al. 2005a)]. The covalent modification of proteins and the 
oxidation of protein thiols are believed to correlate with paracetamol- 
induced toxicity (Davis et ol 1974; Potter et al. 1974; Roberts et al. 
1987; Bartolone et al. 1988). This cellular protein modification has been 
suggested to be associated with mitochondrial dysfunction, decreased 
ATP synthesis and the disruption of calcium homeostasis (Jaeschke et al. 
2006). The disruption of calcium homeostasis can alter cell permeability, 
leading to the formation of blebs on the cell membrane, causing lost of 
membrane integrity (Lee 2003). Nevertheless, the depletion of GSH and 
the covalent binding of proteins by NAPQI will not only result in cellular 
toxicity (David Josephy 2005) but also activate the cellular adaptive 
defence response during drug exposure (Park et al. 2005a), for a 
summary see Fig 1.3.
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NAPQI
Protein
Cell toxicity
Glutathione
o—Glucuronide
Paracetamol
Excreted
°—Sulphate
Figure 1.2: Paracetamol Metabolism. The therapeutic dose of 
paracetamol is mainly excreted through the formation of glucuronide 
and sulphate conjugates by UGT and ST, respectively. About 5% of 
paracetamol is bioactivated by CYP450 enzymes to form the reactive 
metabolite NAPQI. During a therapeutic dose, NAPQI is detoxified by 
GSH constitutively or through GST-mediated conjugation. However, 
during overdose, the main conjugation pathway is saturated and NAPQI 
formation increases. This results in NAQPI accumulation and depletion 
of GSH. The accumulated NAPQI can bind to proteins which is believed 
to be the primary initiating event during drug-induced liver toxicity 
(Zhou et al. 2005).
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Chapter 1
1.4 CELLULAR DEFENCE AGAINST CELLULAR STRESS 
1.4.1 Glutathione and glutathione-dependent enzymes
Glutathione (GSH) is at the front line in cellular defence as it is 
the most abundant (up to lOmM) non-protein tripeptide thiol (Meister 
1988; DeLeve et af. 1991). GSH serves as a primary defence mechanism 
by acting as a redox buffer for chemical and oxidative stress (DeLeve et 
al. 1991). The synthesis of GSH involves two steps: 1) the rate-limiting 
conjugation step of L-giutamate conjugation to cysteine via the y- 
glutamylcysteine ligase catalytic subunit (GCLc) to form y- 
glutamylcysteine and 2) the conjugation of glycine to y-glutamylcysteine, 
via glutathione synthetase to yield GSH (Kaplowitz et al. 1985). The 
reactive cysteine thiol of GSH serves as a nucleophilic group which 
permits the major function of GSH, the detoxification of reactive oxygen 
species and conjugation of reactive electrophiles which help maintain 
the thiol status of other proteins (DeLeve et al. 1991). The detoxification 
and conjugation of CRMs can be spontaneous, partially with "soft" 
electrophiles, or enzymatically via the activity of glutathione S- 
transferase (GST) with "hard" electrophiles (DeLeve et al. 1991; Hayes et 
al. 1999). GSTs are highly diverse enzymes and their primary role is the 
conjugation of GSH to electrophiles and peroxidation of lipid 
hydroperoxides (DeLeve et al. 1991). During AFAR toxicity, NAPQI is 
formed from the metabolism of AFAR by CYP450, particularly 2E1, 1A2 
or 3A. NAPQI is rapidly quenched by GSH spontaneously or via GST 
mediation. Hence, GSH and GSTs play in an important role in cellular 
defence by quenching CRMs by forming GSH-conjugates.
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1.4.2 Phase I, II drug metabolism and III drug transporters
The first tier in cellular defence against drugs and xenobiotics, 
once GSH levels have been depleted, is comprised of the phase I, II drug 
metabolising enzymes and III transporters. Phase I drug metabolism 
enzymes include the CYP450 enzymes which are found in high 
abundance in the liver. The CYP450 superfamilies are membrane-bound 
microsomal enzymes (Meyer 1996; Guengerich 2003). There are five 
families of CYP450 involved in drug metabolism, CYP1, CYP2, CYP3, CYP4 
and CYP7 (Wrighton et al. 1996; Xu et al. 2005). The primary role of 
CYP450 enzymes is to act as a detoxification pathway and to metabolise 
endogenous and exogenous compounds. However, the process may 
actually generate compounds that are more reactive than the parent 
compounds, a process known as bioactivation, which is important in the 
initiation of some adverse drug reactions (Park et oL 2005b; Antoine et 
al. 2008).
Phase IE drug metabolising enzymes consist of a diverse group of 
enzymes varying in abundance within the liver. UDP- 
glycosyltransferases, UGT, ST, methyltransferases, acetyltransferases, 
and GSTs make up the majority of the phase II enzymes. The main 
functional role of phase II enzymes is the addition of a polar group onto 
a functionalised molecule (the result of phase I metabolism). This 
enables the excretion of drugs and xenobiotics into the bile and urine. 
With respect to the formation of CRMs from phase 1 reactions, phase II 
serves as a detoxification pathway to bioinactivate these and facilitate 
their subsequent removal from the cell (Timbrell et al. 2000; Gibson et 
al. 2001).
The removal of bioinactivated metabolites also involves phase III 
transporters. These transporters play a role in the transportation and
15
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removal of endogenous and exogenous compounds (Borst et al. 2002). 
The liver expresses the following drug transporters: the multi-drug 
resistance protein (MDR) 1 and 2 (P-glycoprotein); the multi-drug 
resistance associated protein (MRP) 1, 2, 3, and 4; breast cancer 
resistance protein (BCRP); organic anion (OAT) 2; and bile salt export 
pump (BSEP). These transporters are all involved in the transportation of 
drugs, drug conjugates, glutathione conjugates, glucuronide conjugates 
and bile (Klaassen etal. 2010).
The role of phase I, II and III proteins in cellular defence during 
drug exposure can be illustrated by the detoxification pathway of 
paracetamol (APAP) using Nrf2 knockout and wild type mouse. Nrf2 
knockout mice have been demonstrated to be compromised in their 
cellular defence systems, they appears to have a lower basal and/or 
inducible expression of cytoprotective proteins in the liver (Itoh et al. 
1997; Chan et al. 2000; Kwak et al. 2001; Ramos-Gomez et al. 2001; 
Chanas etal. 2002; lida etal. 2004). Furthermore, Nrf2 knockout mouse 
have been observed to be highly susceptible to APAP induced toxicity 
due to the lack of expression of Nrf2-dependent genes (Enomoto et al. 
2001; Reisman et al. 2009). Therefore, a comparison of phase I, II and III 
pathways between the wild type mouse liver against the Nrf2 knockout 
mouse liver was used in the illustration (Fig 1.4).
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AA-SULF
NQOl
AA-GLUC
AA-GSH
Wild Type
• AA-SULF and AA-GLUC are major 
metabolites
• AA-GSH is a minor metabolite
NHCOCHj SUITS
AA-SULF
P450s: 2E1,1A2 
\ NCOCH,
AA-GSH
Nrf2-/-
Increased AA-SULF in plasma, bile,
liver
• Decreased AA-GLUC in plasma, 
increased in liver
Figure 1.4: Control of disposition of paracetamol by phase I, II and III 
proteins in wild type and Nrf2-null murine hepatocytes. In wild type 
hepatocytes, the majority of paracetamol is metabolised by UGT and ST 
and excreted as glucuronide and sulphate conjugates. A minor amount 
of acetaminophen is metabolised to NAPQI and rapidly quenched by 
GSH. Glucuronide and sulphate conjugates are transported out of the 
hepatocyte by phase III transporters. In Nrf2-null hepatocytes there is a 
decrease in UGT. Therefore the majority of paracetamol is either 
metabolised by STs or to NAPQI by CYP450s and excreted as sulphate or 
GSH conjugate. There is also a decreased efflux of conjugates from the 
decrease in expression of Nrf2 dependent phase III transporters. (Maher 
et al. 2007; Aleksunes et al. 2008; Reisman et al. 2009)
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1.4.3 The redox-sensitive transcription factors implicated in the cellular 
response to chemically reactive metabolites
For a schematic overview of this section, specifically with respect to 
APAP exposure, and which, to some extent, can be considered a 
paradigm for the response to other CRMs, see Figure 1.3.
1.4.3.1 The cap V collar (CNC) family
Cells are constantly challenged with harmful endogenous 
compounds, reactive oxygen species, lipid hydroperoxides or exogenous 
compounds such as UV radiation or environmental pollutants. In order 
to deal with constant exposure to such stresses, mammalian cells have 
evolved a number of second tier adaptive cellular defence mechanisms. 
The adaptive defence response involves the CNC family of transcription 
factors, amongst which Nrf2 is now considered to be the most important 
member, which are able to rapidly respond to a range of different forms 
of oxidative and chemical stress [for reviews, see (Hayes et al. 2009; 
Copple et al. 2010a)]. The Nrfl, Nrf2 and Nrf3 proteins are part of the 
CNC family, which heterodimerise with small Maf proteins via the bZip 
domain (Andrews et al. 1993; Marini et al. 1997; Kobayashi et al. 1999). 
This heterodimerisation between Nrf subunits and Maf proteins can 
enable recognition and binding to the antioxidant response element 
(ARE), a c/s-acting enhancer with a sequence motif of 5'- 
gagTcACaGTgAGtCggCAaaatt-3'. Critical nucleotides are annotated in 
capital letters (Nioi et al. 2003). The ARE sequence motif is found in the 
promoter region of anti-oxidant and phase II genes. Activation of the 
ARE leads to the transcription of these cytoprotective proteins 
(Rushmore et al. 1991; Prestera et al. 1995; Blank etal. 1997).
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Nrfl
Nrfl is a member of the CNC family and shares several 
similarities with Nrf2; mainly the highly conserved CNC domain, a 43 
amino acid sequence found between the N-terminal and the basic 
domain (Blank et al. 1997). Nrfl is able to heterodimerise with small Maf 
proteins to bind to ARE motifs and it is abundantly expressed in major 
organs (Marini et ol. 1997; Motohashi et al. 2002). There are two forms 
of Nrfl, a 120kDa and 65kDa isoform which could be formed through 
alternative translation initiation (Chan et al. 1993). The larger Nrfl 
isoform is expressed ubiquitously in the cytoplasm. However, unlike 
Nrf2, Nrfl is not sequestered by Keapl, even though it can interact with 
Keapl. It has been suggested that Nrfl is localised to the cytoplasm by 
its interaction with the endoplasmic reticulum (ER) and the 65kDa 
isoform of Nrfl (Nrfl-p65) is found in the nucleus (Wang et al. 2006). It 
has been identified in monkey kidney cells in the ER membrane- and 
nuclear envelope- enriched fractions (Zhang et al. 2009b). The N- 
terminal domain of Nrfl contains a transmembrane domain which is 
absent in Nrf2. This targets Nrfl to the ER (Wang et al. 2006; Zhang et al. 
2006) and is glycosylated at the NST domain, a seven asparagine (-Asn-X- 
Ser/Thr) - glycosylation consensus site (Zhang et al. 2007b). Hence, the 
glycosylation may play a part in the localisation of Nrfl in the ceil.
Nrfl has been shown to play an essential role in sustaining liver 
development (Chen et al. 2003) as the Nrfl knockout mouse shows 
embryonic lethality (Chan et al. 1998). Although the role of Nrfl in 
cellular defence remains unclear, Nrfl knockout primary hepatocytes 
have been shown to be more susceptible to oxidative stress (Chen et al. 
2003). Furthermore, Nrfl has been shown to be involved in the control 
of several cytoprotective genes, i.e. GCL catalytic subnit (GCLc) and the
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GCL modifier subunit (GCLm) (Kwong et al. 1999; Chen et at. 2003; Zhao 
et al. 2010), Heme oxygenase-1 (HO-1), glutathione peroxidase 1 (Chen 
et al. 2003), metallothionein (MT) 1 and 2 (Chen et al. 2003; Ohtsuji et 
al. 2008), NAD(P)H: quinone oxidoreductase 1 (NQ.01) (Venugopal et al. 
1996; Zhao et al. 2010) and the sulfotransferase family 3A member 1 
(Ohtsuji et al. 2008). The Nrfl-p65 was suggested to be able to compete 
with Nrf2 for small Maf proteins by also binding to the ARE and 
inhibiting the oxidative stress response (Wang et al. 2007). Nrfl have 
also been shown to dimerise with MafG proteins which bind to 
consensus sequences that are identical to ARE sequence. The evidence 
for the involvement of Nrfl in the regulation of cell defence genes is 
based on either Nrfl knockout or conditional Nrfl knockout animals or 
hepatocytes. Until recently there has been little compelling evidence of 
the direct induction of Nrfl by chemically reactive compounds or 
oxidative stress. Zhang and colleagues demonstrated that tert-butyl 
hydroquinone (tBHQ) increases Nrfl activity and that mutations in 
amino acids 31-90 of the NTD domain disrupt the activity (Zhang et al. 
2009b). The increase in Nrfl activity has been postulated to be a 
consequence of the chemical stress caused by the formation of the tBHQ 
reactive metabolite, 2-t-butyl-l, 4 benzoquinone from bioactivation by 
CYP1A1 (Gharavi et al. 2007). Activation may also occur through the 
depletion of GSH by tBHQ (Nakamura et al. 2003) leading to the 
induction of oxidative stress. Furthermore, inorganic arsenic has also 
been shown to result in the activation of Nrfl and the induction of GCLc, 
GCLm and NQOl through ARE binding (Zhao et al. 2010). In summary, 
Nrfl may be activated by the presence of CRMs and the depletion of 
GSH but its mechanism remains elusive and more work needs to be 
done in this area.
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Nrf2
The most studied member of the CNC family is Nrf2. This protein 
is expressed in most tissues but especially those involved in 
detoxification and/or constant exposure to the external environment 
(Motohashi et al. 2002). In a homeostatic environment, Nrf2 is 
sequestered by its inhibitor protein, Kelch-like erythroid cell-derived 
protein with CNC homology (ECH)-associated proteinl (Keapl), in the 
cytosol (Itoh et al. 1999b). A Keapl homodimer interacts with Nrf2 and 
targets it for ubiquitination and subsequent proteosomal degradation by 
functioning like a substrate adaptor for a Cullin-dependent E3 ubiquitin 
ligase complex (Cul3 ligase) (Cullinan et al. 2004b; Kobayashi et al. 
2004a; Zhang et al. 2004; Furukawa et al. 2005). This accounts for the 
relatively short half life of Nrf2 (10-30min) (Alam et al. 2003; Itoh et al. 
2003; McMahon et al. 2003; Nguyen et al. 2003; Stewart et al. 2003; 
Yamamoto et al. 2007). Under chemical or oxidative stress, Keapl is 
unable to repress Nrf2, allowing Nrf2 nuclear accumulation leading to 
the transcription of ARE-regulated genes (Itoh et al. 1999a; 
Dhakshinamoorthy et al. 2001). Classical examples of Nrf2-ARE 
dependent gene transcription and their functions are NQ.01 
(Dhakshinamoorthy et al. 2000), which catalyses two electron reduction 
and detoxification of quinones (Venugopal et al. 1996), HO-1 (Prestera 
et al. 1995) which catabolises heme to yield biliverdin, free Iron and 
carbon monoxide (Alam et al. 1999; Ishii et al. 2000), the aldo-keto 
reductase family 1 (AKR1) (Kwak et al. 2003) which reduces aldehydes 
and ketones to primary and secondary alcohols (Nishinaka et al. 2005; 
Lou et al. 2006), GSTs (Itoh et al. 1997) which catalyse the conjugation of 
GSH to electrophiles (Hayes et al. 2000; McMahon et al. 2001), GCLc and 
GCLm (McMahon et al. 2001) and UDP-glucuronosyltransferases (UGTs) 
(Enomoto et al. 2001; Thimmulappa et al. 2002), which catalyse the
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conjugation of UDPGA to lipophilic substrates (Shelby et al. 2006; Yueh 
et al. 2007). Fig 1.4 illustrates the role of Nrf2 in the control of genes 
involved in defence, specifically with respect to APAP exposure. 
Together these proteins comprise much of the second tier of the 
defence response. The mechanism of Nrf2 activation by drug or 
xenobiotics-induced stress has not been fully clarified but there are 
currently two major hypotheses proposed, which are not necessarily 
mutually exclusive, i.e. the modification of cysteine residues in Keapl 
and the phosphorylation of Nrf2, which will be discussed in detail in 
section 1.6.
Therefore, the generation of CRMs by phase I enzymes can have 
a direct effect on the cellular defence mechanism via the I\lrf2/Keapl 
pathway as shown by NAPQI formation during acute APAP-induced 
hepatotoxicity. Even at a sub-toxic level of exposure to APAP, NAPQI 
causes GSH depletion and can covalently bind to Keapl. This has been 
postulated to lead to the induction of an Nrf2 mediated cellular defence 
response and the transcription of Nrf2-ARE dependent genes (Goldring 
etal. 2004; Copple etal. 2008a; Randle etal. 2008).
Nrf3
The newest member of the CNC family is NrfB, discovered and 
characterised by Kobayashi and colleagues (Kobayashi et al. 1999). NrfB, 
in common with other Nrf family members, shares structural similarity in 
its CNC domains and can heterodimerise with small Maf proteins to bind 
to ARE motifs (Kobayashi et al. 1999). It is expressed in major organs but 
is most abundant in the placenta (Kobayashi et al. 1999). Recent work 
has suggested that NrfB is localised and bound to the ER membrane, and
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like Nrfl, it is glycosylated (Nouhi etal. 2007; Zhang etal. 2009a; Pepe et 
al. 2010).
The role of Nrf3 remains unknown but it has been suggested 
recently that the upregulation of Nrf3 plays an important role in smooth 
muscle cell differentiation (Pepe et al. 2010). The Nrf3 knockout mouse 
has no noticeable phenotype when compared to the wild type and there 
is no effect on phase 2 gene expression (Derjuga et al. 2004; Kobayashi 
et al. 2004b). There is currently no direct evidence of chemical or 
oxidative stress activating Nrf3. However, there is contradicting 
evidence as to the role of Nrf3 in activating ARE gene expression. 
Sankaranarayanan and Jaiswal suggested that human Nrf3 negatively 
regulates the expression of NQOl (Sankaranarayanan et al. 2004). These 
authors noted that Nrf3 overexpression depressed the expression and 
induction of NQOl in response to tBHQ. Interestingly, RNA interference 
directed against Nrf3 reversed these effects. This is in line with a current 
report that overexpression of Nrf3 also negatively regulates the 
expression of NQOl (Pepe et al. 2010). However, Zhang and colleagues 
have shown that mouse Nrf3 activity is only slightly induced by tBHQ 
and sulforaphane when analysing an ARE reporter construct gene. The 
authors noted that the ARE reporter gene used by Sankaranarayanan 
and Jaiswal was different to their, by the absence of an AP-1 binding 
motif. Hence, they postulated that the presence of the AP-1 binding 
motif allowed Nrf3 to be recruited, forming a heterodimer with c-Fos or 
Fral to compete out Nrf2 (Zhang et al. 2009a).
1.4.3.2 NF-kB family
NF-kB exists in the cytoplasm of unstimulated cells as homo- or 
hetero-dimers, bound to a family of inhibitory proteins known as 
Inhibitor of kB (IkB), via non-covalent interactions. There are five
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members belonging to the mammalian NF-kB family [p65 (RelA), RelB, c- 
Rel, p50/pl05 (NF-kB1) and p52/pl00 (NF-kB2)] which may form part of 
the second tier of the cellular defence response. They are characterised 
by a conserved 300 amino acid N-terminal region called the Rel- 
homology domain (RHD) which is required for dimerisation between NF- 
kB family subunits and also for interaction with the IkB inhibitory 
proteins (May et al. 1998; Hayden et al. 2004). This interaction conceals 
the nuclear localisation signal (NLS) of p65 in the p65/p50 dimer which 
can prevent the NF-kB:IkB complex from translocating to the nucleus, 
thereby maintaining NF-kB in an inactive state (Jacobs et al. 1998). 
Although the complex is predominantly localised to the cytoplasm, the 
NLS of p50 is not concealed by the binding of IkB. The nuclear export 
sequence (NES) found on IkB allows the shuttling of the complex 
between the nucleus and the cytoplasm (Johnson et al. 1999; Huang et 
al. 2000b; Hayden et al. 2004).
Activation of NF-kB requires the dissociation and degradation of 
IkB from the NF-kB:IkB complex, allowing unbound NF-kB to be released. 
Upon the release of NF-kB from the NF-kB:IkB complex, NF-kB can 
translocate to the nucleus. The RHD binds to kB elements with a 
consensus sequence of S'-GGGRNYYYCC-S7 (N=any base, R=purine and 
Y=pyrimidine) (Chen et al. 1999) and can trigger gene transcription. After 
binding to the kB elements, the promotion and enhancement of gene 
transcription requires the presence of a transactivation domain (TAD). 
This domain is located on the C-terminal region of p65, RelB and c-Rel. 
The homodimers of p52 and p50 therefore lack this domain. This can be 
seen in the transcriptional activity of p65, RelB, c-Rel and the repressive 
activity of p52 and p50 homodimers (Zhong et al. 2002; Chen et al. 2004; 
El Gazzar etal. 2007).
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NF-kB transcriptional activity can trigger inflammatory responses, 
cell proliferation, cell survival and anti-oxidant responses. NF-kB 
achieves cell survival by initiating the transcription of anti-apoptotic 
proteins such as XIAP (Stehlik et al. 1998; Braeuer et at. 2006; Kairisalo 
et al. 2007), clAPs (Chu et al. 1997; Wang et al. 1998), c-FLIP (Kreuz et al. 
2001; Micheau et al. 2001), Al (Zong et al. 1999), A20 (Malewicz et al. 
2003) and BCL-xL (Chen et al. 2000). It initiates cell proliferation by 
initiating the transcription of cell cycle regulators and cyclins 
(Kucharczak et al. 2003), and causes inflammation by the induction of 
expression of inflammatory proteins such as tumour necrosis factor-a 
(TNF-a), interleukins (IL), interferon-p, macrophages colony stimulating 
factor (M-CSF), granulocyte macrophages colony stimulating factor (GM- 
CSF), cyclooxygenase II (COX-II), inducible nitric oxide synthase (iNOS) 
(Pahl 1999) and several anti-oxidant proteins such as manganese- 
dependent SOD (Mn-SOD) (Delhalle et al. 2002; Tanaka et al. 2002; 
Djavaheri-Mergny et al. 2004) and ferritin (Pham et al. 2004).
NAPQI and its parent compound APAP can abrogate IMF-kB 
binding activity in cells (Blazka et al. 1995; Boulares et al. 1999) and 
attenuate TNF-a induction of NF-kB in vivo (Matsumaru et al. 2003). 
Blazka has previously demonstrated that mice treated with APAP show a 
rapid decrease in NF-kB binding associated with an increase in damaged 
hepatocytes. The induction of NF-xB-dependent genes, iNOS and IAP-1 
by TNF-a was also reduced after exposure to APAP in vivo. Moreover, 
this effect was not observed when repeated in Huh7 ceils which lack 
P450 activity. Therefore, these studies show that the reactive metabolite 
of APAP can inhibit NF-kB and its dependent genes.
Recently, it has been suggested that NF-kB plays a role in the 
expression of cytochrome P450 proteins (Ishibe et al. 2009). The
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interleukin-1 receptor antagonist (IL-lra) knockout mouse has a higher 
level of expression of NF-kB and suppressed CYP450 enzymes. This 
observation is also associated with reduced levels of APAP toxicity. Also, 
the induction of NF-kB activity by IL-la suppresses the expression of 
CYP450 in wild type mouse hepatocytes (Ishibe et ol. 2009). NF-kB and 
its inducers, TNF-ct and IPS, have also been shown to repress the activity 
of the aromatic hydrocarbon receptor (Ahr). It has been hypothesed that 
RelA is able to associate with Ahr, forming an inactive complex capable 
of inhibiting the transcription of CYP1A1 and CYP1A2 (Tian et al. 1999; 
Ke et al. 2001). Suppression of CYP2E1 enzymes by IPS was abrogated 
with the co-administration of curcumin, a NF-kB inhibitor, which 
suggests that NF-kB plays a critical role (Sewer et al. 1996; Cheng et al. 
2003). Another CYP450 family involved in the bioactivation of APAP to 
NAPQI is the CYP3A family. CYP3A4 and CYP3A11 are partly regulated by 
the pregnane X receptor (PXR)-retinoid X receptor (RXR) complex and 
are affected by NF-kB. It has been suggested that NF-kB can bind to RXR 
forming a NF-kB-RXR-PXR complex. This inactive complex can lead to 
the inhibition of CYP3A enzyme transcription (Gu et al. 2006; Zhou et al. 
2006). In summary, NF-kB can play a role in the suppression of CYP450 
enzymes by inhibiting their transcription through the formation of 
inactive complexes amongst various nuclear receptors. Therefore, it is 
possible that NAPQI may augment APAP toxicity by inhibiting NF-kB 
binding activity which may ultimately lead to the loss of CYP450 
suppression mediated by NF-kB. This increased expression of CYP450 
would be expected to lead to an enhanced formation of NAPQI from 
APAP, further increasing toxicity. However, more investigation is 
required to test this hypothesis.
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1.4.3.3 Activating protein-1
Activating protein-1 (AP-1) is comprised of a family of 
transcription factors made up of homo- and hetero-dimers of Jun (v-Jun, 
c-Jun, JunB, JunD), Fos (v-Fos, c-Fos, FosB, Fral, Fra2) or activating 
transcription factor (ATF2, ATF3/LRF1, B-ATF) basic region leucine zipper 
(bZIP) proteins. AP-1 may serve as an additional secondary cellular 
defence mechanism. Jun, Fos and ATF2 can heterodimerise with each 
other. Jun and ATF2 can form homodimers amongst themselves but Fos 
cannot homodimerise. The major isoform of AP-1 is the c-Jun and c-Fos 
heterodimer (Karin et al. 1997). The activity of AP-1 is dependent on the 
regulation of AP-1 gene transcription and post-translational 
modifications (Karin 1995). Whilst the constitutive expression of c-Jun 
and c-Fos is very low in the nucleus of many cells, they are very rapidly 
and transiently transcribed upon induction by extracellular signals 
(Abate et al. 1991). The binding to the AP-1 binding response element 
(TRE) initiates transcription of proteins that are involved in cell 
proliferation, differentiation, cell survival and death. Thus, AP-1 
mediates cell proliferation and differentiation by the regulation and 
expression of cell cycle regulators such as cyclin D, cyclin A, cyclin E, p53, 
p21 and pl6. It also mediates ceil death by the expression of TNF-a, Fas 
Ligand (FasL) and its receptor (Fas), and also controls cell survival by 
inhibition' of the tumour suppressor gene p53 (Hess et al. 2004). 
Although induction of AP-1 DNA binding activity may, to some as yet 
unknown degree, be involved in the regulation of anti-oxidant proteins 
such as HO-1, CuZn SOD (Chiu et al. 2003), GCLc and GCLm (Kitteringham 
et al. 2000), this activity is not now considered to be as critical in the 
transcriptional defence response as that observed with Nrf2. 
Furthermore, whilst the other roles of AP-1 described above may be
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important in defining how the liver responds to CRM formation, there is 
still no definitive evidence for this.
1.4.3.4 Heat Shock Proteins
The HSPs are a family of molecular chaperone proteins that are 
highly conserved and basally expressed at low levels under normal 
physiological conditions. They assist protein folding, protein synthesis 
and prevent protein aggregation or direct poorly-folded proteins for 
degradation (Freeman et ai 1996; Kalmar et al. 2009). During chemical 
stress, protein adduction can occur, and HSPs are postulated to enhance 
the solubility of denatured proteins and eventual degradation of these 
proteins (Beckmann et al. 1992; Ciocca et al. 1993). The HSP family 
consists of small HSPs (16-30), HSP40, HSP60, HSP70, HSP90, HSP110 
and mitochondrial HSP. By increasing their expression, HSPs can respond 
to different forms of cellular stress such as hyperthermia and oxidative 
or chemical stress. This process is known as the heat shock response 
(Lindquist 1986) and is mediated by Heat Shock transcription Factors 
(HSFs) which bind to consensus sequences known as heat shock 
response elements (HSE) on the promoter region of HSP genes 
(Whitesell et al. 2009). HSF-1, HSF-2 and HSF-3 have been identified as 
regulators of HSPs transcription in humans, where HSF-1 plays the 
dominant role in the expression of inducible HSP during the heat shock 
response (Pirkkala etal. 2001; Whitesell etal. 2009).
The upregulation of HSPs during cellular cytoprotection has been 
shown to diminish the effect of hepatotoxicity (Salminen et al. 1996). 
The induction of HO-1, which is also known as HSP32, during 
perturbations in cellular redox such as GSH depletion or oxidative stress 
demonstrates that HSPs are redox sensors (Ewing et al. 1993; Motterlini 
et al. 1996). Heat stress has been shown to upregulate the inducible
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form of HSP70 (HSP70i) in HEPG2 cells which can protect against 
hepatotoxicity (Salminen et al. 1996). The HSPs' cellular defence 
capability can be illustrated for APAP toxicity. HSP25 and HSP70I have 
been shown to be induced by hepatotoxic doses of APAP (Salminen etal. 
1997a; Sumioka et al. 2004). Furthermore, prior upregulation of HSP25 
and HSP70i by heat stress reduces the hepatotoxicity from an acute 
dose of APAP in vivo (Salminen et al. 1997b). The overexpression of 
HSP25 in cells has been shown to increase the level of GSH (Baek et al. 
2000). In a HSP70i knockout murine model, there is evidence of APAP- 
induced toxicity compared to wild-type animals, thus indicating an 
important role of HSP70i in APAP toxicity (Tolson et al. 2006). From the 
literature there is evidence to suggest that HSPs can be upregulated by 
cellular stress and can protect cells and reduce APAP cellular toxicity. In 
summary, the HSPs probably play an important role in the cellular 
response and defence against APAP toxicity.
1.5 PROTEIN THIOL MODIFICATIONS
The thiol-containing cysteine amino acid is one of the most 
reactive among all amino acids (Davies 2005), allowing them to readily 
undergo oxidation (Paulsen et al. 2010) or alkylation by electrophiles 
(Marnett et al. 2003). The modification of cysteine can alter the function 
or the conformation of the protein via the oxidation or reduction of 
electrons at the thiol group (Cooper et al. 2002). The cysteine thiol 
group (-SH) can be oxidised to the sulphenic acid (-SOH), which is 
unstable and reversible, and can be further oxidised to the irreversible 
sulphinic (-SO2H) and sulphonic acids (-SO3H). The -SH group can also 
form a disulphide linkage (S-S), either within a single protein or with 
other proteins. Thiol groups can also undergo S-glutathionyiation (-SSG) 
with GSH. In the presence of nitric oxide, the -SH group can be modified
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to form S-nitrosothiol {-SNO). Electrophiles can also alkylate the cysteine 
thiol group resulting in the formation of cysteine-electrophile adducts 
(Fig 1.5) (Rudolph et ah 2009; Paulsen et ol. 2010). Therefore, the 
concept that protein function can be regulated by a change in cysteine 
chemical state is important. This is exemplified by the activation of 
apoptosis signal-regulating kinase 1 and the inhibition of protein 
tyrosine phosphatase IB by cysteine modification (Spickett et al. 2010). 
A more detailed discussion of the regulation of protein function by 
cysteine modification is in section 1.6.
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Figure 1.5: Schematic overview of cysteine post-translational 
modifications. The thiol group within cysteine can be (a) oxidised to 
different oxidation states, oxidation, (b) formed disulphide linkages, (c) 
glutathionylated and (d) nitrosylated. (e) Alkylation/Arylation can also 
occurred on the thiol group by reactive intermediates. (Rudolph et al. 
2009; Paulsen et al. 2010).
31
Chapter 1
1.6 THE REDOX-TRANSCRIPTION FACTOR PATHWAYS
This section emphasises in detail the signalling pathways of NF-kB and 
Keapl/Nrf2.
1.6.1 NF-kB Pathways
The NF-kB pathway is characterised by three pathways, the 
classical, alternative and atypical pathways. The three pathways are 
activated by different stimuli such as pro-inflammatory cytokines, the 
immune response and by oxidative stress (Gloire et al. 2009).
1.6.1.1 The classical Pathway
The classical NF-kB pathway is commonly stimulated by a pro- 
inflammatory cytokine such as tumour necrosis factor-a (TNF-a), 
iipopolysaccharide (IPS) and interleukin-1 {IL-1) (Fig 1.6a). The initiation 
of the classical pathway by these pro-inflammatory compounds relies on 
the dissociation of IkB from the NF-kB, which is initiated by the 
phosphorylation of serine residues 32 and 36 on IkB-cx, by IkB kinase 
(IKK) (Brockman et al. 1995; Brown et al. 1995). This then directs IkB-cx 
for ubiquitination by the members of the Skpl-Culin-Rocl/Rbx/Flrt-1- 
Fbox (SCF or SCRF) family of ubiquitin ligases, leading to the 
proteosomal degradation of IkB (Scherer et al. 1995; Ben-Neriah 2002). 
IKK is a dimer consisting of two different subunits, IKKa and IKKP, which 
is held in an IKK complex with a regulatory subunit called NF-kB essential 
modifier (NEMO) (Scherer et al. 1995; Mercuric et al. 1997; Mercuric et 
al. 1999; Ben-Neriah 2002). IKKa and IKKp are serine/theronine kinases 
which are able to phosphorylate members of the IkB family (DiDonato et 
al. 1997). The classical pathway controls the transcription of genes 
involved in cell proliferation, survival/death, differentiation and the 
inflammatory response (Perkins 2007).
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1.6.1.2 The alternative pathway
The alternative pathway can be initiated by LPS, lymphtoxin 
receptors and CD40. This is triggered when the IKKa subunit is activated 
by NF-kB inducing kinase (NIK) instead. The plOO of the NF-kB family is 
phosphorylated by IKKa, leading to the ubiquitination and processing of 
plOO to p52. This allows the newly processed p52 and its associated 
partner, RelB, to translocate into the nucleus. The alternative pathway 
activates the transcription of genes involved in lymphoid organ 
development and adaptive immunity (Fig 1.6b) (Bonizzi et ol. 2004).
1.6.1.3 The atypical pathway
The atypical pathway activates NF-kB by an IKK-independent 
mechanism. Stimuli such as ultraviolet light, reactive oxygen species and 
hydrogen peroxide can result in the phosphorylation of IxB-a (Gloire et 
ai. 2006; Perkins 2006; Lluis et al. 2007). Expression of the HER2 
oncogene results in the phosphorylation of the IxB-a's PEST domain by 
casein kinase-ll (CK-II) (Schoonbroodt et al. 2000; Kato et al. 2003). The 
phosphorylated IkB-a is either degraded or dissociated from NF-kB (Fig 
1.6c) (Perkins 2006). Alternatively, the depletion of GSH has been 
suggested to activate the NF-kB pathway (Fig 1.6) (Rahman et al. 2000; 
D'Alessio et al. 2004; Filomeni et al. 2005), but the mechanisms remain 
unclear. However, there are suggestions that this could involve the 
formation of oxidised GSSG from hydrogen peroxide stimulation (Droge 
et al. 1994) or that it may occur through the formation of reactive 
oxygen species and hydrogen peroxide (Gloire et al. 2006; Lluis et al. 
2007).
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1.6.1.4 The role of cysteine in NF-kB activity
The NF-kB pathway can be inhibited by protein cysteine 
modification. Both endogenous and exogenous compounds have been 
shown to inhibit this pathway. It has been suggested that cysteine 179 in 
the activation loop of IKKp is involved in the activation of the NF-kB 
pathway. Therefore, endogenous compounds like 15-Deoxy-A12,14- 
prostaglandin J2 (15d-PGJ2) (Rossi et al. 2000; Straus et al. 2000), 4- 
hydroxynonenai (Ji et ol. 2001) and exogenous compounds such as 
triterpenoids; 2-cyano-3,12-dioxooieana-l,9,-dien-28-oic acid (CDDO), 
the C-28 methyl ester of CDDO (CDDO-Me), l-[2-cyano-3,12- 
dioxooleana-l,9(ll)-dien-28-oyl]imidazole (CDDO-lm), xanthohumol (a 
prenylated chalcone) and N-Tosyl-L-phenylalanine chioromethyl ketone 
(TPCK) (a serine/cysteine protease inhibitor), can inhibit the NF-kB 
pathway by covalent modifications of cysteine 179 within IKKP (Ahmad 
et al. 2006; Yore et al. 2006; Ha et al. 2009; Harikumar et al. 2009). 
Hence, this modification will block the phosphorylation of IkBcx by IKKP 
and will inhibit the activation of NF-kB. NF-kB DNA binding can also be 
inhibited by cysteine modification by exogenous and endogenous 
compounds. For example, endogenous compounds such as ISd-PGJz and 
ethyl pyruvate (Straus et al. 2000; Cernuda-Morollon et al. 2001; Han et 
al. 2005) have been shown to covalently modify cysteine 38 and 62 of 
p65 and p50, respectively. In addition, exogenous compounds such as 
TPCK, xanthohumol and organoselenium compounds (Chen et al. 2007; 
Ha et al. 2009; Harikumar et al. 2009) also show similar cysteine 
modification on p65 and p50.
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Classical Pathway 
(TNF-a,IL-l,LPS)
Figure 1.6: The classical NF-kB activation pathway (a). The classical 
pathway depends on the activation of IKKp to phosphorylate IkB-cx to 
allow p65/p50 NF-kB complex nuclear translocation. Adapted from 
(Perkins 2007).
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b Alternative Pathway (LPS, lymptoxin receptors and CD40)
i
i
Figure 1.6: The alternative NF-kB activation pathway (b). The
alternative pathway depends on the activation of IKKa by NIK to 
phosphorylate plOO NF-kB subunit and subsequent ubiquitination and 
processing to p52. This can lead to the activation of p52/RelB NF-kB 
complex nuclear translocation. Adapted from (Perkins 2007).
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Figure 1.6: The atypical NF-kB activation pathway (c). The atypical 
pathway involves kinases to phosphorylate IkB-q and may be involved in 
the mechanism of p65/p50 NF-kB complex activation from GSH 
depletion. Adapted from (Perkins 2007).
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1.6.2 The Keapl/Nrf2 pathway 
1.6.2.1 The structure of Nrf2
Nrf2 is a member of the CNC family (see 1.4.3.1). Mouse and 
human Nrf2 contains six Nrf2-ECH homology (Neh) domains (Table 1.2) 
(Itoh et al. 1997) which are highly conserved among vertebrates (Fig 1.7) 
(Kobayashi et al. 2002). Nrf2 binding to the ARE involves a highly 
conserved cysteine residue (C506) in the Nehl domain which leads to 
the transcription of Nrf2-dependent genes (Bloom et al. 2002). The 
binding of Nrf2 to the ARE results in the recruitment of coactivators of 
transcription such as the cAMP response element binding protein (CREB) 
- binding protein (CBP) and BRG1 (Brahma-related gene 1) through the 
Neh4 and Neh5 domains (Zhang et al. 2007a). Therefore, the interaction 
between Nrf2 and the transcriptional activators enables Nrf2 to regulate 
the transcription of its cytoprotective genes described in 1.4.3.1. Nrf2 
also contains cysteine residues that are conserved through evolution. 
The mouse and rat Nrf2 contain 7 cysteines whilst the human Nrf2 
contains 6 cysteines. The mouse Nrf2 which contains 7 cysteines is 
shown schematically in Fig 1.7 (He et al. 2009).
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Figure 1.7: Schematic representation of the Nrf2 Neh domains. The six
Neh domains are represented by blue boxes with each domain labelled. 
The line above represents the numbered Nrf2 cysteine residue.
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Domain Location
in mouse
Nrf2
Functions References
Neh2 1-96 Contains DIG /DIDLID and
ETGE motifs which binds to 
Keapl
Lysine-rich region for 
ubiquitinations
Contain nuclear import signal 
(NLS) (amino acids 42-53)
(Itoh et al. 1999b; 
McMahon et al. 
2004; Katoh et al. 
2005; McMahon 
et al. 2006; Tong 
et al. 2006a; 
Theodore et al. 
2008)
Neh4 111-141 Transactivation
Interactions with transcription 
coactivator, CBP
(Katoh etal. 2001)
Neh5 172-201 Transactivation
Interactions with transcription 
coactivators. CBP and BRG1 
Contain nulcear export signal 
(NES) (amino acids 175-186)
(Katoh etal. 2001;
Li et al. 2006; 
Zhang et al. 
2007a)
Neh6 330-380 Regulate Nrf2 degradation in 
the nucleus of cell under
oxidative stress
(McMahon et al. 
2004)
Nehl 427-560 Contains the CNC and bZip 
regions
Allows dimerisation with other 
bZip proteins
Binds to ARE
Contains NLS (amino acids 
494-511 & 587-593) and NES 
(amino acids 545-554)
(Itoh et al. 1999b; 
Bloom et al. 2002; 
Jain et al. 2005; 
Theodore et al. 
2008)
NehB 561-597 Transactivation (Nioi et al. 2005)
Table 1.2: Functions of Nrf2 Neh domains.
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1.6.2.2 The role of phosphorylation in the regulation of Nrf2 activity
The activation of Nrf2 upon cellular stress is mainly based on the 
hypothesis of Keapl cysteine covalent modification. This will be 
discussed in detail in 1.6.2.5. However, there are suggestions that the 
phosphorylation of Nrf2 can activate Nrf2 activity and the induction of 
its downstream cellular defence genes. There are many studies which 
have suggested that the phosphorylation of Nrf2 can act as a regulatory 
pathway for Nrf2 activation. These studies used pharmacological 
inhibitors of specific protein kinases and showed reduced Nrf2 activation 
by known activating molecules (Nguyen et al 2000; Lee et al. 2001; 
Johnson et al, 2002; Bloom et al. 2003; Numazawa et al. 2003; Lee-Hilz 
etal. 2006). The potential role of protein kinase C in the phosphorylation 
of Nrf2 has been shown (Huang et al. 2000a; Huang et al. 2002; Bloom et 
al. 2003; Niture et al. 2009), as well as other protein kinases such as 
extracellular signal-regulated kinasel (ERK-1) (Papaiahgari et al. 2006), 
phosphoinositide-3-kinase (PI3K) (Kang et al. 2002), c-Jun N-terminal 
kinase 1 (JNK1) (Keum et al. 2003), glycogen synthase kinase-3fJ (GSK- 
3p) (Salazar et al. 2006), protein kinase R (PKR)-like endoplasmic 
reticulum kinase (PERK) (Cullinan et al. 2003; Cullinan et al. 2004a), 
Mitogen-activated protein kinases (MARK) (Cullinan et al. 2003; Zipper et 
al. 2003; Keum et al. 2006) and CK-II (Pi et al. 2007; Apopa et al. 2008) . 
Therefore, phosphorylation of Nrf2 may play an important regulatory 
step in Nrf2 activation.
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1.6.2.3 The role of cysteines in Nrf2 activity
The regulation of Nrf2 activity is thought to be not solely 
governed by phosphorylation. The modification of Nrf2 cysteine residues 
can play a role in Nrf2 activity. A recent report by He and Ma suggested 
that Nrf2 cysteine residues can function as sensors in response to 
cellular stress (He et ol. 2009). The report shows that known ARE 
inducers, arsenic and phenylarsine oxide (PAO), are able to induce Nrf2 
activation by binding to Nrf2 cysteine residues. The mutation of Nrf2 
cysteines to alanine (C235A, C311A-C316A, C414A or C506A) also shows 
an inhibition of the binding of PAO. Furthermore, arsenic induction of 
Nrf2 and NQOl proteins was reduced by introducing mutation at C191A, 
C235A, C311A/C316A, C414A and C506A (He et al. 2009). However, 
more work has to be done to fully consolidate these findings and 
elucidate how Nrf2 cysteine residues play a role in the Nrf2 response to 
cellular stress.
1.6.2.4 The role and structure of Keapl
Keapl is the inhibitory protein of Nrf2. It binds to the Neh2 
domain of Nrf2, sequestering it in the cytoplasm under homeostatic 
conditions (Itoh et oi. 1999b), and has similar sequence motifs found on 
the actin-binding Kelch protein in Drosophila (Xue et al. 1993). By 
binding to the actin cytoskeleton, Keapl is located in the cytosol of the 
cells (Kang et al. 2004). The Keapl protein, similar to Nrf2, is highly 
conserved in vertebrates (Fig 1.8) (Kobayashi et al. 2002) and it contains 
five domains, but only three of which are functional (Table 1.3). The 
human and mouse Keapl proteins are cysteine-rich, consisting of 27 and 
25 cysteines, respectively. The ratio of cysteines to other amino acids is 
4.3% and 4.0% in human and mouse Keapl respectively. This is above 
the average of 2.3% across all human and mouse proteins (Miseta et al.
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2000). Furthermore, many Keapl cysteine residues are flanked by one or 
more basic amino acids (arginine, lysine, histidine), resulting in them 
having low predictive pKa values and therefore making them highly 
reactive (Snyder et al. 1981). Keapl has not only been suggested to 
serve as the regulator of Nrf2 but also to act as a 'sensor' for chemical 
and oxidative stresses (Prestera et al. 1993a; Talalay et al. 1995). The 25 
Keapl cysteines within the mouse protein are represented schematically 
in Fig 1.8.
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1 61 180 315 599
N-term BTB IVR DGR C-term
Figure 1.8: Schematic representation of Keapl domains. The five 
domains are represented by red boxes with each domain labelled. The 
line above represents the numbered Keapl cysteine residue.
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Domain Location
in mouse 
Keapl
Functions References
BIB (Broad 
complex/Tramt 
rack/Bric-a- 
brac)
67-178 Keapl homodimerisation 
Cul3 ligase interaction
(Zipper et al. 
2002; Cullinan 
et al. 2004b)
IVR
(Intervening
region)
179-321 Cysteine-rich region (8 
cysteine residues in 102 
amino acids)
DGR (double 
glycine 
repeats)
322-608 Contains 6 double glycine 
repeats
Interactions with Nrf2
Neh2 domain
Binds to actin 
cytoskeleton
(Itoh et al. 
1999b; Kang 
et al. 2004; Li 
et al. 2004; 
McMahon et 
al. 2006; Tong 
etal. 2006a)
Table 1.3: Keapl functional domains.
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1.6.2.5 The evidence for the chemical modification of Keapl cysteine 
residues in the regulation of IMrf2 activity
There has been compelling evidence that shows reactive 
chemicals are able to modify sulphydryl groups resulting in the 
activation of the Keapl/Nrf2 pathway. This evidence was provided 
through the use of biotinylated Nrf2 inducing compounds (Itoh et al. 
2004; Levonen et al. 2004), spectroscopic binding experiments and mass 
spectrometry {Dinkova-Kostova et al. 2002). These chemicals have been 
shown to react with the recombinant Keapl by binding to cysteine 
residues, leading to activation of Nrf2 in vitro (Dinkova-Kostova et al. 
2002; Dietz et al. 2005; Eggler et al. 2005; Hong et al. 2005a; Hong et al. 
2005b; Liu et al. 2005; Luo et al. 2007; Coppie et al. 2008a). Chemically- 
reactive compounds can also bind to Keapl cysteines selectively in living 
cell-based models (Hong et al. 2005a; Coppie et al. 2008a; Rachakonda 
et al. 2008).
Amongst all of the Keapl cysteine residues that can be modified 
by chemicals, there are four cysteines (Cys257, Cys273, Cys288 and 
Cys297) located in the IVR domain, that have been consistently 
suggested to be highly sensitive and to be the ultimate effector of Nrf2 
response (Dinkova-Kostova et al. 2002). Two out of these, Cys273 and 
Cys288, have been demonstrated to be important for the repressive 
activity of Keapl under basal conditions (Zhang et al. 2003; Levonen et 
al. 2004; Wakabayashi et al. 2004; Kobayashi et al. 2006a; Yamamoto et 
al. 2008). Mutatgenesis studies in vitro show that the mutation of 
cysteines 273 or/and 288 to serine or alanine does not affect the 
association between Keapl and Cul3 ligase (Kobayashi et al. 2004a) but 
it does abrogate the ubiquitination of Nrf2 by Cul3 ligase and 
subsequent proteasomal degradation, which is also observed by us in
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the Centre for Drug Safety Science (CDSS) (unpublished data). This 
therefore permits Nrf2 accumulation and transcription of cytoprotective 
genes (Zhang et al. 2003; Levonen et al. 2004; Wakabayashi et al. 2004; 
Kobayashi et al. 2006a) and in vivo (Yamamoto et al. 2008). Another 
cysteine, CyslSl, which has not been identified as part of the highly 
sensitive cysteine group mentioned previously, has also been postulated 
to be highly sensitive as well (Eggler et al. 2005). CyslSl, which is 
located within the BIB domain of Keapl, also appears to play an 
important role in the repression of Nrf2 during chemical and oxidative 
stresses (Zhang et al. 2003; Zhang et al. 2004; Eggler et al. 2005). The 
CyslSl mutation to serine causes the abrogation of Nrf2 stabilisation to 
the presences of Nrf2 inducers (Zhang et al. 2003; Gao et al. 2007). It has 
been suggested that the inhibition of Nrf2 ubiquitination during cellular 
stress was due to the covalent modification of CyslSl which resulted in 
the dissociation of Cul3 ligase from Keapl (Rachakonda et al. 2008). 
Hence, the evidence shown suggests strongly that the chemical 
modification of Keapl cysteine residues, especially CyslSl, Cys273 and 
Cys288, may be important in the activation of Nrf2. However, there is 
also the possibility that oxidative stress without 
drugs/electrophiles/reactive intermediates binding to cysteines can also 
activate Nrf2. It has been postulated that the oxidation of one or more 
cysteines in Keapl can lead to the formation of sulphenic acid and the 
eventual formation of cysteine disulphide linkages (Wakabayashi et al. 
2004). It has been shown that the depletion of GSH, without covalent 
binding to Keapl, can also lead to Nrf2 activation (Copple et al. 2008a). 
Therefore, the generation of CRMs may either form covalent adduct 
with Keapl or induce cysteine oxidation within Keapl by GSH depletion 
to activate Nrf2.
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1.6.2.6 Keapl regulation and the interaction with Nrf2
A two-site substrate recognition 'hinge and latch' model was 
recently proposed to be a key regulatory mechanism of Nrf2 regulation 
under homeostatic or stressed conditions (Tong et al. 2006a; Tong et al. 
2006b). Keapl has been suggested to exist as a homo-dimer 
intracellularly (McMahon et al. 2006), and that this binds to Nrf2 at a 2:1 
ratio (Wakabayashi et al. 2004; Lo et al. 2006; Tong et al. 2006a). Keapl 
binds to Nrf2 through the Neh2 domain. This interaction is permitted via 
the strong affinity ETGE motif (Kobayashi et al. 2002), the 'hinge' that 
allows Nrf2 to move freely in space (McMahon et al. 2006), and via the 
weaker affinity DIG motif, the 'latch' that positions Nrf2 for the 
ubiquitination of lysine residues (McMahon et al. 2006; Tong et al. 
2006a). In line with this, the deletion or mutation of the ETGE motif 
attenuates the binding between Keapl and Nrf2, resulting in an 
abrogated degradation of Nrf2 and subsequent accumulation (Kobayashi 
et al. 2002; Kobayashi et al. 2004a; Furukawa et al. 2005). On the 
contrary, the deletion or mutation of the DIG motif does not affect the 
binding between Keapl and Nrf2 but it still abolishes Nrf2 degradation 
which also results in the accumulation of Nrf2 (McMahon et al. 2004; 
McMahon et al. 2006).
Nrf2 inducers can also activate the Keapl/Nrf2 pathway by 
promoting the accumulation of Nrf2 in the cytoplasm and nucleus. 
However, there is currently no evidence to suggest that they cause the 
complete disruption between Keapl and Nrf2 binding which results in 
the release of Nrf2 (Zhang et al. 2003; Zhang et al. 2004; Eggler et al. 
2005; Kobayashi et al. 2006a). Indeed, evidence suggests that these Nrf2 
inducers may actually increase the interaction between Keapl and Nrf2, 
probably through the reduction of Keapl-bound Nrf2 degradation (Hong
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et al. 2005b; Hu et at. 2006; Kobayashi et al. 2006a). This is noticeable 
when protein synthesis is inhibited by cyclohexamide. Nrf2 nucleus 
accumulation is inhibited when cells are exposed to tBHQ, suggesting 
that de novo Nrf2 protein synthesis and not Nrf2 released from Keapl 
accumulates in the nucleus (Kobayashi et al. 2006a). Under conditions of 
cellular stress, the ubiquitination of Nrf2 is attenuated through the 
disruption of the Nrf2/Keapl/Cu!3 ligase complex in the 'hinge and 
latch' model (Zhang et al. 2004; Hu et al. 2006; Kobayashi et al. 2006a). 
The disruption of the complex is suggested to occur via the loss of the 
DLG motif interaction from Keapl resulting in a conformational change 
via cysteine modification (McMahon et al. 2006; Tong et al. 2007). Due 
to the disruption of the Nrf2/Keapl/Cul3 ligase complex, Nrf2 is no 
longer targeted for ubiquitination and is therefore degraded. However, 
in this situation, Nrf2 is still bound to Keapl via the ETGE motif. Thus, 
Keapl is saturated and newly synthesised Nrf2 proteins are allowed to 
accumulate within the nucleus and induce the transcription of IMrf2- 
dependent genes (Fig 1.9) (Tong et al. 2006b). The evidence presented 
in this chapter support the major role played by the Keapl/Nrf2 
pathway activated during cellular stress as part of a targeted cellular 
defence response.
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Figure 1.9: The 'hinge and latch' model of Nrf2 activation. Under basal 
conditions, the Keapl homodimer, consists of BIB, IVR and DGR 
domains, binds to the ETGE and DIG motifs within the Nrf2 molecule, 
allowing Nrf2 ubiquitination and proteasomal degradation (a). In the 
presence of cellular stress, the modification of cysteines by electrophiles 
or from oxidative stress causes the disruption of the weaker affinity DIG 
motif (latch), probably through the induced conformational change in 
Keapl, while the binding of the stronger affinity ETGE motif (hinge) 
remains. The Nrf2 protein is still able to bind to Keapl but is no longer 
being ubiquitinated and degraded. Hence, Keapl is saturated with Nrf2 
and newly synthesised Nrf2 can accumulate within the nucleus and lead 
to the transcription of cytoprotective genes (b). Adapted from (Tong et 
al. 2006b).
1.7 THE SYNCHRONIZED CELLULAR DEFENCE RESPONSE AGAINST 
CELLULAR TOXICITY
The cellular defence response consists of a variety of proteins 
such as the GSH biosynthetic enzymes, phase I and II enzymes, 
transcription factors and heat shock proteins (see Fig 1.10). Phase I or 
CYP450 enzymes form part of the cellular detoxification pathway. 
However, the generation of CYP450-dependent CRMs may still occur, as 
seen with the formation of NAPQI from APAP. These can be quenched 
by GSH and GSTs, or metabolised by Phase II enzymes, which also serve 
as a cellular detoxification pathway. Both pathways are part of the first 
line of cellular defence. If both pathways are overwhelmed, the 
transcription factors involved in cellular defence will be activated. These 
are the CMC family, NF-kB family, AP-1 family and HSF. The CNC family is 
made up of Nrfl, Nrf2 and NrfS. Nrf2 in particular plays a major role in 
cellular defence by inducing the transcription of phase II metabolising 
enzymes and anti-oxidant proteins. The NF-kB family may play a role in 
cellular defence through the induction of anti-oxidant proteins, although 
its activity has been shown to be inhibited by CRMs. The AP-1 family has 
also been observed to protect cells by inducing the transcription of anti-
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oxidant and GSH synthesis proteins. Heat shock proteins have been 
shown to be upregulated by cellular stress and to protect cells. HO-1 
(HSP32), HSP25 and HSP70I have been reported to be induced during 
cellular stress and decrease cellular toxicity.
In conclusion, to respond to reactive drug metabolites, cells 
possess both basal and inducible layers of cell defence (Fig 1.3). Both 
forms of cellular defence play an important role in the cytoprotection of 
cells against the generation of reactive metabolites that may cause cell 
damage with the potential for ultimately triggering adverse effects.
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Figure 1.10: Schematic overview of the proteins involved in cellular 
defence, with an emphasis on redox-sensitive transcription factors 
involved in the APAP mechanism of hepatotoxicity. The first line of 
defence: APAP is bioinactivated by UDP-glucuronosyltransferase and 
sulphotransferase to the glucuronide and sulphate conjugates. Some of 
the APAP dose will be bioactivated by CYP450 to NAPQI. The generation 
of NAPQI is normally rapidly quenched by GSH/GSTs. During GSH 
depletion, where APAP reaches high levels, excess NAPQI generated can 
either activate or inhibit second line defence. Second line of defence: 
activated transcription factors include Nrf2, AP-1 and HSF which enable 
the transcription of cytoprotective proteins, antioxidants, GCLc, GCLm 
phase II enzymes and HSPs. NF-kB is inhibited by NAPQI which may lead 
to the inhibition of antioxidant transcription but may also down-regulate 
the anti-apoptotic role of NF-kB. However, this remains to be proven. 
Furthermore, inhibited NF-kB may not be able to bind to CYP450 nuclear 
receptors and suppress the transcription of CYP450. This could 
potentially result in an increase in CYP450 and an elevated formation of 
reactive drug metabolites, although, again this mechanism is still 
unproven (Blazka et al. 1995; Salminen et al. 1997a; Boulares et al. 1999; 
Tian et al. 1999; Kitteringham et al. 2000; Ke et al. 2001; Chiu et al. 
2003; Goldring et al. 2004; Sumioka et al. 2004; Zhou et al. 2005; Gu et 
al. 2006; Zhou et al. 2006; Copple et al. 2008a; Randle et al. 2008).
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1.8 THESIS AIMS
The liver can defend itself against chemical or oxidative stress 
triggered by drugs or their reactive metabolites, through the 
upregulation of its defence response. In order to remove the toxic insult 
as a result of cellular stress, the hepatic defence response will trigger a 
series of different tiers of defence. The adaptive defence tier is partly 
regulated by a group of transcription factors which play a critical role in 
the defence response against cell stress. Hence, understanding the 
molecular mechanisms that underlie the activation of these 
transcription factors is important in elucidating the events leading to the 
progression and consequences of cell damage, liver injury and possibly 
DILI. Two of the key pathways involved in these regulations are 
Keapl/Nrf2 and NF-kB.
A limited degree of inter-individual variability in the Keapl/Nrf2 
pathway has been observed within the human population. 
Polymorphisms in the promoter region of NRF2 gene in humans 
(Yamamoto et al. 2004; Arisawa et al. 2007; Marzec et al. 2007; Arisawa 
et al. 2008; Hua et al. 2010) and mice (Cho et al. 2002) have been 
identified, and these mutations are linked with an increase in 
susceptibility to some diseases (Cho et al. 2002; Arisawa et al. 2007; 
Marzec et al. 2007; Arisawa et al. 2008; Hua et al. 2010), such as 
hypoxia, chronic obstructive pulmonary and peptic ulcer diseases. 
Currently, there is no evidence of predisposing polymorphisms in the 
human or mouse KEAP1 genes. On the other hand, cancer development 
related to somatic Nrf2 mutations have been observed in lung, 
laryngeal, oesophageal and skin carcinomas (Kim et al. 2010b), and loss- 
of-function somatic mutations in KEAP1 resulting in uncontrolled Nrf2 
activation have been identified in lung, breast and bile duct cancer cell 
lines, bile duct and gall bladder primary tumours and also in lung cancer
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patients (Padmanabhan et al. 2006; Singh et al. 2006; Nioi et al. 2007; 
Shibata et al. 2008). Hence, variability can influence cellular defence and 
it is important to determine how the Keapl/Nrf2 pathway is activated, 
as well as how its threshold is set for prevention of cellular damage. By 
understanding how ceils defend themselves, we may ultimately begin to 
explore the question as to whether individuals are more prone to 
damage if this normal pathway is perturbed.
Furthermore, little is known regarding the control of this 
pathway in the context of the key transcription pathway NF-kB, crucial 
to how hepatocytes respond to chemical injury. Therefore, the aims of 
this thesis are to: 1) Explore the simultaneous regulation of transcription 
factors Nrf2 and NF-kB under cellular stress, and therefore the balance 
between cell protection and cell death. 2) To explore further the 
mechanism(s) of Nrf2 activation, either by (i) cysteine modifications 
within Keapl or (ii) GSH depletion without concomitant Keapl cysteine 
modification, through the usage of a panel of chemicals. 3) To evaluate 
novel click compounds in the investigation of Nrf2 activation. 4) To 
establish the Keapl thiol status during basal conditions and 5) to begin 
to address the question do the Keapl cysteines undergo oxidation as 
well as covalent modification during chemical or oxidative stress?
Addressing these aims will improve the understanding of the role 
of both pathways regulated during chemical stress and may gain further 
insight into the role of cellular protection during DILI.
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CHAPTER 2
Differential effect of covalent protein modification 
and glutathione depletion on the transcriptional 
response of Nrf2 and NF-kB
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2.1 INTRODUCTION
Man is constantly exposed to chemical stress which can be 
exacerbated by the increasing use of therapeutic drugs. However, under 
extreme level of exposure, such as an overdose, manifestation of toxicity 
may occur. The mechanisms underlying the toxicity associated with 
exposure to these therapeutics agents are not clearly defined but are 
likely to involve chemical stress and/or oxidative stress. Chemical stress 
comprises the generation of a reactive drug metabolite from its parent 
compound and subsequent covalent modification of critical proteins 
(Zhou et ol. 2005). Oxidative stress is the generation of reactive oxygen 
species from the metabolism of drugs by cytochrome P450 enzymes and 
through mitochondrial uncoupling, but it may also arise from 
mitochondria permeability transition. (Jaeschke etal. 2002). Hence, both 
chemical and oxidative stress can evoke cellular defence response via 
transcription factors during drug induced liver injury (DILI).
DILI is a major cause of hospital admissions (Pirmohamed et a/. 
2004), and one of the principal reasons for attrition of new chemical 
entities (Park et al. 2005a). For example, acetaminophen (APAP), a 
commonly used analgesic known to induce liver injury on overdose, 
accounts for the most common form of acute liver failure in the United 
States (Ostapowicz eta/. 2002). A proportion of the pathogenesis of DILI 
may occur through the generation of chemically reactive metabolites 
(CRMs), usually formed through oxidative metabolism of drugs by phase 
1 enzymes (Park et al. 2005a). CRMs can covalently modify critical 
proteins, and bind to and deplete glutathione (GSH), the predominant 
cellular redox buffer. This causes disturbance to the cellular redox 
potential yielding a more oxidising environment (DeLeve et al. 1991). 
Although there are defence mechanisms present to counter such
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disturbances (Prestera et al. 1995), if the chemical challenge is 
overwhelming and the defence is breached, a switch from cell defence 
to cell death is favoured either by apoptosis or necrosis [for a review, 
see (Park et al. 2005a)]. Thus, a cell will defend itself where possible, but 
under extreme conditions it may allow itself to die. The ability of a cell to 
respond to chemical stress occurs at least partially through the 
activation of transcription factors. These transcription factors are 
constitutively present in the celt or are rapidly synthesised when 
required, facilitating the upregulation of proteins implicated in cell 
defence or cell death. Nuclear factor-erythroid 2 (NF”E2)-related factor 
(Nrf2) and NF-kappa B (NF-kB) are two redox-sensitive transcription 
factors, which have been extensively investigated with aim to determine 
the role of transcriptional adaption to chemical stress.
Nrf2 plays a crucial role in cellular defence, and is the major 
regulator of antioxidant response elements (AREs) present in the 
regulatory region of the majority of cytoprotective genes (Itoh et al. 
1997). Under basal conditions, Nrf2 is sequestered by Keapl in the 
cytoplasm (Itoh et al. 1999b), and is constitutively targeted for 
ubiquitination by the CullinB-dependent E3 ubiquitin ligase complex, 
which results in its subsequent proteasomal degradation (Zhang et al. 
2004). Under certain stress conditions, such as exposure to electrophiles 
or an increase in reactive oxygen species (ROS), cysteine residue on 
Keapl are readily modified. This suggests that Keapl undergoes a 
conformational change, blocking Nrf2 ubiquitination and enabling 
nuclear accumulation of Nrf2 and transactivation of ARE-dependent 
genes (Dinkova-Kostova et al. 2002; Zhang et al. 2003).
Nuclear factor kappa-light-chain-enhancer-of activated B cells 
(NF-kB) comprises five members belonging to the mammalian NF-kB
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family, i.e., p65 (Rel A), RelB, c-Rel, p50/pl05 (NF-kB1) and p52/pl00 
(NF-KB2). NF-kB exists in the cytoplasm of unstimulated cells as homo- 
or hetero-dimers, bound to a family of inhibitory proteins known as 
IkappaB (IkB) via non-covalent interactions. The predominant hetero­
dimer present in cells is p65/p50 dimer (Hayden et al. 2004). Upon 
stimulation, the IkB kinase (IKK) complex which consists of a complex 
with two subunits, IKKct and IKKfJ, and a regulatory subunit, NF-kB 
essential modifier (NEMO) (Mercurio et al. 1999), phosphorylates IxB-a 
(Brockman et al. 1995). Upon phosphorylation, IxB-a is targeted for 
ubiquitination and directed for proteasomal degradation (May et al. 
1998). This allows the release of NF-kB and its nuclear accumulation 
resulting in the transcription of genes involved in the inflammatory 
response, cell proliferation, cell survival and to a limited degree, the 
anti-oxidant response.
To date, there is little evidence for simultaneous regulation of 
Nrf2 and NF-kB within cells and little is known about the cellular 
consequences of such co-regulation. It may be valuable to understand 
what is happening to both transcription factors simultaneously to begin 
to understand the likely mechanisms that occur when a cell is exposed 
to chemical stress. I have attempted to begin to explore the role of 
simultaneous regulation of these two transcription factors through the 
experiments presented in this chapter, which are designed to investigate 
the functional outcome of chemical stress/protein modification on the 
transcription factors as well being informative of how the cells actually 
detect these stresses. In this study, I hypothesised that the balance 
between both transcription factors might serve as a key cytoprotective 
mechanism to detect and respond to cell stress, where activation or
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inhibition of NF-kB, or Nrf2, or both transcription factors, may dictate 
the cellular response to stress.
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2.2 MATERIALS AND METHODS 
2.2.1 Materials
The mouse hepatoma cell line, Hepa-lclc7 was obtained from 
American Type Culture Collection (Manassas, VA, USA). The rabbit anti­
mouse Nrf2 primary antibody was kindly donated by Professor John 
Hayes (Biomedical Research Centre, University of Dundee, UK). The 
recombinant mouse His-tagged Nrf2 was kindly donated by Dr Ian 
Copple (MRC Centre of Drug Safety Science, University of Liverpool, UK) 
Rabbit anti-mouse NF-kB p50, monoclonal anti-mouse NF-kB p65. Goat 
anti-mouse Keapl primary antibodies were from Santa Cruz 
Biotechnology (Heidelberg, Germany). Rabbit anti-goat HRP-conjugated 
secondary antibody was from Dako UK (Ely, UK). DMEM and 
trypsin/versene were from Lonza Biologies (Slough, UK). The Wilovert 
D6330 light microscope was from Wili-Wetziar (Wetzlar, Germany). The 
SP2 AOBS confocal microscope was from Leica Microsystems (Milton 
Keynes, UK). Nunclon A cell culture flasks, dishes, multi-well plates and 
LabTek II chamber slides were from Nalge-Nunc International (c/o VWR 
international, Lutterworth, UK). Vectashield was from Vector 
Laboratories (Peterborough, UK). Protein assay dye reagent, Precision 
Plus protein Kaleidoscope standards, non-fat dry milk, Mini Trans-Blot 
Cell and the GS-710 calibrated imaging densitometer were from Bio-Rad 
(Hemel Hempstead, UK). FBS, NuPAGE Novex 4-12% Bis-Tris gels, 
NuPAGE LDS sample buffer, sample reducing agent and antioxidant, 
XCell Surelock mini-cell, Hoechst 33258, Lipofectamine 2000, NF-kB p65 
and control RNAi duplexes were from Invitrogen (Paisley, UK). The Nrf2, 
Keapl and control RNAi duplexes were from Dharmacon (Lafayette, 
USA). The Cytotoxicity Detection Kit was from Roche Diagnostics 
(Burgess Hill, UK). The MRX microplate reader was from Dynatech 
Laboratories (Billingshort, UK). The TotalLab 100 software was from
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Nonlinear Dynamics (Newcastle, UK). Western Lightening Enhanced. 
Chemiluminescence reagents and adenosine 5'-triphosphate, [y-32P] 
ATP were from Perkin Elmer (Seer Green, UK). The Hybond nitrocellulose 
membranes, Hyperfilm HCL, Hoefer SE600 Ruby electrophoresis system 
and Polydeoxy(lnosinate-Cytidylate) Acid, Sodium Salt were from GE 
Healthcare Life Sciences (Little Chalfont, UK). Storage Phosphor Screen, 
Phosphor Imager and ImageQuant software were from Molecular 
Dynamics (Sunnyvale, CA). Consensus NF-kB oligonucleotide, T4 
Polynucleotide Kinase and buffer were from Promega (Southampton, UK). 
Penicillin-streptomycin solution, Trypan Blue solution, NAPQI, DNCB, 
DMSO, BSO, BSA, MOPS, DTNB, GSH, NADPH, GSH reductase, (3- 
mercaptoethanol, Triton X-100, spermidine, spermine, protease 
inhibitor cocktail, the rabbit anti-actin primary antibody, the goat-anti 
rabbit HRP-conjugated secondary antibody, anti-rabbit IgG (whole 
molecu!e)-FITC antibody produced in goat, anti-mouse IgG (whole 
molecuie)-FITC antibody produced in goat, the Kodak BioMax MS 
intensifying screen, Kodak developer and fixer solution, Ponceau S 
solution, Tween 20, PBS tablet, paraformaldehyde, sulphosalicyclic acid, 
HEPES and Coomassie Brilliant Blue G-250 dye were from Sigma-Aldrich 
(Poole, UK). All other reagents were of analytical or molecular grade and 
were from Sigma-Aldrich.
2.2.2 Cell Culture and Cell Count
The mouse hepatoma cel! line, Hepa-lclc7, which has been 
employed by others in previous studies of the Keapl/Nrf2 pathway 
(Jowsey et al. 2003; Natsch et at. 2008; He et at. 2010; Nguyen et at. 
2010) and NF-kB pathway (Korashy et al. 2008), was maintained at 37°C 
in a 5% COz atmosphere in conventional growth medium Duibecco's 
modified Eagle's medium (DMEM) supplemented with 584mg/L L-
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gutamine, 10% fetal bovine serum (FBS), 100 U/ml penicillin, and 
lOOug/ml streptomycin. Cells were grown in 75cm2 Nunclon A culture 
flasks and routinely passaged every 2-3 days, at around 80% confluency. 
Following a wash with unsupplemented DMEM, cells were incubated 
with 5ml of trypsin/versene for Imin at room temperature. Removal of 
trypsin/versene and the cells were returned to the incubator for 5min 
allowing sufficient time to enable complete detachment of cells from 
the flask surface. Cells were then resuspended in 10ml growth medium 
and homogenised five times through a 21-gauge needle, using a 10ml 
syringe to break up any cell clumps. For continuation, cells were re­
seeded at a cells:growth medium ratio of 1:4.
Cells were counted using Trypan Blue solution (0.4% 
weight/volume; w/v) and a haemocytometer to ensure that an accurate 
numbers of cells were seeded. Cells were detached as mentioned above, 
45pl aliquot of cells was combined with 5}xl Trypan Blue solution. lOpI of 
this mixture was transferred to the edge of a haemocytometer. Cells 
were visualised using 20X objective of a Wilovert D6330 light 
microscope. Viable cells (no Trypan Blue dye up take) within the central 
5x5 square (equivalent to 0.1mm3) were counted and the original cell 
density was calculated as follows: Number of cells counted x 1.1 (to 
correct for dilution with Trypan Blue solution) = cells per 0.1mm3 x 
10,000 = cells per 1cm3 = cells per 1ml
2.2.3 Cell Treatment
Hepa-lclc7 cells were seeded onto 96-well plates, 24-well 
plates, 56.7cm2 Nunclon A culture dishes at 2 x 104 cells/well, 2 x 10s 
cells/well, 5 x 106 celis/dish respectively on the previous day. Cells were 
washed once with unsupplemented DMEM and then 99|il, 495pl and 
9.99ml of unsupplemented DMEM was added to 96-well plates, 24-well
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plates and culture dish, respectively. IM-acetyl-p-benzoquinoneimine 
(NAPQI) and dinitrochlorobenzene (DNCB) were dissolved in dimethyl 
sulfoxide (DMSO) except for buthionine sulfoximine (BSO), which was 
dissolved in dHzO, at lOOx the final concentration. To each dish, 10p.l of 
the dissolved compounds or DMSO were added (1:1000 dilutions). For 
96-well plates and 24-well plates, all compounds or DMSO were further 
diluted 10-fold in unsupplemented DMEM, and then Ipl and 5pl were 
added to each well (1:100 dilution) respectively. The overall 
concentration of DMSO in the cell culture medium was 0.1% 
(votume/volume; v/v). The cells were then placed back in the incubator 
for the indicated time.
2.2.4 Preparation of cytosolic and nuclear extracts and whole cell 
lysates
After treatment, cells were washed once with unsupplemented 
DMEM, removed from the surface of the culture dish by scraping and 
resuspended in 1 ml buffer A (lysis; 50mM NaCI, lOmM 4-(2- 
hydroxyethyl)-l-piperazineethanesulfonic acid (HEPES), ImM 
ethylenediaminetetraacetic acid (EDTA), O.SrnM sucrose, O.SmM 
spermidine, O.lSmM p-mercaptoethanol, 0.2% (v/v) protease inhibitor 
cocktail, 0.2% (v/v) Triton X-100). Lysates were centrifuged at 3500rpm, 
40C, for 5min, and the supernatant was retained as the cytosolic 
fraction. For nuclear protein extraction, the pellet was washed in 0.5ml 
buffer B (wash; 25% (v/v) glycerol, 50mM NaCI, lOmM HEPES, ImM 
EDTA, O.SmM spermidine, O.lSmM spermine, lOmM (3- 
mercaptoethanol, 0.2% protease inhibitor cocktail) and centrifuged at 
3500rpm, 4°C, for 5min. Following removal of the supernatant, the 
pellet was resuspended in 0.1ml buffer C (extraction; 0.35M NaCI, 25% 
(v/v) glycerol, lOmM HEPES, ImM EDTA, O.SmM spermidine, O.lSmM
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spermine, 10mM p-mercaptoethanol, 0.2% protease inhibitor cocktail) 
and incubated on ice for 30min, to facilitate the osmotic extraction of 
nuclear proteins, which was clarified with a final centrifugation at 
3500rpm, 4°C, for Smin (Dignam et al. 1983). All subcellular fractions 
were stored at -80°C before analysis.
For whole cell lysate preparation, cells were lysed with 0.1m! 
radioimmunoprecipitation assay (RIPA) buffer (0.15M NaCI, 1% (v/v) NP- 
40, 0.5% (v/v) sodium deoxycholate, 0.1% (v/v) SDS, 25mM Tris-CI, 0.2% 
(v/v) protease inhibitor cocktail) and incubated on ice for Smin before 
storing at -80°C to quick freeze cells. Clarification before analysis was 
necessary as freeze-thaw cycles may denature protein aggregates. Cell 
lysates were clarified with centrifugation at 3500rpm for lOmin to pellet 
cell debris.
2.2.5 Measurement of protein content
The total protein content of cytosolic and nuclear fractions was 
determined using Protein Assay Dye Reagent based on the method of 
Bradford (Bradford 1976). This assay relies on the binding of Coomassie 
Brilliant Blue G-250 dye to basic and aromatic amino acids, that results 
in a change in dye colour from red to blue, and a consequent change in 
absorbance maximum from 465 to 595nm. Hence, the increase in 
absorbance at 570nm, measured using a MRX microplate reader, is 
proportional to the amount of dye and to the amount of protein 
present. A standard curve, ranging from 0.0125 - 0.25|ng bovine serum 
albumin (BSA) was used to calculate the protein content.
2.2.6 Western immunoblotting
Cytosolic (ISpg) or nuclear extracts (5pg) or whole cell 
lysates(lOpg) were added to 5pl loading buffer (70% (v/v) NuPAGE 
sample loading buffer, 30% (v/v) Nupage reducing agent) and denatured
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by incubating at 80°C for 5min. Samples were loaded onto pre-cast 4- 
12% NuPAGE Novex bis-tris ployacrylamide gels, alongside PrecisionPlus 
Protein Kaleidoscope standards. Samples were resolved by 
electrophoresis in a XCell Surelock mini-cell, using a 3-(N- 
morpholino)propanesulphonic acid (MOPS) running buffer (50mM 
MOPS, 50mM tris base, 3.5mM sodium dodecyl sulphate, ImM EDTA, 
0.25% (v/v) NuPAGE antioxidant), running at 90V for lOmin, followed by 
60min at 170V. Separated proteins were transferred to Hybond 
nitrocellulose membranes using Bio-Rad Mini Trans-Blot cell, in 
accordance with the manufacturer's instructions. To determine that the 
transfer process was successful, membranes were stained with Ponceau 
S solution for lOsec. Membranes were blocked for 15min with 10% 
(w/v) non-fat dry milk (Bio-Rad) in tris-buffered saline (TBS; 0.15M NaCI, 
25mM Tris base, 3mM KCI, pH 7.0) containing 0.1% (v/v)Tween 20. 
Blocked membranes were probed with rabbit anti-mouse Nrf2 (1:5000 
in TBS-Tween containing 2% (w/v) BSA) or anti-goat Keapl (1:2000 in 
TBS-Tween containing 2% (w/v) BSA) for Ihr. After several washes, 
membranes were probed with goat anti-rabbit or rabbit anti-goat 
(1:10000 in TBS-Tween containing 2% (w/v) non-fat dry milk) 
horseradish peroxidise (HRP)-conjugated secondary anti-IgG for Ihr. 
Western blots were visualised using Western Lightening Enhanced 
chemiluminescence reagent and exposed to Hyperfilm ECL under 
darkroom conditions, using a Kodak BioMax MS intensifying screen and 
developed using Kodak developer and fixer solutions. All blots were also 
probed with rabbit anti-(3-actin primary (1:5000 in TBS-Tween containing 
2% (w/v) BSA) and goat anti-rabbit HRP-conjugated secondary anti-IgG 
for Ihr to ensure equal loading. Recombinant mouse His-tagged Nrf2 (+ 
con) was loaded as a standard to confirm antibody specificity. Western 
blot films were scanned using a GS-710 calibrated imaging densitometer.
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western blot band volumes were quantified using TotalLab 100 software 
and normalised against actin.
2.2.7 NF-kB Electrophorectic mobility shift assay (EMSA)
A consensus NF-kB wild type (WT) oligonucleotide probe 5' to 3' 
strand: (S'-AGT TGA GGG GAC ITT CCC AGG C-3') (Lenardo et al. 1989) 
was 5' end-labelled with adenosine 5'-triphosphate, Ey-32P] ATP. The 
oligonucleotide labelling was prepared by addition of 20% (v/v) NF-kB 
WT probe (1.75pmol/pL) to 10% (v/v) T4 Polynucleotide Kinase 10X 
buffer, 10% (v/v) [y-32P] ATP (2501101), 50% (v/v) water and 10% (v/v) T4 
Polynucleotide Kinase (5-10U/ul). The labelled oligonucleotide was 
incubated for 20min at 37°C; the reaction was terminated by the 
addition of 10% (v/v) 0.25M EDTA and reconstituted in 90% (v/v) IX Tris- 
EDTA buffer. The radiolabelled oligonucleotide was stored at -20°C.
EMSA loading samples consisted of; 5X binding buffer (20% (v/v) 
Ficoll, 100mM HEPES, 175mM NaCI, 300mM KCI, 0.05% (v/v) NP40 and 
lOmM dithiothreitol (DTT)), poly dl.dc (O.lug/ul), nuclear extracts and 
water. The EMSA loading samples were prepared in order indicated in 
table 2.1 and were incubated at room temperature for lOrnin.
5x Binding Buffer 2pl
Poly dl.dc Ipl
Distilled Water make up to volume of lOpI
Nuclear extracts 5pg (volume not greater than 4pl)
Table 2.1: Preparation of EMSA loading samples as indicated.
To the EMSA loading samples, Ipl of radiolabelled oligonucleotide was 
added and incubated at room temperature for 20min. The definition of a 
NF-kB specific shift was made according to the following criteria; 
supershift assays using NF-kB specific antibodies, addition of lp.1 of
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mouse anti-p65 and/or anti-p50 (Santa Cruz) and a control non-specific 
antibody was added to the loading sample. For competition assays, lp.1 
of unlabelled wild-type (WT) or mutant (MUT) (5-AGTTGAGGCGACITT 
CCC AGG C-3') oligonucleotides were added to the loading sample. The 
antibodies, or unlabelled WT and MUT oligonucleotides, were added 
lOmin prior to addition of labelled oligonucleotide. Samples were 
loaded onto a 5% polyacrylamide gel, which was pre-run for 30min at 
160V. The protein-DNA complexes were resolved by non-denaturing 
electrophoresis using a Hoefer SE 600 Ruby vertical electrophoresis 
system for l.Shr at 200V in 0.5x Tris-Borate-EDTA buffer. After 
electrophoresis, the gel was fixed in 10% (v/v) methanol/10% (v/v) 
acetic acid for 30min. The fixed gel was transferred onto a sheet of filter 
paper, covered with Saran wrap and vacuum-dried. Dried gels were 
subsequently exposed to a Storage Phosphor Screen for 12hr, before 
being scanned by a Phosphor Imager. The gels were visualised and 
bands were quantified using ImageQuant software.
2.2.8 Confocal Microscopy
Hepa-lclc7 cells were plated out on Lab-Tek II chamber slides at 
2.5 x 105 cells/chamber for 24hr before treatment. Following treatment, 
cells were washed 2 x 3min with 0.5ml IX phosphate-buffered saline 
(PBS; 0.137M NaCI, lOmM NA2HPO4, 1.8mM KH2PO4, 2.7mM KCI, pH7.4) 
and fixed in 0.5ml fresh 4% (w/v) paraformaldehyde at 4°C for 30min, 
and cells were then washed 4 x 3min with 0.5ml IX PBS. Fixed cells were 
then permeabilised with 0.5ml of 0.2% (v/v) Triton X-100, quenched 
with 0.5ml lOOmM glycine and blocked with 0.5ml of 10% (v/v) FBS, for 
lOmin each. Cells were then incubated with 0.2ml of rabbit anti-mouse 
Nrf2 or monoclonal anti-mouse NF-kB p65 (1:500) in 2% (v/v) FBS at 
37°C for Ihr. Following 3 x 3min washes with 0.5ml IX PBS, cells were
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incubated with 0.2ml of FITC-conjugated goat anti-rabbit or FITC- 
conjugated goat anti-mouse (1:250) in 2% FBS at 37°C for Ihr. Cells were 
washed 3 x 3min again with 0.5ml IX PBS and nuclei DNA were counter- 
stained with 0.2ml of Hoechst 33258 (2ug/ml) in PBS at room 
temperature for lOmin. Cells were then washed 3 x 3min with 0.5ml IX 
PBS. Chambers were detached from the slides using the splitting tool 
provided by manufacturer, and allowed to dry at room temperature for 
5min. Coverslips were mounted using Vectashield hard-set medium in 
accordance with the manufacturer's instructions. Slides were covered 
with aluminium foil and stored at 4°C before confocal analysis. 
Immunofluoresence was visualised using a Leica SP2 AOBS confocal 
microscope.
2.2.9 RNA interference
Short interfering RNA (siRNA) has been used as an analytical tool 
for the study of genes function in mammalian cells. Hence, depletion of 
Nrf2, Keapl and NF-kB in Hepa-lclc7 cells was achieved using RNAi, 
which works on the process of post-transcriptional gene silencing by 
cleavage and degradation of the messenger RNAs (mRNAs) with 
complementary sequences (Leung et ol. 2005). RNAi is triggered when a 
cell encounters a long double stranded RNA (dsRNA) molecule (Fire et al. 
1998). The dsRNA is cleaved by an enzyme called Dicer into shorter 
fragments known as small interfering RNAs (siRNA) consisting of 21-22 
nucleotide. The cleaved siRNAs will produce "sense" and "antisense" 
strand siRNA. The "sense" strand will be degraded and "antisense" 
strand will be incorporated in a RNA-inducing silencing complex (RISC). 
RISC will be activated upon the binding of the "antisense" siRNA and 
degradation of targeted complementary mRNAs (Elbashir et al. 2001; 
Novina etal. 2004; Preall etal. 2005)(Fig 2.1).
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Figure 2.1: Mechanism of RNAi pathway. The RNAi pathway is triggered 
when the cell encounters a dsRNA molecule. The dsRNA is cleaved into 
siRNA by the enzyme, dicer. The sense strand siRNA will be degraded. 
The antisense strand siRNA will be incorporated into RISC which will be 
activated and triggers cleavage of targeted mRNA complementary 
sequence resulting in degradation of mRNA. As a result of this mRNA 
degradation, no protein was translated and gene expression is 
effectively silenced post-transcriptionally. (Adapted from Leung and 
Whittaker, 2005)
Short interfering RNA (siRNA) duplexes targeting mouse Keapl, 
Nrf2 and NF-kB, p65 were used. The siRNA duplexes were as follows; si- 
Nrf2 sense S'- GCA AGA AGC CAG ADA CAA A-3', antisense S'- U UUG 
UAU CUG GCU UCU UGC- 3', si-Keapl sense S'- GCU AUG ACC CGG ACA 
GUG A -3', antisense S'- U CAC UGU CCG GGU CAU AGC - 3', si-p65#l 
sense S'- UUC AUC UCC GGA GAG ACC AUU GGG A - 3', anti-sense 5' - U 
CCC AAU GGU CUC UCC GGA GAU GAA - 3', si-p65#2 sense S'- AGG UUC 
UGG AAG CUA UGG AUA CUG C - 3', anti-sense 5' - UCC AAG ACC UUC 
GAU ACC UAU GAC G - 3', si-p65#3 sense S'- AUA CAC CUC AAU GUC 
UUC UUU CUG C - 3', anti-sense 5' - UAU GUG GAG UUA CAG AAG AAA
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GCA G - 3'. Hepa-lclc7 were plated out onto 96 well plates at 1 x 104 
cells/well for NF-kB sIRNA validation, 96 well plates at 7 x 103 cells/well 
for LDH assay, 24 well plates at 5 x 104 cells/well for GSH assays and 10- 
cm dishes at 4 x 106 cells/dish for nuclear extractions. Cells were 
transfected with lOnM of siRNA directed against Keapl or Nrf2, and 
3nM siRNA against p65 for 48hrs, using Lipofectamine 2000 according to 
the manufacturer's instructions.
2.2.10 Measurement of Lactate Dehydrogenase Leakage
Measurement of cellular cytotoxicity was determined by 
measuring the leakage of the cytoplasmic enzyme lactate 
dehydrogenase (LDH) into the cell culture media. This involves a two- 
step enzymatic process; in the first step, LDH reduces NAD+ to NADH + 
H+ by the oxidation of lactate to pyruvate. The second step is the 
transfer of 2H from NADH + H+ to the yellow tetrazolium salt 2-[4- 
iodophenyl]-3-[4-nitropheny!]-5-phenyltetrazolium chloride by a catalyst 
(diaphorose) which yields a red formazan dye with an absorbance 
maximum of 500nm. Hence, the amount of the red formazan formed 
over time is directly proportional to the LDH activity in the culture 
media, and therefore correlates to the degree of cell death. The amount 
of LDH leakage corresponds to the degree of membrane damage and it 
is normally used as a marker for cellular necrosis.
Hepa-lclc7 cells were plated out on 96-well plates at 2 x 104 
cells/well for 24 hrs or as stated in the RNAi treatment section (section 
2.2.6). Following treatment, the plates were centrifuged briefly at 
SOOOrpm to pellet ceils, and cell-free culture media was removed to a 
new 96-well plate. Cells were lysed with 40pl of DM EM containing 2% 
(v/v) Triton X-100, followed by centrifuged at 3000rpm for 5min. To a 
new 96-well plate, 50pl of cell-free culture media (diluted 1:4 in DMEM)
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and cell lysate (diluted 1:20 in DMEM) were transferred separately. LDH 
leakage was measured using a Cytotoxicity Detection Kit; 50pl assay 
reagent (Ipl catalyst per 45pl dye solution) was then added to each well. 
The plate was incubated in the dark for 30min and air bubbles were 
removed by brief centrifugation of the plates at 3000rpm. Formation of 
red formazan salt was measured at 490nm on a MRX microplate reader. 
Blank readings were obtained from wells containing SOpI DMEM and 
subtracted from the sample readings. LDH leakage from cells into the 
culture medium (extracellular) is expressed as a percentage of total LDH 
(intracellular plus extracellular).
2.2.11 Measurement of Glutathione
Total glutathione (GSH) content was quantified using the 5,5 0- 
dithiobis(2-nitrobenzoic acid) -GSH reductase recycling method, as 
previously described by Vandeputte et al (Vandeputte et al. 1994). In 
this method, GSH is oxidised by DTNB to yield GSSG and the 5-thio-2- 
nitrobenzoic acid (TNB) chromophore (1), which has an absorbance 
maximum of 412nm. GSSG is reduced to GSH by the action of GSH 
reductase in the presence of NADPH (2). Thus, the rate of formation of 
TNB was measured at 405nm, which is proportional to the sum of GSH 
and GSSG present in each sample.
2GSH + DTNB-----► GSSG + TNB (1)
GSSG + NADPH + H+-----► 2GSH + NADP* (2)
Hepa-lclc7 cells were plated out on 24-well plates at 2 x 105cells/well 
for 24hr. Following treatment, ceils were scraped and resuspended in 
0.125ml of lOmM HCI. An aliquot was used to measure total protein 
content as described in section 2.2.5. 6.5% of sulphosalicylic acid was 
added to the remaining samples to a final concentration of 1.3% (w/v),
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and protein precipitation was facilitated by incubating on ice for lOmin. 
Protein was pelleted by centrifugation at 18,000g for 5min. 20|ul 
supernatant was transferred to a clear 96-well plate, and combined with 
20|il of assay buffer (0.143M NaHzPO^ 6.3mM EDTA, pH 7.4) for 5min. 
The enzymatic reaction was initiated by the addition of 0.35U GSH 
reductase and measured kinetically at 405nm for 5min on a MRX 
microplate reader. The rate of TNB formation was calculated as the 
change in absorbance min"1. Sample GSH concentrations were calculated 
via reference to a standard curve ranging from 0-50 mol/mL GSH. The 
GSH concentration for each sample was normalised to total protein 
content.
2.2.12 Data Analysis
Data are expressed as mean ± standard deviation of the mean. 
Normality was assessed by the Shapiro-Wilk Test. The significance of 
differences within the data was assessed by a One-way ANOVA or 
Student's t-test for normally distributed data, and Kruskal-Wallis analysis 
of variance (ANOVA) for non-parametric data. A difference was 
considered significant at p<0.05.
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2.3 RESULTS
2.3.1 NAPQI and DNCB activate Nrf2 but inhibit NF-kB activity
In common with all mammalian hepatoma cell lines, Hepa-lclc7, 
lacks metabolic competence and therefore cannot directly bioactivate 
acetaminophen. Consequently, NAPQI, the chemically reactive 
metabolite of acetaminophen (Dahlin et al. 1984), was used in these 
studies along with DNCB, a model alkylating agent and contact sensitizer 
(Lowney 1971). Both have been previously shown to deplete 6SH and 
covalently bind cellular proteins {Potter et al. 1974; Potter et al. 1986; 
Huang et al. 2001; Aleksic et al. 2007; Copple et al. 2008a). Following a 
Ihr exposure, nuclear accumulation of Nrf2 increased with increasing 
concentrations of NAPQI {Fig 2.2a) and DNCB (Fig 2.2b); an increase in 
Nrf2 after exposure to NAPQI or DNCB has been demonstrated 
previously in the CDSS (Copple et al. 2008a). Immunochemical analysis 
of Nrf2 and NF-KB-p65 cellular localisation shows an increase in NF-kB- 
p65 cellular abundance (Fig 2.8a, second panel) and a clear increase in 
Nrf2 (Fig 2.8b, second panel) accumulation in the nucleus after 1 hr of 
DNCB treatment. These ceils consistently express low but detectable 
levels of NF-kB DNA binding activity (Fig 2.3), however on the contrary to 
Nrf2 expression, NF-kB DNA binding decreased with increasing 
concentrations of NAPQI (Fig 2.3a) and DNCB (Fig 2.3b). Both chemicals 
caused a depletion of total GSH, which fell to 20% of the control at the 
highest dose of NAPQI (Fig 2.4a) and to undetectable levels at the 
highest dose of DNCB (Fig 2.4b). Lactate dehydrogenase (LDH) leakage 
assays show limited leakage after exposure of cells to test compounds 
for Ihr, although this is significant at 300pM of NAPQI (Fig 2.4c). The 
assay demonstrates substantial toxicity at 24hr following exposure to
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concentration of NAPQI at lOO^M and BOOpiM, and with DNCB at all 
concentration between lO^M to 100|iM (Fig 2.4d).
NAPQI [pM]
Figure 2.2: Chemical stress activates Nrf2. Hepa-lclc? cells were 
treated for Ihr with NAPQI (a) or DNCB (b) and nuclear protein resolved 
on SDS-PAGE and probed for Nrf2. NAPQI (a) and DNCB (b) activates 
Nrf2 nuclear accumulation dose-dependently. Actin is shown as loading 
control. Recombinant mouse His-tagged Nrf2 was loaded as a positive 
control on the blot (+con). The bottom panel shows the densitometric 
analysis of Nrf2 positive bands normalised against actin. One-way 
ANOVA, *p<0.05, ***p<0.001. Kruskal Wallis, +p<0.05, +++p<0.001. The 
control cells were treated with 0.1% DMSO. Representative gel from n=3 
is shown. Error bars = Standard deviation of mean, n=3.
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Figure 2.3: Chemical stress inhibits NF-kB. Hepa-lclc? cells were 
treated for Ihr with NAPQI (a) or DNCB (b) and nuclear protein was 
assayed using EMSA for NF-kB activity. NAPQI (a) and DNCB (b) inhibits 
NF-kB binding activity dose-dependently.The EMSA assay was specific 
for the NF-kB protein as addition of a 50-fold excess of wild-type 
oligonucleotide (wt) to the control reaction (Con) displaced the bound 
protein from the radiolabelled oligonucleotide, while this was not 
observed with the addition of excess mutant (Mut) oligonucleotide. The 
addition of specific anti-NF-xB antibody (p65), as opposed to non­
specific antibody (con Ab) to the binding control reaction (Con) caused a 
supershift in the NF-kB band confirming the composition of the NF-kB 
complex. The data demonstrate the densitometric analysis of NF-kB 
normalised against control treatment since normalisation to an internal 
control in EMSA is not possible. Kruskal-Wallis, *p<0.05, ***p<0.001. 
The control cells were treated with 0.1% DMSO. Representative gels 
from n=3 is shown. N.S; non-specific binding.
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Figure 2.4: Chemical stress depletes GSH and induces toxicity over 
24hr. Hepa-lclc? was treated for Ihr with NAPQI (a) or DNCB (b) and 
lysed with lOmM HCL. GSH depletion reaches 80% of control with 
highest dose of NAPQI (a) and 100% of control with highest dose of 
DNCB (b). Total GSH normalised against total protein content. Kruskal 
Wallis, **p<0.01, ***p<0.001. Cells were treated for Ihr with NAPQI or 
DNCB (c) and 24hr with NAPQI or DNCB (d). LDH assay shows minimal 
leakage upon treatment with NAPQI or DNCB for Ihr (c). LDH assay 
shows substantial leakage upon treatment with NAPQI or DNCB (d) after 
24hr. Extracellular LDH activity is expressed as a percentage of total 
(extracellular plus intracellular) LDH activity. One-way ANOVA, +p<0.05, 
tt+p<0.001, tttp<0.001. The control cells were treated with 0.1% 
DMSO. Error bars = Standard deviation of mean, n=3.
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2.3.2 Glutathione depletion activates both Nrf2 and NF-kB activities
I then examined whether GSH depletion and/or the protein 
covalent modification due to the electrophilic nature of these 
compounds was responsible for the different effects observed on these 
pathways. We therefore used L-buthionine (S,R)-sulfoximine (BSO), 
which depletes intracellular GSH efficiently by irreversible inhibition of 
the rate limiting enzyme of GSH synthesis, GCLc (Griffith 1982). It is now 
well-accepted that depletion of GSH due to exposure of cells to BSO 
leads to redox perturbation in a variety of cell models, for recent 
examples see (Zhou et al. 2005; Cristofanon et al. 2009). BSO 
concentrations of 3pM to 30|iM depletes GSH after 24hr exposure (Fig 
2.5a), but does not induce NF-kB binding activity (Fig 2.5b). However, 
lOOpM to 500pM of BSO increased NF-kB binding activity (Fig 2.6b) and 
increased nuclear accumulation of Nrf2 (Fig 2.7a), which correspond 
with GSH levels being depleted to below 20% of the basal level (Fig 
2.6a); a BSO-mediated increase in Nrf2 has been seen previously in the 
CDSS (Copple et al. 2008a). Immunochemical analysis of Nrf2 and NF-kB 
cellular localisation after 24hr of BSO exposure indicates some cellular 
accumulation of NF-kB (Fig 2.8a, third panel) and substantial nuclear 
accumulation of Nrf2 (Fig 2.8b, third panel). After a 24hr exposure to 
BSO there was no evidence of cytotoxicity (Fig 2.7b).
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Figure 2.5: Depletion of GSH activates NF-kB at high dose only. Hepa- 
lclc7 cells were treated for 24hr with BSO and lysed with lOmM HCL. 
GSH was depleted dose-dependently (a). Total GSH normalised against 
total protein content. Kruskal-Wallis, +p<0.05, +t+p<0.001. Cells were 
treated for 24hr with BSO and nuclear protein was assayed for NF-kB 
activity. BSO activates the translocation and binding of NF-kB at BOOuM 
only (b). The EMSA assay was specific for the NFkB protein as addition of 
a 50-fold excess of wild-type oligonucleotide (wt) to the control reaction 
(Con) displaced the bound protein from the radiolabelled 
oligonucleotide, while this was not observed with the addition of excess 
mutant (Mut) oligonucleotide. The addition of specific anti-NF-xB 
antibody (p65), as opposed to non-specific antibody (con Ab) to the 
binding control reaction (Con) caused a supershift in the NF-kB band 
confirming the composition of the NF-kB complex._The control cells were 
treated with dH20. Error bars = Standard deviation of mean, n=3. 
Representative gel from n=3 is shown. N.S; non-specific binding.
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Figure 2.6: Severe depletion of glutathione activates NF-kB . Hepa- 
lclc7 cells were treated for 24hr with BSO and lysed with lOmM HCL. 
GSH was depleted by a maximum of 80% of control (a). Total GSH 
normalised against total protein content. Kruskal-Wallis, *p<0.05, 
***p<0.001. Cells were treated for 24hr with BSO and nuclear protein 
was assayed for NF-kB activity. BSO activates the translocation and 
binding of NF-kB dose-dependently (b). The EMSA assay was specific for 
the NFkB protein as addition of a 50-fold excess of wild-type 
oligonucleotide (wt) to the control reaction (Con) displaced the bound 
protein from the radiolabelled oligonucleotide, while this was not 
observed with the addition of excess mutant (Mut) oligonucleotide. The 
addition of specific anti-NF-KB antibody (p65), as opposed to non­
specific antibody (con Ab) to the binding control reaction (Con) caused a 
supershift in the NF-kB band confirming the composition of the NF-kB 
complex. The data shows the densitometric analysis of NF-kB normalised 
against control treatment since normalisation to an internal control in 
EMSA is not possible. Kruskal-Wallis, *p<0.05. The control cells were 
treated with dH20. Error bars = Standard deviation of mean, n=3. 
Representative gel from n=3 is shown. N.S; non-specific binding.
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Figure 2.7: Depletion of glutathione activates Nrf2. Hepa-lclc7 was 
treated for 24hr with BSO and nuclear protein resolved on SDS-PAGE 
and probed for Nrf2. BSO activates Nrf2 nuclear accumulation dose- 
dependently (a). Actin is shown as loading control. Recombinant mouse 
His-tagged Nrf2 was loaded as a positive control on the blot (+con). The 
bottom panel shows densitometric analysis of Nrf2 normalised against 
actin. Cells were treated for 24hr with BSO. LDH assay shows minimal 
leakage upon treatment with BSO (b). Extracellular LDH activity is 
expressed as a percentage of total (extracellular plus intracellular) LDH 
activity. The control cells were treated with dH20. Error bars = Standard 
Deviation of mean, n=3. Representative gel from n=3 is shown. N.S; non­
specific binding.
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Figure 2.8: Subcellular localization of p65 (a) and Nrf2 (b) in Hepa- 
lclc7 cells exposed to control and DNCB or BSO for Ihr and 24hr, 
respectively. FITC-conjugate goat anti-p65 (a)(i, ii and iii), FITC-conjugate 
goat anti-Nrf2 (b)(i, ii and iii) and Hoechst 33258 (A)(B)(iv; v and vi) 
immunofluorescence were visualised by confocal microscopy.
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2.3.3 Comparison of Nrf2 and IMF-kB regulation by NAPQI, DNCB and 
BSO
The effect of treatment with NAPQI, DNCB or BSO on Nrf2 and 
NF-kB activity can be seen clearly in figure 2.9. NAPQI (Fig 2.9a) and 
DNCB (Fig 2.10a), which can covalently bind proteins and deplete GSH, 
increased Nrf2 activity and decreased NF-kB binding activity, whilst the 
GSH-depleting agent, BSO (Fig 2.10b), increased both Nrf2 and NF-kB 
activity.
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Figure 2.9: The effect of NAPQI treatment on Nrf2, NF-kB and GSH in 
Hepa-lclc? cells. NAPQI increased Nrf2 nuclear accumulation and 
decreased NF-kB binding activity in parallel with GSH depletion. Error 
bars have been omitted from the graph for visual clarity, n=3.
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Figure 2.10: The effect of DNCB and BSO treatment on Nrf2, NF-kB and 
GSH in Hepa-lclc7 cells. DNCB (a) increased Nrf2 nuclear accumulation 
and decreased NF-kB binding activity in parallel with GSH depletion. BSO 
(b) increased both Nrf2 nuclear accumulation and NF-kB binding activity 
in parallel with GSH depletion. Error bars have been omitted from 
graphs for visual clarity, n=3.
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2.3.4 RNA interference modulates Keapl, Nrf2 and NF-kB, p65 subunit 
expression
RNAi is a conserved mechanism of specific gene silencing through 
post-translational degradation of mRNA (Dykxhoorn et al. 2005). In this 
study, RNAi was used to investigate the physiological and molecular 
effects of Keapl, Nrf2 and p65 silencing on cellular cytoprotection. This 
single dose of siRNA molecules against Keapl was an initiate screening 
to validate which siRNA molecule was the most effective against Keapl 
at lOnM. The basal Keapl protein depletion is below 35% when 
compared to mock transfection and negative control (Fig 2.11a). The 
RNAi depletion of Keapl resulted in a concomitant increase in the 
nuclear Nrf2 level (Fig 2.11b and c). The use of Keapl and Nrf2 RNAi 
have been shown, against the proteins respectively, which resulted in 
80% silencing of each protein (Copple et al. 2008a). RNAi directed 
against NF-kB, p65 subunit expression was also successful. A 70% 
reduction in basal NF-kB p65 expression was detected in cells treated 
with p65 RNAi (Fig 2.12a) concurrently with a decrease in nuclear NF-kB 
DNA binding activity (Fig 2.12b). The co-transfection of two RNAi 
molecules against p65 was compared to single transfection - this did not 
silence NF-kB any further. Therefore, there was no synergistic effect 
from the co-transfection (Fig 2.13).
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Figure 2.11: RNAi modulates Keapl subunit expression. Hepa-lclc7 
cells were transfected with Keapl siRNA for 48hr (Copple et al. 2008a) 
and cytosolic extracts resolved on SDS-PAGE and probed for Keapl. 
Keapl siRNA depleted Keapl protein expression to approximately 70% 
of control for si-Keapl#l, si-Keapl#3 and 50% of control for si-Keapl#4 
(a). Correspondingly, 70% Keapl protein depletion (b) caused an 
approximately 50% increased in nuclear Nrf2 (c). Actin is shown as 
loading control.Actin is shown as loading control. Recombinant mouse 
HIS-tagged Nrf2 was loaded as positive control on the blot (+con). si-neg 
3 is control for all 3 Keapl siRNA. (a) Percentage of Nrf2:actin ratio from 
triplicate measurements, n=l. Representative gel from n=l is shown. 
Densitometry value from n=l. N.S; non-specific binding. IB; 
immunoblotting.
85
Chapter 2
+con 1 31
^ J1
1 3 3 (-) (-) 1 3 nM
p65
actin mwMiri am... mamma.-
t'a •»> '5C> (S'- V'* -Vj) ^
[nM]
Figure 2.12a: RNAi modulates NF-kB, p65 subunit expression. Hepa- 
lclc7 cells were transfected for 48hr with NF-kB siRNA. Cytosolic 
extracts resolved on SDS-PAGE and probed for NF-kB. NF-kB siRNA 
deplete NF-kB protein expression to approximately 70% of control. Actin 
is shown as loading control. Cell lysates from HepG2 overexpressed p65 
was loaded as positive control on the blot (+con). si-negM and si-negl 
are controls for si-p65#l/si-p65#2 and si-p65#3 respectively. The 
bottom panel shows densitometric analysis of NF-kB positive bands 
normalised against actin. Paired t-test, *p<0.05. The data shows the 
densitometric analysis of NF-kB normalised against control. Error bars = 
Standard deviation of mean, n=3. Representative gel from n=3 is shown.
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Figure 2.12b: RNAi modulates NF-kB, p65 subunit expression. Hepa- 
lclc7 cells were transfected for 48hr with NF-kB siRNA. Nuclear protein 
was assayed for NF-kB activity. NF-kB siRNA decreased constitutive 
binding compared to control. The assay was specific for the NFkB protein 
as addition of a 50-fold excess of wild-type oligonucleotide (wt) to the 
reaction displaced the bound protein from the radiolabelled 
oligonucleotide, while this was not observed with the addition of excess 
mutant (Mut) oligonucleotide. The addition of specific anti-NF-KB 
antibody (p50, p65), as opposed to non-specific antibody (con Ab) to the 
binding reaction caused a supershift in the NF-kB band confirming the 
composition of the NF-kB complex. The data shows the densitometric 
analysis of NF-kB normalised against control treatment since 
normalisation to an internal control in EMSA is not possible. 
Representative gel from n=3 is shown. Densitometry value = mean, n=3. 
N.S; non-specific binding.
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Figure 2.13: RNAi modulates NF-kB, p65 subunit expression. Hepa- 
lclc7 cells were transfected for 48hr with either one or two NF-kB 
siRNA. The cytosolic extracts were then resolved on SDS-PAGE and 
probed for NF-kB. NF-kB siRNA deplete NF-kB protein expression to 
approximately 75% of control, the co-transfection of two siRNA had no 
additional effect on depleting NF-kB. Actin is shown as loading control. 
Cell lysates from HepG2 overexpressed p65 was loaded as positive 
control on the blot (+con). si-neg M+L , si-negM and si-negL are controls 
for si-p65#l+3/si-p65#2+3, si-p65#l/si-p65#2/si-p65#l+2 and si-p65#3 
respectively. The bottom panel shows densitometric analysis of NF-kB 
positive bands normalised against actin. Percentage of Nrf2:actin ratio is 
the mean of two independent experiments, n=2. A representative gel 
from n=2 is shown.
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2.3.5 RNAi modulation of NrfZ, Keapl and p65 influences cell defence 
in Hepa-lclc7 cells
Modulation of Nrf2, Keapl and NF-kB, p65 had a profound effect 
on the ability of Hepa-lclc7 cells to elicit a defence response against 
chemical stress. DNCB was again used as a model electrophile to induce 
chemical stress. LDH assays indicated that RNAi knockdown of Keapl 
(Fig 2.14a) protects the cells against DNCB toxicity. DNCB toxicity was 
augmented when Nrf2 was depleted with RNAi directed against Nrf2 (Fig 
2.14b) and p65 was depleted (Fig 2.14c) individually. Interestingly, the 
phenotypic effect of the Keapl knock down was reversed when both 
Keapl and p65 (Fig 2.14d) were depleted simultaneously. The 
comparison of toxicity for each RNAi modulation should be made against 
their respective controls and should not be compared with other RNAi 
treatments.
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Figure 2.14: RNAi modulation of Nrf2, Keapl and p65 influences cell 
defence. Hepa-lclc7 cells were transfected for 48hr with RNAi and 
treated for 6hrs with DNCB. Keapl depletion decreased DNCB toxicity 
(a). Nrf2 (b) depletion increased DNCB toxicity. Increased in DNCB 
toxicity was seen with p65 depletion (c). Keapl and p65 co-depletion 
shows the effect of Keapl knockdown alone is reversed by depletion of 
p65 (d). All data compared to their respective negative controls (si-neg). 
The control cells were treated with 0.1% DMSO. Error bars = Standard 
deviation of mean, n=3-4.
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2.3.6 RNAi depletion of Nrf2 and Keapl, but not p65, influences the 
basal level of GSH in Hepa-lclc7 cells
The effect of modulation of Nrf2, Keapl and p65 on the basal 
level of GSH was then assessed, to determine whether the GSH level has 
an influence on the toxicity seen with DNCB. Keapl silencing increased 
the basal level of GSH by approximately 40% and at 10pM of DNCB, the 
GSH level increased by an additional 20% (Fig 2.15a). Nrf2 silencing 
decreased the basal level of GSH by approximately 20% and at 20pM of 
DNCB, there is a clear decrease in GSH levels to less than 20% of total 
GSH (Fig 2.15b). p65 RNAi did not affect the basal level of GSH or levels 
after treatment with DNCB (Fig 2.15c). Interestingly, in the presence of 
Keapl and NF-KB-p65 RNAi, there was no increase in the basal GSH level 
(Fig 2.15d).
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Figure 2.15: RNAi modulation of NrfZ, Keapl and p65 influences the 
level of GSH. Hepa-lclc7 cells were transfected for 48hr with RNAi and 
treated for 6hrs with DNCB. Keapl depletion increased basal GSH levels 
(a). Nrf2 depletion caused a decrease in basal GSH level (b). With p65 
depletion there is no change in basal GSH level (c). Where both Keapl 
and p65 are depleted simultaneously, there is no increase in basal GSH 
levels (d). Total GSH was normalised to total protein content versus si- 
neg control untreated. All data are compared to their respective 
negative controls (si-neg). Kruskal-Wallis, *p<0.05 si-keapl#3 versus si- 
neg, +p<0.05 si-Nrf2 versus si-neg. Kruskal-Wallis, tp<0.05 si-Keapl#3 + 
p65#l versus si-neg. The control cells were treated with 0.1% DMSO. 
Error bars = Standard deviation of mean, n=3-4.
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2.3.7 Simultaneous depletion of Keapl and NF-KB-p65 by RNAi 
Influences the basal level of Nrf2 in Hepa-lclc7 cells
In order to investigate the possible influence of NF-KB-p65 on the 
activity of Nrf2, the effect of RNAi depletion of NF-KB-p65 on Nrf2 
expression was determined in Hepa-lclc7 cells. p65 RNAi alone had no 
effect on the cellular expression of Nrf2, however, when co-transfected 
with Keapl RNAi, p65 depletion reversed the induction of Nrf2 caused 
by Keapl depletion (Fig 2.16). This suggests that p65 may play a role in 
the modulation of Nrf2 expression.
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Figure 2.16: Simultaneous RNAi modulation of Keapl and p65 
influences the level of Nrf2 protein. Hepa-lclc7 cells were transfected 
for 48hr with RNAi. Whole cell lysates were resolved on SDS-PAGE and 
probed for Nrf2 protein. Keapl depletion increases Nrf2 and the 
depletion of Nrf2 decreases Nrf2. p65 depletion had no effect on basal 
Nrf2 levels in Hepa-lclc7 cells. The depletion of Keapl and p65 
simultaneously reduced the expression of Nrf2 basally. All data are 
compared to their respective controls. Actin is shown as loading control. 
Recombinant mouse His-tagged Nrf2 was loaded as a positive control on 
the blot (+con). The bottom panel shows the densitometric analysis of 
Nrf2 normalised against actin. One-way ANOVA, **p<0.01, ***p<0.001. 
Representative gel from n=4. Error bars = Standard deviation of mean, 
n=4.
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2.4 DISCUSSION
The importance of the NF-kB pathway in cellular survival, 
proliferation and the inflammatory response are well documented, 
along with the role of the Nrf2/Keapl pathway in the cellular defence. 
However, it is still unclear as to how both pathways simultaneously 
respond to chemical stress and redox perturbation. In this study, both 
chemical stress and GSH depletion induced Nrf2, detected as nuclear 
accumulation observed by confocal microscopy (Fig 2.8) and western 
blotting. DNCB induced chemical stress caused a decrease in NF-kB 
binding activity (Fig 2.2d) despite the cellular accumulation of NF-KB-p65 
(Fig 2.3b). On the other hand, redox perturbation that ensues from the 
GSH-depleting action of BSO activates nuclear translocation of Nrf2 as 
well as causing increased DNA-binding activity of NF-kB (Figs 2.7a and 
2.6b). This is consistent with the notion that Nrf2 can be activated 
through covalent modification as well as GSH depletion. In the case of 
NF-kB, activity can either be enhanced by GSH depletion, or inhibited by 
reactive chemical exposure, through cysteine modification by covalent 
binding to one or more subunits in NF-kB, or to other factors that 
regulate NF-kB. Here we have observed that NAPQI and DNCB inhibit 
NF-kB DNA activity. However, whether both chemicals control NF-kB 
through an upstream effect such as, IKK complex or IkB or by directly 
interfering with its activity remains unclear and hence further 
investigation is needed. For both transcription factors, nevertheless, it 
should be noted that a definitive link between critical cysteine(s) 
modification, which may be irreversible or reversible, as a consequence 
of covalent binding or GSH depletion, still remains to be determined 
experimentally.
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Our observations are in agreement with previous studies in 
animal and cell-based models indicating that NAPQI induces the 
activation of Nrf2 (Goldring et al. 2004; Copple et al. 2008a) and inhibits 
NF-kB DNA-binding activity (Blazka et al. 1995). BSO depletes GSH by 
binding to the active site of GCLc non-covalently, inhibiting the activity 
of GCLC (Griffith 1982). In the ceil-based model, I have shown that 
depletion of GSH by BSO induces the nuclear accumulation of Nrf2 and 
increases NF-kB binding concurrently (Fig 2.6 and Fig 2.7a). The 
depletion of GSH over 24hrs by BSO does not elicit cytotoxicity (Fig 
2.7b). This is in agreement with the previous finding in which BSO 
induced nuclear accumulation of Nrf2 (Copple et al. 2008a) and findings 
by others in which BSO induced NF-kB activity (D'Alessio et al. 2004; 
Filomeni et al. 2005). It should be emphasized that the induction of Nrf2 
and NF-kB by BSO only occurs if the depletion of GSH is below 20% of 
total cellular GSH content at lOOpM, which may be the threshold level 
to induce both transcription factors. In addition, both of the Nrf2 and 
NF-kB responses to NAPQI, DNCB and BSO occurred in the absence of 
toxicity, highlighting their ability to detect and respond to either 
chemical or GSH depletion before toxicity emerges.
It has been shown previously that 15-deoxy-A12, 14-
prostaglandin J2 (15d-PG J2), an endogenous cyclopentenone 
prostaglandin molecule which can exert a powerful anti-inflammatory 
activity, is able to induce Nrf2/Keapl and inhibit NF-kB (Straus et al. 
2000; Hosoya et al. 2005). Whilst 15d-PGJ2 has been reported to directly 
bind to Keapl thiol residues and induce Nrf2, without the depletion of 
GSH (Itoh et al. 2004; Copple et al. 2008a), NF-kB binding activity can be 
inhibited by 15d-PGJ2 through the direct modification of the p65 subunit 
(Straus et al. 2000). Therefore, it is becoming clear that exogenous and
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endogenous compounds possessing the potential for protein covalent 
binding display very different effects on the Nrf2/Keapl and NF-kB 
pathways. In contrast, agents such as BSO, which deplete GSH may have 
similar effects on both redox-sensitive transcription factors. Hence, 
these factors may serve as sensors to different types of stress, allowing 
cells to adapt and respond accordingly.
An important issue that needs to be considered regarding the validity of 
experiments such as those in the present study, is the fact that a 
reactive metabolite (in this case NARQI) is added exogenously to cells 
rather than being generated endogenously. The necessity to add a 
reactive metabolite outside of the cell, remains a major hurdle in 
attempting to study the molecular pathways elicited by exposure of cells 
to drugs that require bioactivation. Nevertheless, data from this 
laboratory addressing the reactivity of residues in several proteins (i.e. 
GST-P and Keapl - the regulator of Nrf2) show that these proteins 
demonstrate similar profiles of cysteine reactivity, as assessed by mass 
spectrometry, whether the protein is present at endogenous levels (GST- 
P) or is over-expressed (Keapl), to the profile of NAPQI binding to the 
recombinant proteins in vitro (Copple et ol. 2008a; Jenkins et al. 2008). 
Therefore, whilst there are certainly limitations that need to be 
considered when a reactive metabolite is added exogenously to a cell 
rather than generated intracellularly, for certain reactive metabolites 
the profiles of modification outside and inside a cell may be similar.
Both Nrf2 and NF-kB play important roles in cellular defence, by 
inducing antioxidant enzymes, phase II enzymes and anti-apoptotic 
proteins. Co-regulation has not been shown before, therefore I have 
attempted to explore the consequences of such co-regulation by 
studying the effect of modulating the level of each transcription factor
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pathway both separately and simultaneously. Using RNAi with DNCB as a 
model electrophile, I have shown here that an increase in cellular Nrf2, 
caused by Keapl silencing, shifts the DNCB toxicity curve to the left, 
demonstrating increased resistance to DNCB toxicity when compared to 
its negative control. Conversely, decreased Nrf2 protein expression 
resulted in an increased susceptibility to DNCB toxicity when compared 
to its negative control. These findings support previous reports (Copple 
et al. 2008a) and emphasise the importance of Nrf2 in cellular defence. 
From these data, p65 does not appear to play a significant role in cell 
protection since si-p65 reduced the DNCB IC5o by only 4uM {Fig 2.14c). 
To better understand the role of each transcription factor individually 
and in concert with respect to cell defence and protection, we used RNAi 
simultaneously against Keapl and p65, in order to: monitor how 
changes in one transcription factor pathway alters the response 
mediated by the other pathway and to attempt to model previous 
responses of Nrf2 and NF-kB observed in the cell during DNCB induced 
chemical stress. As predicted, depletion of Keapl, the inhibitor of Nrf2, 
increased cellular defence. The co-transfection of RNAi against Keapl 
and p65 reversed the phenotypic effect seen with individual Keapl 
knock-down {Fig 2.14d). The protective effect of Nrf2 induction caused 
by the loss of Keapl was reduced when p65 was depleted, implying a 
role for p65 as a modulator of Nrf2-dependent cell protection. This 
therefore suggests that modulation of p65 has an effect on the ability of 
the cell to defend against toxicity via the Nrf2/Keapl pathway, and that 
the Nrf2 and NF-kB pathways are linked.
GSH is a major antioxidant that quenches reactive xenobiotics 
and endogenous oxidative stress. Therefore, I examined if the depletion 
of Keapl, Nrf2 and p65 has any effect on the basal level of GSH, further
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influencing the cells7 ability to defend against electrophile reactive 
metabolite. I have demonstrated that the depletion of Keapl increases 
the basal level of GSH {Fig 2.15a), and depletion of Nrf2 decreases the 
basal level of GSH (Fig 2.15b). This is consistent with previous 
investigation indicating that Nrf2 is one of the main regulators of GSH 
synthesis {Enomoto et al. 2001; McMahon et al. 2001; Copple et al. 
2008a; Copple et ol. 2008b). RNAi depletion of p65 has no effect on the 
level of GSH basally or in the presence of DNCB {Fig 2.15c). I have also 
shown that co- modulation of Keapl and p65 affects the cell's ability to 
defend against DNCB toxicity. Interestingly, the simultaneous depletion 
of p65 and Keapl prevented the increase in basal levels of GSH (Fig 
2.15d) seen with Keapl knockdown only. In line with this I have shown 
that the expression of Nrf2 was reduced by the co-depletion of Keapl 
and p65 (Fig 2.16). The decrease in basal Nrf2 protein expression may 
explain the reverse in DNCB toxicity protection and the reduction of 
basal GSH by Keapl depletion. Consequently, these observations imply 
that p65 may play an important role in the expression and the function 
of Nrf2.
The results of this study, indicating crosstalk between the Nrf2 
and NF-kB pathways support evidence from other groups demonstrating 
that the GSH rate-limiting synthetic enzyme, GCLc, is regulated by Nrf2 
indirectly through NF-kB (Yang et al. 2005a; Yang et al. 2005b; Kimura et 
al. 2009). Recently, it has also been shown that Keapl is able to interact 
directly with IKK|3 and the overexpression of Keapl was seen to repress 
TNF-a induced NF-kB activity (Lee et al. 2009; Kim et al. 2010a), whilst 
the depletion of Keapl by RNAi induced the nuclear accumulation and 
activity of NF-kB (Lee et al. 2009). However, the mechanism of how 
Keapl regulate IKKfS remains unknown, but there are suggestions that
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Keapl regulates IKK(3 either by promoting its proteasomal degradation 
via ubiquitination in human cells (Lee et al. 2009) or suppression 
through autophagic degradation and phosphorylation inhibition (Kim et 
al. 2010a). This suggests that Keapl not only plays an important role in 
regulating Nrf2 but may also be a key regulator of the NF-kB pathway.
In conclusion, I have demonstrated that the transcription factors, 
Nrf2/Keapl and NF-kB, respond differently to arylating and GSH- 
depleting agents. During chemical stress, it is likely that the cell attempts 
to protect itself by activating Nrf2, inducing a pleotropic transcriptional 
response of cytoprotective proteins. However, when this protective 
mechanism is overwhelmed and cellular damage is too great, it may be 
more beneficial for the cells to undergo apoptotic cell death due to the 
inhibition of NF-kB. During redox perturbation, to which the cell is 
constantly exposed under physiological conditions, activation of both 
Nrf2 and NF-kB may occur to protect the cells and prevent further 
damage (Fig 2.17). Protein modification by chemical arylation or 
oxidation as a consequence of GSH depletion on other signal 
transduction pathways involved in cellular protection or toxicity needs 
to be examined. Also, the use of GSH modulators such as N- 
acetylcysteine and GSH ester, or GSH depletors such as diethylmaleate 
and phorone, and the measurement of oxidative stress using chemical 
probes should be considered in future investigations. Our results also 
suggest a cross-talk between Nrf2/Keapl and NF-kB pathways, where 
p65 was shown to modulate the expression and functionality of Nrf2. 
More work is required to fully define the emerging links between the 
Nrf2/Keapl and NF-kB pathways, and how these impact on cellular 
response to drug exposure.
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Figure 2.17: Proposed regulation of Nrf2 and NF-kB by protein 
modification or GSH depletion. Protein covalent modification associated 
with exposure to chemically-reactive metabolites activates Nrf2 inducing 
the transcription of cytoprotective proteins. However, protein covalent 
modification inhibits NF-kB, thereby reducing the transcription of anti- 
apoptotic and anti-oxidant proteins. This leads to cellular protection 
through the Nrf2 pathway, but if the protection is overwhelmed, cell 
death may ensue due to inhibition of NF-kB. GSH depletion without 
covalent modification will cause intracellular redox perturbation, 
activation of both Nrf2 and NF-kB, inducing the transcription of 
cytoprotective proteins, and anti-apoptotic and anti-oxidant proteins, 
respectively. This may lead to cellular protection against the potentially 
damaging effects of redox perturbation. [This scheme is based upon 
data derived in this study and other work (Blazka et al. 1995; D'Alessio et 
al. 2004; Goldring et al. 2004; Filomeni et al. 2005; Copple et al. 2008a; 
Ghosh et al. 2009)].
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Mechanism of Nrf2 activation - via chemical adduct 
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3.1 INTRODUCTION
Keapl/I\irf2 pathway plays an important role in cellular 
protection during DILI. Keapl controls the regulation of Nrf2 
physiologically; Keapl represses Nrf2 level in the cell by subjecting Nrf2 
to ubiquitination and proteosomal degradation (Zhang et al. 2004). 
Alternatively, during chemical or oxidative stress, the repression of Nrf2 
by Keapl is disrupted, leading to the Nrf2 nuclear accumulation and 
transactivation of ARE-dependent genes (Itoh et al. 1997; Itoh et al. 
1999b). However, the molecular mechanism underlying the Nrf2 
activation by chemical or oxidative stress has not been fully clarified.
The current hypothesis of Nrf2 activation mechanism centres on 
the modification of Keapl cysteine residues by chemical or oxidative 
stress. There is compelling evidence postulating that chemicals and 
reactive metabolites are able to chemically modify cysteine residues on 
Keapl, thereby biochemically triggering the Nrf2 pathway (Dinkova- 
Kostova et al. 2002; Zhang et al. 2003; Hong et al. 2005a). Specific 
cysteine residues have been shown to be modified by these chemicals 
on recombinant Keapl in cell free in vitro systems associated with Nrf2 
activation (Dinkova-Kostova et al. 2002; Dietz et al. 2005; Eggler et al. 
2005; Hong et al. 2005b; Liu et al. 2005; Sakurai et al. 2006; Luo et al. 
2007; Yamamoto et al. 2008) and can also bind to ectopic Keapl in cell 
based models (Hong et al. 2005a; Rachakonda et al. 2008). Glutathione 
(GSH) is the most abundant non-protein tripeptide thiol, serving as the 
primary defence mechanism by playing a role in redox buffer against 
chemical and oxidative stress (DeLeve et al. 1991). The depletion of GSH 
has been shown to activate Nrf2 and the induction of ARE-dependent 
genes (Shertzer et al. 1995; Lee et al. 2008), but the mechanism of how 
GSH depletion activates Nrf2 remains to be clarified. It has been shown
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that treatment with Nrf2 inducers lead to the formation of a disulphide 
bond within Keapl in cells via the formation of an intermediate cysteine 
oxidation product, sulphenic acid (Wakabayashi et al. 2004). Cysteine 
residues can be readily oxidised, forming different intermediates. In 
many proteins, cysteine residues are able to be oxidised to cysteine 
sulphenic acid (R-SOH) which is considered unstable and can undergo 
further rapid oxidation to form a disulphide bond with either GSH or 
another protein cysteine. The formation of both cysteine sulphenic acid 
and the disulphide bond are reversible, and can be reduced back to 
former cysteine (Claiborne et al. 1999). The cysteine sulphenic acid can 
also be further oxidised to irreversible oxidations; sulphinic acid (R- 
S02H) and sulphonic acid (R-S03H) (Hamann et al. 2002; Wang et al. 
2004). Therefore, modification of cysteine on Keapl by oxidation from 
GSH depletion may lead to the activation of Nrf2 (Fig 3.1).
It has previously been indicated that Nrf2 activation can occur as 
a result of covalent modification of cysteine residues on Keapl but also 
as a consequence of GSH depletion without concomitant chemical 
modification. Investigations in this chapter have focused on further 
exploring the specific pre-requisites for Nrf2 activation. Therefore, a 
panel of known Nrf2 inducing molecules were used. This panel of probe 
molecules is known to induce Nrf2 activation via the cysteine 
modification and/or by GSH depleting (Fig 3.2 and Fig 3.3). From this 
panel, molecules which expressed the following properties were chosen 
to investigate this: Cysteine modification and GSH depletion; cysteine 
modification but no GSH depletion; or GSH depletion but no cysteine 
modification. The three molecules chosen which exhibit the above 
mentioned three properties are iodoacetamide (IA), dexamethasone 21- 
mesylate (Dex-mes) and buthione (S,R)-sulfoximine (BSO) respectively.
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These chosen molecules were investigated alongside three other 
molecules which exhibit different chemistries in binding proteins (Fig 
3.2). Hence, the aim of this chapter is to further our understanding as to 
whether it is cysteine covalent modification, or oxidative stress by GSH 
depletion without concomitant chemical modification that is a 
prerequisite for Nrf2 activation, or in fact whether these properties of an 
Nrf2 inducer are not mutually exclusive. Hence, this study may give 
further insight on the mechanism of Nrf2 activation.
a) Oxidation
-S-OH
Sulphenic acid
n o
[0]
--------- > * 0
Sulphinic acid Sulphonic acid
Irreversible
b) Disulphide linkage
-S—SG
clGlutathionvIation
Fig 3.1: Schematic diagram of protein cysteine oxidation. Protein 
sulphydryl can be oxidised to sulphenic acid which can be further 
oxidised to (a) irreversible oxidation sulphenic and sulphonic acids. 
Sulfenic acid can also react with another protein sulphydryl or GSH to 
form (b) disulphide linkage or be (c) s-glutathionylated.
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e:Buthionine (S,R)-sulfoximine (BSO) f:Resveratrol (Res)
Figure 3.2: Chemical structure of the Nrf2-inducing molecules chosen 
for investigation in this chapter
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(15d-PGJ2) (IMA)
Figure 3.3: Chemical structure of the Nrf2-inducing molecules chosen 
for investigation in this chapter
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3.2 MATERIALS AND METHODS
3.2.1 Materials
The pGL3B-1016/nc7o5'-/i/c reporter plasmids was kindly donated 
by Professor John Hayes (Biomedical Research Centre, University of 
Dundee, UK). Reporter lysis 5X buffer, the P-galactosidase Enzyme Assay 
System, the Bright-Glo Luciferase Assay System and QuantiLum 
recombinant luciferase were from Promega (Southampton, UK). The 
FL600 fluorescence microplate reader was from BioTek instruments 
(Winooski, USA). GeneJuice was from Novagen (Nottingham, UK). The 
nitroso sulfamethoxazole was kindly donated by Dr Dean Naisbitt (MRC 
Centre of Drug Safety Science, University of Liverpool, UK). 
Dexamethasone 21—mesylate was obtained from Steraloids (Newport, 
Rl, USA). 15-deoxy-A-(12,14)-prostaglandin J2 was from Alexis 
Biochemicals (Lausen, Switzerland). The benzyl Isothiocyanate, 
iodoacetamide, tert-butylhydroquinone, resveratrol, buthionine (S,R)- 
sulfoximine, dinitrochlorobenzene, trimellitic anhydride and 
sulfamethoxazole were from Sigma-Aldrich (Poole, UK). ). All other 
reagents were of analytical or molecular grade were from Sigma-Aldrich.
3.2.2 Cell Culture and Cell Count
Hepa-lclc7 cells were maintained and counted as detailed in 
section 2.2.2.
3.2.3 Cell Treatment
Hepa-lclc7 cells were seeded onto 96-well plates, 24-well plates 
and 56.7cm2 Nunclon A culture dishes at 2 x 104 cells/well, 2 x 105 
cells/well and 5 x 106 cells/dish respectively on the previous day. All 
compounds (Fig 3.2) were dissolved in dimethyl sulfoxide (DMSO) except 
for buthionine sulfoximine (BSO), which was dissolved in distilled water, 
at lOOx the final concentration. ISd-PGJi was supplied pre-dissolved in
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methyl acetate, the solvent was removed by evaporation, under a gentle 
stream of nitrogen gas. The solute was reconstituted in DMSO, at lOOx 
the final concentration, before each treatment. Cells treatment was 
prepared as detailed in section 2.2.3.
3.2.4 Preparation of cytosolic and nuclear extracts and whole cell 
lysates
For cytosolic and nuclear extracts and whole cell lysate 
preparation was detailed as in section 2.2.4.
3.2.5 Measurement of protein content
The total protein content was determined as detailed in section
2.2.5.
3.2.6 Western immunobiotting
Nrf2 western immunobiotting was prepared as detailed in 
section 2.2.6.
3.2.7 Measurement of Glutathione
Total GSH content was quantified as detailed in section 2.2.11.
3.2.8 Analysis of Mouse Nqol ARE Reporter Activity
Hepa-lclc7 were seeded onto 96-well plates at 2 x 104 cells/well 
and transfected for 24hr with 100 ng of either pGL3B-1016/nqo5'-luc 
wild-type reporter plasmid or a mutant plasmid containing an entirely 
scrambled ARE sequence, as previously described by Nioi et al (Nioi et ol. 
2003). pGL3B-1016//?<7o5,-/uc represents the pGL3 basic luciferase
vector into which a 1016 bp S'-upstream region of the mouse Nqol gene 
has been subcloned, enabling ARE-mediated regulation of modified 
firefly luciferase gene expression. Transfections were performed using 
GeneJuice reagent (Novagen, Nottingham, UK), in accordance with the 
manufacturer's instructions. Treatment of cells is as followed in section
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3.2.3. Following treatment, media was removed and cells were lysed in 
situ using 0.1ml IX Reporter Lysis Buffer (Promega, Southampton, UK). 
Lysates (20pl) were transferred to a white 96-well plate and 20p.l Bright- 
Glo Luciferase assay reagent was added. 15|ig QuantiLum recombinant 
firefly luciferase was used as a positive control for the assay. Air bubbles 
were removed by centrifuging briefly at 3000rpm. Firefly luciferase 
activity was measured immediately on BioTek FL600 fluorescence 
microplate reader, adapted to measure luminescence (BioTek 
Instruments, Winooski, VT). Blank readings were obtained from wells 
contain in IX Reporter Lysis Buffer and Bright-Glo Reagent, and 
subtracted from sample readings. Blank readings were obtained from 
wells containing IX Reporter Lysis Buffer and IX Assay Buffer, and 
subtracted from sample reading.
3.2.9 Data Analysis
Data are expressed as mean ± standard deviation of the mean. 
Normality was assessed by the Shapiro-Wilk test. The significance of 
differences within the data was assessed by a one-way analysis of 
variance (ANOVA) or Student's t-test for normally distributed data, and 
Kruskal-Waliis ANOVA for non-parametric data. A difference was 
considered significant at p<0.05.
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3.3 RESULTS
3.3.1 Nrf2 activation and GSH depletion by a panel of Nrf2 inducing 
molecules
Hepa-lclc7 cells were exposed to a number of Nrf2 inducing 
molecules with the aim to determine which of these are the most potent 
Nrf2 inducers and whether they also result in GSH depletion. This was an 
initial screen that was carried out to select probe Nrf2-inducing 
chemicals with different properties for further detailed study. 
Consequently, only single dose ranging studies for each chemical were 
carried out, although triplicate measurements were made on all of the 
samples. Therefore statistical analysis was not appropriate for these 
sample sets but is carried out on the endpoints generated from the 
smaller selected chemical panel used in the subsequent experiments in 
this thesis. Within this panel, the molecules that increased Nrf2 
activation and causes GSH depletion were BITC, tBHQ and IA. Those 
molecules that increased Nrf2 activation and had no effect on GSH 
content were Dex-mes, 15d-PGJ2 and SMX-NO. Res and SMX had no 
effect on both Nrf2 activation and GSH depletion (Fig 3.3a-f). From this 
panel of Nrf2 inducers, three molecules with the greatest Nrf2 activation 
from dose range used in this investigation were selected; IA, a sulphydryl 
alkylating agent which covalently modified cysteine and depleted GSH 
(Fig 3.2b); Dex-mes, a sulphydryl reactive steroid, which covalently 
modified cysteine but did not deplete GSH (Fig 3.2d) and finally BSO, an 
inhibitor of GCLc which depleted GSH but did not result in covalent 
modification of cysteine (Fig 3.2e).
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Figure 3.3: Effects of probe molecules on Nrf2 and GSH in Hepa-lclc7 
cells, (a) Western blot analysis of whole cell Nrf2 content in Hepa-lclc7 
cells exposed to the indicated concentrations of Dex-mes, Res and BITC 
(Ihr exposure). Actin was probed as a loading control. The bottom panel 
shows the densitometric analysis of Nrf2 positive bands normalised 
against actin. Recombinant mouse Nrf2-His was loaded onto the gels as 
a standard (Std.). (b) Total GSH, normalised to total protein content, 
following exposure of Hepa-lclc7 cells to the indicated concentrations 
of Dex-mes, Res and BITC (Ihr exposure). Results are expressed as the 
change in GSH level relative to control cells. The control cells are treated 
with 0.1% DMSO. Representation gels from n=l is shown. Total GSH 
level from triplicate measurements, n=l.
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Figure 3.3: Effects of probe molecules on Nrf2 and GSH in Hepa-lclc7 
cells, (c) Western blot analysis of whole cell Nrf2 content in Hepa-lclc7 
cells exposed to the indicated concentrations of SMX, SMX-NO and IA 
(Ihr exposure). Actin was probed as a loading control. The bottom panel 
shows the densitometric analysis of Nrf2 positive bands normalised 
against actin. Recombinant mouse Nrf2-His was loaded onto the gels as 
a standard (Std.). (d) Total GSH, normalised to total protein content, 
following exposure of Hepa-lclc7 cells to the indicated concentrations 
SMX, SMX-NO and IA (Ihr exposure). Results are expressed as the 
change in GSH level relative to control cells. The control cells are treated 
with 0.1% DMSO. Representation gels from n=l is shown. Total GSH 
level from triplicate measurements, n=l.
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Figure 3.3: Effects of probe molecules on Nrf2 and GSH in Hepa-lclc7 
cells, (e) Western blot analysis of whole cell Nrf2 content in Hepa-lclc7 
cells exposed to the indicated concentrations of tBHQ (Ihr exposure) 
and BSO (24hr exposure). Actin was probed as a loading control. The 
bottom panel shows the densitometric analysis of Nrf2 positive bands 
normalised against actin. Recombinant mouse Nrf2-His was loaded onto 
the gels as a standard (Std.). (f) Total GSH, normalised to total protein 
content, following exposure of Hepa-lclc7 cells to the indicated 
concentrations of tBHQ (Ihr exposure) and BSO (24hr exposure). Results 
are expressed as the change in GSH level relative to control cells. The 
control cells are treated with 0.1% DMSO except for BSO which is 
treated with water. Representation gels from n=l is shown. Total GSH 
level from triplicate measurements, n=l.
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3.3.2: Mouse Nqol ARE-regulated reporter assay by panel of Nrf2 
inducing molecules
The activity of a reporter assay controlled by the promoter 
region of the mouse Nqol gene, which contains a functional ARE motif, 
was used to assess if the increases in cellular Nrf2 are functionally 
relevant. The wildtype (WT) and mutant (MUT) ARE reporter constructs 
have been described previously (Nioi et al. 2003). Hepa-lclc7 cells were 
transfected with wild WT and MUT ARE construct for 24hr, and exposed 
to Nrf2 inducing molecules for Ihr, the media was then replaced with 
treatment-free media and allowed to incubate for a further 15hr. This is 
also an initial screen that was carried out as another test to investigate 
effect of Nrf2 inducing molecules on Nrf2 activation via ARE binding. The 
molecules selected from the panel were, BITC (Fig 3.2a), Dex-mes (Fig 
3.2d), tBHQ (Fig 3.2d) and Res (Fig 3.2g) with the addition of DNCB (Fig 
3.2i).There was no increase in ARE reporter activity with the wild type 
and no difference was evident in ARE reporter activity between the WT 
and MUT construct, when exposed to Nrf2 inducing molecules (data not 
shown).
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3.3.3. Activation of Nrf2 by lodoacetamide, Dexamethasone 21- 
mesylate and Buthionine (S,R) sulphoximine
The aim of this experiment was to further validate the three 
selected Nrf2 inducing molecules for their ability to activate Nrf2 
with/without cysteine covalent modification or GSH depletion. Larger 
dose ranges of BSO, Dex-mes and IA, spanning from Op.M to SOOpM, 
were applied to the Hepa-lclc7 cells. Ail three molecules induced Nrf2 
activation (Fig 3.4). BSO depleted GSH dose-dependently, resulting in 
80% depletion in comparison to the control at 300pM (Fig 3.4b). Nrf2 
activation was induced to a greater extent when GSH was depleted to 
approximately 20% of control after 24hr (Fig 3.4a). Dex-mes was able to 
induce Nrf2 activation at 3pM to lOOpM (Fig 3.4c) in the absence of GSH 
depletion (Fig 3.4d). IA activated Nrf2 dose-dependently (Fig 3.4e) and 
depleted GSH to undetectable levels within 1 hr at lOOpM (Fig 3.4f).
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Figure 3.4: Effects of selected molecules on Nrf2 and GSH in Hepa- 
lclc7 cells. Western blot analysis of whole cell Nrf2 content in Hepa- 
lclc7 cells exposed to the indicated concentration of BSO(a) (24hr 
exposure), Dex-mes (c) or IA (e) (Ihr exposure), p-actin was probed as a 
loading control. Recombinant mouse Nrf2-His was loaded onto the gels 
as a standard (Std.).Total GSH, normalised to total protein content, 
following exposure of Hepa-lclc7 cells to the indicated concentrations 
of BSO (b) (24hr exposure, Dex-mes (d) or IA (f) (Ihr exposure). Results 
are expressed as the change in GSH level relative to control cells. The 
control cells are treated with 0.1% DMSO except for BSO which is 
treated with water. Kruskal Wallis, **p<0.01, ***p<0.001.
Representative gel from n=l is shown. Error bars = Standard Deviation of 
Mean, n=3
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3.3.4 The role of cysteine adduct formation and GSH depleting 
molecules Nrf2 activation and its nuclear translocation
To investigate our hypothesis, and explore if either Keapl 
cysteine adduct formation, GSH depletion or both mechanisms can 
trigger Nrf2 activation, we employed a panel of selected molecules with 
different chemical properties and measured their effects on Nrf2 in 
Hepa-lclc7 cells. The probe molecules selected were 15d-PGJ2, TMA, 
Dex-mes, DNCB, IA and BSO (Fig 3.5). These molecules were incubated 
with Hepa-lclc7 cells and their ability to deplete cellular GSH was 
measured. Within this panel of molecules, the thiol-reactive steroid 
Dex-mes, the cyclopentenone 15d-PGJ2 and the lysine-reactive 
respiratory allergen TMA did not affect GSH levels in Hepa-lclc7 cells 
over the concentration range of O.BpM to lOOpM (Fig 3.6). In contrast, 
the alkylating agents DNCB, IA and BSO caused the concentration- 
dependent depletion of GSH, with maximal depletion observed with 
100pM DNCB and IA, with 100% depletion within Ihr exposure. BSO 
resulted in 87% ± 8% depletion at 300pM over a 24hr exposure period 
(Fig 3.6). The probe molecules were then further investigated, assessing 
their Nrf2 activation potency and subsequent Nrf2 accumulation in 
Hepa-lclc7 cells. Cells were exposed to 15d-PGJ2 (10pM), Dex-mes 
(30pM), IA (30jiM), DNCB (30|iM), TMA (30pM) (Ihr exposure) or BSO 
(300pM) (24hr exposure). With the exception of TMA, all of the 
molecules caused the stabilisation and nuclear translocation of Nrf2 in 
Hepa-lclc7 cells (Fig 3.7).
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Figure 3.5: Chemical structures of panel of selected molecules for further 
investigation of GSH depletion, Nrf2 activation and Nrf2 nuclear 
accumulation.
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Figure 3.6: Effects of probe molecules on total GSH content in Hepa- 
lclc7 cells. Total GSH, normalized to total protein content, following 
exposure of Hepa-lclc7 cells to the indicated concentrations of 15d- 
PGJ2/ Dex-Mes, DNCB, IA, TMA (Ihr exposure) or BSO (24-hour 
exposure). Results are expressed as the change in GSH level relative to 
control cells, in which GSH content was 37.3 ± 5.4 nmol/mg. One-way 
ANOVA, *p<0.05, **p < 0.01, ***p <0.001 versus vehicle control. Error 
bars = Standard deviation of mean, n=3.
121
Chapter 3
Whole cell Nucleus Whole cell Nucleus
15d-PGJ2(|iM): 0 0.3 1 3 10 Std. 0 10 Std. DNCB(nM): 0 1 3 10 30 Std. 0 30 Std.
Nrf2 ►
ttt it i
tm He Nrf2 ► •*** *
Actin ► — Actin ►
Dex-mes (nM): 0 l 3 10 30 Std. 0 30 Std. IA(hM): 0 1 3 10 30 Std. 0 30 Std.
Nrf2 ► • Nrf2 ► n;i Hi
Actin ► mm Actin ►
mm
BSO(hM): 0 10 30 100 300 Std. 0 300 Std. TMA(hM): 0 1 3 10 30 Std. 0 30 Std.
Nrf2 ►
titti•i* lit Nrf2 ► A
Actin ► 9 j 0 Actin ► — —
Figure 3.7: Effects of probe molecules on Nrf2 in Hepa-lclc7 cells.
Hepa-lclc7 cells were exposed to the indicated concentrations of 15d- 
PGJ2, Dex-mes, DNCB, IA, TMA (Ihr exposure) or BSO (24hr exposure). 
Western blot analysis of whole cell and nuclear Nrf2 fractions was then 
performed, p-actin was probed as a loading control. Recombinant 
mouse Nrf2-His was loaded onto the gels as a standard (Std). Untreated 
cells were treated with 0.1% DMSO except for BSO which is treated with 
water. A representative gel from n=3 is shown.
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3.4 DISCUSSION
Previously work in the CDSS in Liverpool has shown that the 
Keapl/Nrf2 pathway, which serves to protect mammalian cells against 
chemical/oxidative stress, is activated in mouse liver following the 
administration of acetaminophen in vivo (Goldring et al. 2004). Others 
have shown that chemical modification of Keapl's cysteine residues by 
chemically reactive metabolites lead to the activation of Nrf2 (Dinkova- 
Kostova et al. 2002; Zhang et al. 2003; Hong et al. 2005a). The possibility 
exists of formation of disulphide linkage or glutathionylation within 
Keapl cysteines by redox perturbation (Holland et al. 2008), and that 
this can lead to the activation of Nrf2 (Wakabayashi et al. 2004; 
Fourquet et al. 2010). Although there are several mechanisms that have 
been proposed to explain the ability of Keapl/Nrf2 to respond to a 
diverse range of chemical and oxidative stress (Giudice et al. 2006; 
Giudice et al. 2010), the molecular mechanisms remain unclear. From 
functional studies, three cysteines in particular, namely CyslSl, Cys273 
and Cys288, have been identified to play an important role in Keapl 
function. The mutation of CyslSl, Cys273 or Cys288 leads to Keapl 
being unable to repress Nrf2 basally; mutation of CyslSl have been 
shown to cause the dissociation of Cullin3-based E3 ubiquitin ligase 
(Cul3 ligase) from Keapl leading to the abrogation of Nrf2 ubiquitination 
(Zhang et al. 2003; Zhang et al. 2004; Rachakonda et al. 2008; Eggler et 
al. 2009); mutation of either Cys273 or Cys288 have been suggested to 
abrogate the ubiquitination of Nrf2 and subsequent proteosomal 
degradation (Zhang et al. 2003; Levonen et al. 2004; Kobayashi et al. 
2006a; Yamamoto et al. 2008). In fact modification studies have also 
shown that Keapl cysteines including CyslSl, Cys273 and Cys288, are 
highly reactive and are easily modified by chemicals and electrophiles - 
in vitro and in vivo? (Dinkova-Kostova etal. 2002; Dietz etal. 2005; Hong
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et al. 2005a; Hong et a!. 2005b; Eggler et al. 2007; Luo et al. 2007; 
Kobayashi et al. 2009). Therefore these data provide strong evidence to 
support the hypothesis that modification of certain cysteine residues 
within Keapl may form a mechanism for the activation of Nrf2 (Dinkova- 
Kostova et al. 2002; Dietz et al. 2005; Eggler et al. 2005; Hong et al. 
2005b; Liu et al. 2005; Luo et al. 2007; Yamamoto et al. 2008).
Within this study, comprehensive analysis of the panel of Nrf2 
activating molecules, I found that molecules known to alkylate cysteine 
residues, Dex-mes, IA, DNCB and 15d-PGJ2 do, as expected, induce Nrf2. 
The induction of Nrf2 leads to a subsequent downstream effect, which 
leads to the transcription and induction of cytoprotective genes. These 
cytoprotective genes involved are; phase II detoxify enzymes (Talalay et 
al. 1995), G5H and its synthesis proteins (McMahon et al. 2001), NQOl 
(Dhakshinamoorthy et al. 2001), heat shock proteins and DNA repair 
enzymes (Kwak et al. 2003; Hu et al. 2006). Unfortunately, it is unclear 
whether Nrf2 activation by Dex-mes and DNCB induces that subsequent 
downstream effect, as our Nqol ARE reporter activity investigation was 
unsuccessful. The possibilities that Nqol ARE reporter activity being 
unsuccessful may either be because of poor transfection of the reporter 
plasmid into the cells or the poor expression of reporter plasmid in the 
cells, as the iuciferase values emitted from the WT treatment 
correspond to the Iuciferase values emitted from the MUT treatment. 
The other reason may be that the cells are undergoing cytotoxicity, 
where treatment of Hepa-lclc7 with molecules for 15hr may induce 
toxicity. Improvments can be made for the ARE reporter transfections; 
by co-transfecting with pCMV SPORT-p-galactosidase plasmid as an 
internal control, in which the E.Coli p-galactosidase gene is under the 
control of the upstream cytomegalovirus (CMV) promoter. The p-
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galactosidase measured in the cells can serve to ensure that the 
transfection is successful; cellular cytotoxicity can be assessed to ensure 
that the treatment with molecules does not cause toxicity. Furthermore, 
the reporter plasmid could only increase luciferase activity by 40% after 
treatment when compared to untreated cells (Copple et al. 2008a). 
Therefore, the induction of luciferase is not high so nuclear 
accumulation of Nrf2 by Western blotting was used to determine Nrf2 
activation was used instead. On the other hand, with the exception of 
Dex-mes and 15d-PGJ2, all the other molecules depleted cellular GSH. 
Hence, given that Dex-mes and 15d-PGJ2 exposure results in Nrf2 
activation in the absence of GSH depletion, it can be concluded that GSH 
depletion is not a prerequisite for Nrf2 activation. BSO, when 
phosphorylated, inhibits the activity of GCLc by binding tightly but non- 
covalently in the enzyme active site (Griffith 1982). BSO activated Nrf2 
only when cellular GSH was depleted to 20% of basal levels, a finding 
which is consistent with previous reports that only substantial depletion 
of GSH activates the Nrf2/Keapl pathway (Levonen et al. 2004; Maher et 
al. 2007) and previous work from this laboratory showed that a more 
modest depletion of GSH by BSO to 40% of basal levels in vivo is not 
sufficient to activate Nrf2 (Goldring et al. 2004). There was no evidence 
for direct chemical modification of Keapl by BSO (data not shown), 
which is consistent with its known biochemical mechanism of action and 
chemical structure (Griffith 1982). Therefore, it is possible that from the 
ability of BSO to deplete GSH and causing cellular redox perturbation, 
which could lead to the activation of Nrf2 by Keapl cysteines oxidation. 
These oxidations may be either R-SOH and disulphide bonds or R-S02H 
and R-S03H, which are reversible oxidation or irreversible oxidation 
respectively (Ghezzi et al. 2003). Alternatively, the changes in cellular 
oxidative status that is provoked by the depletion of GSH may also
125
Chapters
induce alternative signalling pathways that are involved in the activation 
of Nrf2 [for a review, see (Giudice et al. 2006; Giudice et al. 2010)]. The 
alternative signalling pathways that are induced by oxidative stress 
involved kinases; protein kinase C (PKC), mitogen-activated protein 
kinase (MARK) cascades and casein kinase II (CK-II). The hypothesis is 
that these kinases are involved in the possible phosphorylation of Nrf2 
leading to the Nrf2 activation. PKC (Bloom et al. 2003; Niture et al. 
2009), MARK (Cullinan et al. 2003; Zipper et al. 2003; Keum et al. 2006) 
and CK-II (Pi et al. 2007; Apopa et al. 2008) have been suggested to be 
involved in the phosphorylation of Nrf2, and this would alter the 
association of Nrf2 and Keapl; either allowing or inhibiting the nuclear 
translocation of Nrf2.
Through the utilisation of this panel of molecules with different 
electrophilic properties to test the possibility that Nrf2/Keapl pathway 
can be induced through a mechanism other than the direct modification 
of Keapl's cysteine residues, the results in this chapter demonstrated 
that Nrf2 can be activated (1) by Dex-mes and 15d-PGJ2 in the absence 
of GSH depletion but where cysteine residues are alkylated, (2) by DNCB 
and IA that deplete GSH and are able to alkylate cysteine residues, and 
(3) by BSO, which depletes GSH but is not able to alkylate cysteine 
residues. The modification of Keapl cysteines have been well described 
in the literature but activation Nrf2 by GSH depletion and its mechanism 
is not so well described yet. Therefore, future experiments need to be 
performed to determine the mechanism behind Nrf2 activation through 
GSH depletion; i.e. is this via the oxidation of cysteines in Keapl, in other 
associated proteins, through the phosphorylation of Nrf2 by kinases, or 
through other as yet unidentified mechanisms?
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In summary, this study has demonstrated that Nrf2 can be 
activated by either direct modification of Keapl or through a profound 
depletion of GSH alone, and that other toxicologically-relevant 
molecules such as TMA that display neither of these properties are 
unlikely to induce Nrf2-dependent cell defence. For molecules that are 
capable of alkylating Keapl and depleting GSH, it is likely that the 
differential contribution of both these mechanism underlies the 
activation of Nrf2 in a molecule-specific manner. Therefore, it is possible 
that both direct modification of Keapl and depletion of GSH are 
involved in the activation of Nrf2. Such multiple mechanisms for 
detecting chemical/oxidative stress might explain the well-established 
versatility of Nrf2/Keapl pathway.
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Chapter 4
Thiol status of Keapl, the regulator of the cell 
defence transcription factor Nrf2, in the cellular
environment
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4,1 INTRODUCTION
Cellular defence against chemical and oxidative stress is largely 
controlled through the specific activation of the Keapl/Nrf2 pathway 
and the transcription of Nrf2 dependent genes (Copple et al. 2008b). 
Through the action of Nrf2 at AREs, Keapl and Nrf2 control cellular 
defence by regulating the expression of phase II detoxification, 
antioxidant and phase III transport proteins (Itoh et al. 1997; Ishii et al. 
2002; Aieksunes et al. 2009). Currently, the most widely accepted model 
of the Nrf2 activation mechanism induced by chemical and oxidative 
stress is the concurrent oxidation or alkylation of key cysteine residues 
within Keapl (Holtzclaw et al. 2004; Kobayashi et al. 2006b).
The human and mouse Keapl proteins are both cysteine-rich, 
containing 27 and 25 cyteines, respectively. They therefore have a very 
high ratio of cysteine to other amino acids, at 4.3% and 4.0 % when 
compared to other human or mouse proteins, respectively (Miseta et al. 
2000). The cysteines are distributed throughout the Keapl protein in 
four distinct domains; BTB, IVR, DGR and CTR. The role of the cysteine 
residues within Keapl has been the main focus of the Nrf2 activation 
hypothesis. The significant role played by the cysteine residues within 
Keapl has been proposed based on cysteine functional, mutagenesis 
and covalent modification studies. From these investigations, three 
critical cysteine residues (CyslSl, Cys273 and Cys288) have been 
attributed to play a significant role in the mechanism leading to Nrf2 
activation (Zhang et al. 2003; Levonen et al. 2004; Wakabayashi et al. 
2004; Kobayashi et al. 2006a; Yamamoto et al. 2008). Cys273 and 
Cys288, which are located within the IVR region, have been suggested to 
maintain the Keapl-dependent repression of Nrf2 under basal 
conditions in cell-based assays (Zhang et al. 2003; Levonen et al. 2004;
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Wakabayashi etal. 2004; Kobayashi etal. 2006a) and in vivo (Yamamoto 
et al. 2008). Hence, it is believed that the mutation of both cysteines 
causes Keapl not to be in a position to correctly bind Nrf2 for targeted 
ubiquitination and proteosomal degradation. The BTB-located cysteine, 
CyslSl, has been shown to maintain the binding of CulB ligase to Keapl. 
The chemical covalent modification of CyslSl results in the dissociation 
of CulB ligase from Keapl, abrogating the ubiquitination of Nrf2 and the 
mutation of CyslSl can disrupt this dissociation (Zhang et al. 2003; 
Zhang et al. 2004; Rachakonda et al. 2008; Yamamoto et al. 2008; Eggler 
etal. 2009; Kobayashi etal. 2009).
In support of functional and mutagenesis studies of the model, 
covalent modification studies further support the concept that the 
cysteine residues within Keapl play an important role in Nrf2 activation. 
Many reactive chemicals or electrophiles that are able to react and 
covalently modify or adduct Keapl cysteine resisdues, are also able to 
activate Nrf2 (Dinkova-Kostova et al. 2002; Dinkova-Kostova et al. 2005; 
Copple et al. 2008a; Rachakonda et al. 2008). Electrophiles such as N- 
iodoacetyl-N-biotinylhexylenediamine (IAB), l-biotinamido-4-4(4'- 
[maleimidiethylcyclohexane]-carboxamido)butane (BMCC) and DEX-MES 
have been shown to covalently modify cysteines present in recombinant 
mouse or human Keapl in vitro (Dietz et al. 2005; Eggler et al. 2005; 
Hong et al. 2005a; Hong et al. 2005b; Liu et al. 2005; Liebler et al. 2006; 
Luo et al. 2007). Moreover, recent work has demonstrated that Keapl 
cysteines are selectively modified by direct covalent modification in cells 
which over-express Keapl in culture (Hong et al. 2005b; Copple et al. 
2008a; Rachakonda et al. 2008). The panel of electrophiles studied and 
reported in the literature do not target a specific cysteine, instead each 
targets cysteine residues randomly across the Keapl protein (Fig 4.1).
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However, CyslSl, Cys273 and Cys288 are targeted by electrophiles at a 
higher occurrence than the rest of the cysteines. This has lead to the 
hypothesis that these residues act as key sensors of chemical stress (Fig 
4.1). The hypothesis of covalent modification of key sensor cysteines has 
been proposed previously (Kobayashi et al. 2009). However, the exact 
mechanism of how Keapl senses the large number of different Nrf2- 
inducing electrophiles and their reactivity is still not clear.
Therefore, it is also possible that oxidative stress without the 
formation of chemical adducts on Keapl can trigger Nrf2 activation. As 
mentioned previously in chapter 3, substantial depletion of cellular 
glutathione (GSH) can elicit Nrf2 activation in the absence of covalent 
modification. The mechanism by which this occurs is currently unclear, 
however oxidation of cysteine residues has been suggested 
(Wakabayashi et al. 2004). The different forms of cysteine oxidations are 
shown in Fig 3.1. Currently, there is no direct evidence that the cysteine 
residues within Keapl cysteines undergo oxidation in vivo. However, 
Keapl cysteines oxidation have been suggested from the identification 
of inter- or intra-disulphides between cysteines residues and S- 
glutathionylation of cysteine residues using mass spectrometry on 
recombinant Keapl and immunoblotting of Keapl from over-expressing 
cultured cells (Wakabayashi et al. 2004; Holland et al. 2008; Fourquet et 
al. 2010; Zhang et al. 2010).
Despite the extensive mechanistic studies on Keapl cysteine 
residues, the basal thiol status of numerous cysteines in Keapl is yet to 
be determined. With the exception of the eight cysteines located within 
the DGR domain of the human protein appear to be reduced basally, as 
the study has indicated that they do not appear to participate in 
disulphide bonds, at least in the absence of cellular stress (Li et al. 2004).
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Using a cell based model and LC-MS/MS analysis, we have previously 
described in the CDSS (Copple et al. 2008a) are used as experimental 
methods in this chapter. The aims of this chapter are to investigate 
what the Keapl thiol/cysteines status is under basal conditions and to 
further explore the molecular mechanisms underlying the ability of 
Keapl cysteine residues to sense electrophile or oxidative stress.
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Figure 4.1: Schematic overview of human and mouse Keapl cysteine 
residues and their modification by electrophiles. Electrophile 
modification of human Keapl cysteine residues (black box) and mouse 
Keapl cysteine residues (white box). The red box outlines the three 
critical cysteines of Keapl (CyslSl, Cys273 and Cys288). The domains of 
Keapl are outlined at the bottom of the figure and the cysteine numbers 
are annotated at the top and bottom of the figure. The abbreviations of 
the electrophiles are as follows: BMCC; l-biotinamido-4-4(4'- 
[maleimidiethylcyclohexane]-carboxamido)butane (Hong et al. 2005b; 
Luo et al. 2007), IAB; N-iodoacetyl-N-biotinylhexylenediamine (Hong et 
al. 2005b; Eggler et al. 2007), SULF; sulforaphane (Hong et al. 2005a), 
DEX-MES; dexamethasone-21-mesylate (Liebler et al. 2006), ISO; 
isoliquiritigenin, SHO; 10-Shogaol, XAN; xanthohumol (Luo et al. 2007), 
LIQ; liqustilide (Dietz et al. 2008), P-SS-P; protein disulphide, P-SG; s- 
glutathionlyation (Holland et al. 2008), NAPQI; N-acetyl-p- 
benzoquinoneimine, IA; iodoacetamide, DNCB; dinitrochlorobenzene 
(Copple et al. 2008a), DEX-MES (Dinkova-Kostova et al. 2002; Copple et 
al. 2008a), 15d-PGJ2; 15-deoxy-A1214-prostaglandin J2 (Copple et al. 
2008a; Kobayashi et al. 2009), PGA2; prostaglandin A2, DEM; 
diethylmaleate (Kobayashi et al. 2009). [Adapted from (Holland et al. 
2008)].
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4.2 MATERIALS AND METHODS 
4.2.1 Materials
The Mouse Keapl-V5 encoding plasmid was kindly donated by Dr 
Ian Copple (CDSS, University of Liverpool UK). The pcDNA3.1/V5-His- 
TOPO and Lipofeactamine 2000 were purchased from Invitrogen 
(Paisley, UK). The XLIO-Gold ultracompetent E. coli. were purchased 
from Agilent Technologies (Stockport, UK). Sequencing grade modified 
trypsin was from Promega (Southampton, UK). The QIAfilter Plasmid 
Midi Kit was from Qiagen (Crawley, UK). The anti-GSH monoclonal 
antibody was from Virogen (Massachusetts, USA). The deuterated-5- 
NEM was from Qmx Laboratories (Essex, UK). The Series 200 HPLC was 
from Perkin Elmer (Massachusetts, USA). The CIS Uptisphere column 
was from Interchim, Cheshire Sciences Ltd (Chester, UK). The MALDI 
target plate, Voyager-DE PRO MALDI-TOF Biospectrometry Workstation, 
AB Sciex API3000 triple-quadrapole mass spectrometer, API QSTAR 
Pulsar I MS/MS spectrometer. Analyst QS and ProteinPilot software 
packages were from Applied Biosystems (Warrington, UK). The aCHCA 
matrix was from Laserbio Labs (Valbonne, France). The intergrated 
LCPackings System and CIS PepMap column were from Dionex 
(Camberley. UK). PicoTip emitters were from New Objective (Woburn, 
USA). The NanoDrop 1000 UV-spectrophotometer was from Labtech 
International (East Sussex, UK). The Concentrator 5301 was from 
Eppendorf (Cambridge, UK). The Nucleofector® was from Lonza (Slough, 
UK). All other reagents were of analytical or molecular grade and 
purchased from Sigma-Aldrich (Poole, UK).
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4.2.2 Cell Culture and Cell Count
Hepa-lclc7 cells were maintained and counted as detailed in 
section 2.2.2. The human embryonic kidney (HEK293T) cells were 
transformed with the large T antigen of Simian virus 40 (SV40), which 
enables the episomal replication of transfected plasmids that contain 
the SV40 origin of replication (DuBridge et al. 1987). HEK293T cells were 
maintained at 37°C in a 5% C02 atmosphere in conventional growth 
medium DMEM supplemented with 584mg/L L-gutamine, 10% FBS, 100 
U/ml penicillin, and lOOug/ml streptomycin and cultured as described 
for Hepa-lclc7 in section 2.2.2.
4.2.3 Mouse Keapl-V5 plasmid culture
The mouse Keapl-V5-encoding plasmid (Keapl-VS) was 
generated by Dr Ian Copple (Copple et al. 2008a). A mouse Keapl full 
coding sequence with no stop codon was inserted into the TORO cloning 
site of pcDNA3.1/V5-His-TOPO and transformed into XLIO-Gold 
ultracompetent £. coli. A 15% (v/v) glycerol stock of pcDNA3.1/Keapl-V5 
XLIO-Gold E. coli was cultured in 600ml of LB broth supplemented with 
50pg/ml ampicillin and incubated for 24hr at 37°C; 250rpm. The 
pcDNA3.1/Keapl-V5 plasmid was purified using QIAfilter Plasmid Midi 
Kit and eluted into IX TE buffer (lOmM Tris base, ImM EDTA, pH 7.5). 
IpJ of the plasmid was assessed using a NanoDrop 1000 UV- 
spectrophotometer for DNA concentration and purity. An absorbance of 
1.0 at 260nm is equivalent to 50pg/ml of DNA. The purity of DNA in each 
sample was determined via reference to the 260nm:280nm ratio. DNA 
samples with a 260nm:280nm ratio of below 1.8 were deemed as 
impure.
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4.2.4 Transfection of ceils with Keapl-V5
4.2.4.1 Lipofectamine transfection of cells with Keapl-V5
HEK293T or Hepa-lclc7 cells were seeded onto 56.7cm2 Nunclon 
A culture dishes at 4 X 106 cells/dish, on the day previously. Cells were 
transfected with pcDNA3.1/Keapl-V5 plasmid using Lipofectamine 2000. 
For each dish of cells, 1ml DMEM was combined with 40pl of 
Lipofectamine 2000 in a 20ml tube. 1ml DMEM was combined with 16pg 
of plasmid in a 20ml tube. The contents of both tubes were mixed and 
incubated at room temperature for 20min. All of the mixture was added, 
dropwise, to the dish. Cells were returned to a humidified incubator, at 
37DC in a 5% CO2 atmosphere for 24hr.
4.2.4.2 IMucleofector® transfection (nucleofection) of cells with Keapl- 
V5
The Nucleofector® method was attempted for the Keapl-V5 
transfection. Hepa-lclc7 cells were harvested and 1 X 106 or 2 X 106 
ceils were counted. Counted cells were centrifuged at ISOOrpm for 5min 
and the supernatant was discarded. The cell pellet was resuspended at 
room temperature in Nucleofector® Solution provided by the 
manufacturer to a final concentration of 1X 106 - 2 X 106 cells/lOOpl. Ipg 
or 5pg of DNA plasmid was then added to the lOOpI cell suspension. The 
mixture was transferred into a certified cuvette provided by the 
manufacturer, while making sure that the sample covers the bottom of 
the cuvette, avoiding air bubbles and cuvette closed with a blue cap. The 
appropriate Nucleofector® program (H022 or T028) was selected with 
the cuvette inserted into the cuvette holder in the Nucleofector® and 
the programmed transfection was started. The cuvette was taken out 
after the programmed transfection, cells were transferred from the 
cuvettes into prepared 6-well plates. Cells were returned to a humidified
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incubator, at 37°C in a 5% C02 atmosphere for 16hr and 19hr. All 
preparations were done under sterile conditions.
4.2.5 Cell Treatment
Hepa-lclc7 cells were seeded onto 96-well plates and 6-well 
plates at 2 x 104 cells/well and 1 x 106 cells/well respectively on the 
previous day. Diamide was dissolved in water. Cell treatment was 
prepared as detailed in section 2.2.3.
4.2.6 Preparation of whole cell lysates
Whole cell lysate preparation was conducted as in section 2.2.4.
4.2.7 Measurement of Protein content
The total protein content was determined as detailed in section
2.2.5.
4.2.8 Immunopurification of Keapl-V5 after cell treatment
HEK293T cells were seeded onto 56.7cm2 Nunclon A culture 
dishes at 4 X 106 cells/dish. BSO and diamide were dissolved in water 
and IA, NEM and DNCB were dissolved in DMSO. For BSO, diamide and 
DNCB, cell treatment was prepared as detailed in section 2.2.3. IA and 
NEM were dissolved in DMSO at 20x the final concentration. To each 
dish, 500pJ of the dissolved compound or a DMSO control were added 
(1:20 dilutions) for 2min. The cells were lysed for immunopurification of 
Keapl-V5.
Keapl-V5 was immunopurified from whole cell lysate prepared 
in RIPA buffer. 1ml of lysate was incubated with 60pJ anti-V5 agarose 
beads on a mechanical roller for 2hr at 4°C. The beads were collected by 
centrifugation at 5000g for Imin and washed three times with 500pl IX 
PBS.
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4.2.9 Western Immunoblotting
4.2.9.1 Whole cell lysates immunoblotting
Whole cell lysates (lOfig or 25|ig) were immunoblotted for Nrf2 
and Keapl as detailed in section 2.2.6.
4.2.9.2 Immunopurified Keapl-V5 immunoblotting
Immunopurified Keapl-V5 was immunobioted for Keapl and S- 
glutathionylation as detailed in section 2.2.6. Proteins were eluted from 
anti-V5 agarose beads by resuspending in an equal volume of NuPage 
loading buffer. The slurry was heated at 80°C for 5min and the beads 
pelleted by centrifugation for 5min at 5000g. The supernatant was 
loaded onto a pre-cast 4-12% NuPage Novex bis-tris polyacrylamide gel. 
For non-reducing condtions, NuPage reducing sample was replaced with 
distilled water in the loading buffer and NuPage antioxidant was 
removed from the MOPS running buffer. Immunoblotting for S- 
glutathionylation were performed with mouse monoclonal anti-mouse 
glutathione (1:1000 in TBS-Tween containing 2% (w/v) BSA) and mouse 
anti-mouse (1:5000 in TBS-Tween containing 2% (w/v) BSA) HRP- 
conjugated secondary anti-IgG for Ihr.
4.2.10 Coomassie Brilliant Blue Staining and in-gel trypsin digestion
After immunopurification of Keapl-V5 as detailed in 4.2.8, 
proteins were eluted from anti-V5 agarose beads and loaded onto a gel 
as detailed in 5.2.9. After electrophoresis, the gel was fixed for Ihr in 
40% (v/v) methanol containing 7% (v/v) glacial acetic acid. Coomassie 
staining solution was prepared by mixing 4 parts Coomassie stain (0.1% 
(w/v) Coomassie Brilliant Blue G-250 in 2% (w/v) phosphoric acid, 16% 
(w/v) ammonium sulphate) with 1 part 100% methanol. The gel was 
then stained with Coomassie staining solution for l-2hr with gentle
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agitation. The gel was destained with 10% (v/v) glacial acetic acid in 25% 
(v/v) methanol for Imin with gentle agitation. The gel was rinsed in 25% 
(v/v) methanol, and detained further in 25% (v/v) methanol for up to 
24hr and stored at 4°C. The stained gel was placed on a light box and 
bands of interest were excised using a scalpel. The gel pieces were 
individually destained, in 0.1ml of 50mM ammonium bicarbonate 
(AmBic) in 50% (v/v) acetonitrile (ACN) for 15min at room temperature 
with occasional agitation. The destaining solution was removed and gel 
pieces were dried in a Concentrator 5301 for up to 15min. The gel pieces 
were rehydrated with BOfil SOmIVI AmBic containing Sng/pil sequencing- 
grade modified trypsin and incubated overnight at 37°C. After tryptic 
digestion, 30pil of 60% (v/v) ACN, 1% (v/v) trifluoroacetic acid (TFA) was 
added and the samples were placed in a sonicating water bath for 5min 
at room temperature. The gel pieces were pelleted by centrifugation for 
30s at lOOOg, and the supernatant transferred to a new microfuge tube. 
A further 30jil of 60% (v/v) ACN, 1% (v/v) TFA was added to gel pieces, 
and the gel pieces were placed in the sonicating water bath for 5min at 
room temperature. The gel pieces were pelleted by centrifugation for 
30s at lOOOg, and supernatant was combined with that from the 
previous spin. The sample was dried in a Concentrator 5301 and the 
solute was reconstituted in 10}il of 5% (v/v) ACN/0.05% (v/v) TFA.
4.2.11 MALDI-TOF mass spectrometry
Following overnight tryptic digestion, peptide mixtures (0.5p.l) 
were combined with an equal volume of a-cyano-4-hydroxy-cinnamic 
acid (aCHCA) matrix (lOmg/ml aCHCA in 50% (v/v) ACN, 0.1% (v/v) TFA) 
and spotted onto a MALDI-TOF target plate alongside ProteoMass 
MALDI-MS standards (angiotensin II, adrenocorticotropic hormone 
fragment 18-39, oxidised insulin chain B, O.Spmol each), using the dried-
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droplet method. Peptide mass fingerprints were obtained on a Voyager 
DE Pro MALDI time-of-flight (TOP) Biospectrometry Workstation, in 
linear positive ion mode, and used in a MASCOT protein database search 
fhttp://www.matrixscience.com) to enable identification present within 
the sample.
4.2.12 LC-MS/MS methods
Samples were prepared by adding the following in a ratio of 1:5, 
diamide:GSH in water for 30min. The formation of the conjugate was 
measured using a Perkin Elmer Series 200 HPLC, 50pL of sample was 
injected on to a reversed-phase CIS Uptisphere column, 100 x 2.1 mm, 
5p.m and AB Sciex API3000 triple-quadrapole mass spectrometer was 
used for detection. The gradient solvent system used to separate the 
sample compounds consisted of 95% H20 + 0.1% formic acid (A) and 5% 
methanol (B) held for 2min, then increased to 95% (B) linearly for 9mins 
and increased back to 95% (A) held for 2min. The flow rate was 
0.2ml/min, and column temperature was set at 30°C. Mass 
spectrometric data acquisition was performed using the following 
conditions: positive ionisation mode, ionisation voltage 5500V, ion 
source 350°C, nebuliser gas and curtain gas was maintained at settings 
of 12 and 10, respectively. The declustering potential was 51V and 
collision energy was 15V for all MS/MS scan. The mass transitions 
monitored were m/z 173 (diamide), m/z 380 (diamide + GSH), m/z 308 
(GSH), m/z 613 (GSSG) and m/z 175 (hydrazine).
4.2.13 Preparation of NEM-modified human serum albumin for mass 
spectrometry
Human serum albumin (HSA) (2nmol) was dissolved in phosphate 
buffer was incubated with increasing ratios of NEM (1:1, 1:10, 1:100 and 
1:500) dissolved in DMSO or DMSO as control for 2min at room
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temperature. The HSA (20iil) was precipitated with 9 volumes of ice-cold 
methanol and was recovered by centrifuging at 14000g, 4 °C for 10 min. 
This was repeated three times to yield the maximum precipitation of 
HSA. The pellet were reduced by the addition of 20pl of lOmM DTT at 50 
°C for 15min and unmodified cysteines were alkylated with 20|il of 
55mM IA at room temperature for 15min. The HSA was precipitated 
again after treatment and pellet resuspended with 50pl of 50mM AmBic 
and was digested with 3 pg trypsin at 37 °C overnight. For LC-ESI-MS/MS 
analysis, the supernatant containing the peptides were dried in a 
Concentrator 5301. The solute was then reconstituted in 40pl of 5% 
(v/v) ACN, 0.05% TFA.
4.2.14 Preparation of Keapl-V5 for mass spectrometry
After incubation and washing, PBS was removed from Keapl-V5- 
bound anti-V5 agarose beads after centrifugation. The resulting beads 
(40pl dry volume) were reduced by resuspending in 59pl of PBS and Ipl 
of lOOmM DTT. The mixture was incubated on a mechanical roller at 4°C 
for 15min. The beads were washed three times with 500pl of PBS after 
incubation to remove residual DTT. The unmodified cysteines were 
alkylated by resuspending beads in 50pl of PBS and lOpI of 550mM of IA 
or 200mM of IMEM/dsIMEM, and incubated on a mechanical roller at 4°C 
for 15min. The beads were washed three times in 500pl of PBS to 
remove residual IA, NEM or d5NEIVI after incubation. Prior to tryptic 
digestion, beads were washed once with 200pl of 25mM AmBic and 
then resuspended in 20pl of 25mM AmBic. A 400pg/ml stock solution of 
sequencing-grade modified trypsin was diluted 1 in 10 with 25mM 
AmBic and 5pl was added to the beads mixture. Trypsin digestion of the 
protein was performed overnight at 37°C. For LC-ESI-MS/MS analysis, 
the beads were pelleted after trypsin digestion by centrifuging for 30sec
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at 5000g. The resulting supernatant containing the peptides was 
transferred to a new microfuge tube and dried in a Concentrator 5301 
set at 30°C. The solute was reconstituted in 40ni of 5% (v/v) ACN, 0.05% 
TFA.
4.2.15 LC-ESI-MS/MS methods
The reconstituted solute (40p.l) prepared from section 4.2.13 was 
loaded using a 0.1ml loop. The sample was delivered into an API QSTAR 
Plusar i system by automated in-line reversed phase liquid 
chromatography (LC) using an integrated LCPackings System (Famos 
autosampler, Ultimate LC pump, Switches microcolumn switching 
module) and a 75pm x 15cm CIS PepMap Column via a nano­
electrospray source head with a 10pm inner diameter PicoTip emitter. 
LC conditions were as follows; 15min at 5% (v/v) ACN, 0.05% (v/v) TFA, a 
gradient 5-48% (v/v) ACN, 0.05% (v/v) TFA over 60min, lOmin at 99% 
(v/v) ACN, 0.05% (v/v) TFA and 10min at 5% (v/v) ACN, 0.05% (v/v) TFA, 
with a flow rate of 0.35pl/min throughput. Across a mass range of 300- 
2000 Dalton (Da), MS and MS/MS spectra were acquired automatically 
in positive ion mode using information-dependent acquisition powered 
by Analyst QS software. With an above threshold of 5 counts per sec, the 
three most intense ions in each MS spectrum were subjected to MS/MS 
analysis for l.Ssec and subsequently excluded from further analysis for 
40sec. Amino acid modifications were detected with ProteinPilot 
software v2.0 using the Paragon™ algorithm and the most recent version 
of SwissProt database. Carboxyamidomethyl (+57.0Da), NEM 
(+126.0Da), d5NEM (+131.0Da) and dinitrophenyl (DNP; +166.0Da) were 
selected as variable modifications. All adducts were confirmed by visual 
inspection of the MS/MS spectra.
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4.3 RESULTS
4.3.1 Validation of Keapl-V5 transfection in HEK293T and Hepa-lclc7 
cells as models for investigating the thiol status of Keapl
Two methods were employed for the transient expression of 
Keapl-V5 in HEK293T and Hepa-lclc7 cells. Firstly, both cell lines were 
transiently transfected for 16hr with Keapl-V5 via Lipofectamine 2000. 
The expression of Keapl-V5 in HEK293T and Hepa-lclc7 cells by 
Lipofectamine were showed in Dr Ian Copple's thesis and separately 
here (Fig 4.2a). Keapl-V5 was well expressed in HEK293T but no 
expression was seen in the Hepa-lclc7. A time-range investigation was 
used to compare Keapl-V5 transient transfection with Lipofectamine 
between HEK293T and Hepa-lclc7. The Keapl expression by time-range 
transfection at 19hr, 24hr and 28hr with lipofectamine in Hepa-lclc7 
was still not as efficient as in HEK293T at 24hr (Fig 4.2b). Since 
Lipofectamine was effective in transfecting Keapl-V5 into HEK293T, a 
range of Keapl-V5 DNA to Lipofectamine ratios were investigated to 
determine which ratio gave the optimum transfection. From the range 
of ratios investigated, a DNA to Lipofectamine ratio of 1:2.5 was 
determined to be the most efficient (Fig 4.2c). Longer transfection 
periods of 48hr improved the levels of Keap-V5 expression in HEK293T 
(4.2d). Next, a second method of transfection, nucleofection was used to 
try to improve the expression of Keapl-V5 in Hepa-lclc7 cells. The cells 
were transiently transfected for 16hr with Keapl-V5 by nucleofection 
with 5pg of plasmid. These methods were shown to improve the 
expression (Fig 4.3a). Following this, increasing the amount of cells used 
for transfection and increasing the incubation period after nucleofection 
were tested to further improve and optimise the Keapl-V5 expression. 
However, neither increasing the amount of cells nor the longer
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incubation period had any additional improvement on the expression of 
Keapl-V5 (Fig 4.3b and c). In fact, the results shown by nucleofection 
suggested that this method was inconsistent as the expression of Keapl- 
V5 varied with different transfections done. Therefore, Hepa-lclc7 cells 
could not express Keapl-V5 efficiently with both transfection methods 
used. HEK293T transiently expressing Keapl-V5 remained the best 
model for the investigation of the thiol status of cysteine residues within 
Keapl in living ceils.
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Figure 4.2: Transient expression of Keapl-V5 in HEK293T and Hepa- 
lclc7 cells. HEK293T and Hepa-lclc7 cells were transfected with Keapl- 
V5, using lipofectamine (a-d). Cell lysates were resolved using SDS-Page 
and the blots were probed for Keapl. Keapl-V5 was only expressed in 
HEK293T and not Hepa-lclc7 with Lipofectamine (16hr) (a). Time-range 
transfections in Hepa-lclc7 were not as effective as when compared to 
HEK293T (b). A Keapl-V5 DNA:Lipofectamine ratio of 1:2.5 was the 
optimised ratio for efficient expression of Keapl-V5 in HEK293T (c). A 
48hr transfection increased the expression of Keapl-V5 compared to 
24hr transfection (d). Recombinant Keapl-V5 was loaded as a positive 
control on the blot (+con). A representative gel is shown from n=2-3.
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Figure 4.3: Transient expression of Keapl-V5 in HEK293T and Hepa- 
lclc7 cells. HEK293T and Hepa-lclc7 cells were transfected with Keapl- 
V5, using nudeofection (a-c). Cell lysates were resolved using SDS-Page 
and the blots were probed for Keapl. Nudeofection dependent 
transfection improved Keapl-V5 expression in Hepa-lclc7 (a). The 
number of cells did not increase the amount of expression of Keapl-V5 
with nudeofection after 16hr (b). Both 16hr and 19hr incubation periods 
could not reproduce consistent expression (c). Recombinant Keapl-V5 
was loaded as a positive control on the blot (+con). A representative gel 
is shown from n=2-3.
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4.3.2 MALDI-TOF MS identification of expressed and purified Keapl-V5 
in HEK293T
The expression of Keapl-V5 in HEK293T was identified by 
MALDI-TOF. HEK293T cells were transfected with Keapl-V5 for 24hr and 
cells were lysed with RIPA buffer. The cell lysates were incubated with 
anti-V5 agarose beads. Following incubations with cell lysates, proteins 
bound to beads were resolved using SDS-PAGE and Coomassie Brilliant 
Blue G-250 (CCB) staining. Sections of the protein-stained gel were 
excised; bands 1-4 (Fig 4.4) were subjected to tryptic digestion and 
analysed by MALDI -TOF MS analysis. Bands 1 and 2 were identified as 
having mouse Keapl as the major constituent protein. Bands 3 and 4 are 
the mouse immunoglobulin (IgG) heavy and light chains which were 
fragments of the anti-V5 IgG released from the anti-V5 agarose beads 
(Fig 4.4). Mouse Keapl appeared as two bands on the gel, however, a 
MALDI-TOF MS analysis and MASCOT database search did not identify 
any oxidised cysteines on both Keapl-V5 bands (Fig 4.5-4.8).
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Band 1: mouse Keapl-V5 
Band 2: mouse Keapl-V5
Band 3: mouse Immunoglobulin heavy chain
Band 4: mouse Immunoglobulin light chain
Figure 4.4: Identification of anti-V5 immunoprecipitated proteins with 
anti-V5 agarose beads. HEK293T cells were transfected with or without 
Keapl-V5 for 24hr. Whole cell lysates were prepared and incubated with 
anti-V5 agarose beads for 2hr at 4°C. Protein bound anti-V5 agarose 
beads were resolved by SDS page and CCB stained for protein 
visualisation. Stained protein bands were excised, digested with trypsin 
and analysed by MALDI-TOF. The data obtained from the MALDI-TOF MS 
spectra were used in a MASCOT protein database search to identify the 
major protein constituent(s) for each band Proteins with the highest 
degree of confidence were shown.
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Figure 4.5: MALDI-TOF mass spectrum of the tryptic digests from 
proteins present in band 1. Band 1 as depicted in Fig 4.4 was excised, 
digested with trypsin and analysed by MALDI-TOF. The resulting peptide 
mixture was visualised on a Voyager DE Pro MALDI-TOF Biospectrometry 
Workstation, in linear positive ion mode.
Accession Mass Score Description
1. KEAPl.MOUSE 69508 294 Keich-like ECH-associated protein 1 - Mus musculus (Mouse)
2. KEAP1 RAT 69354 261 Kelch-like ECH-associated protein 1 - Rattus norvegicus (Rat)
3. KEAP1_PK3 69771 144 Kelch-like ECH-associated protein 1 - Sus scrofa (Pig)
4. KEAPl.HUMAN 69621 122 Kelch-like ECH-associated protein 1 • Homo sapiens (Human)
5. KEAPl.PONAB 69663 112 Kelch-like ECH-associated protein 1 - Pongo abelii (Sumatran orangutan)
Match to: KEAPl_MOUSE Kelch-like ECH-associated protein 1 - Mus musculus (Mouse)
Sequence Coverage: 57%
1 MQPEPKLSGA PRSSQaPLW SKCPEGAGDA VMYASTECKA EVTPSQDGNR 
51 TFSYTIEDHT KQAFGVMNEL RLSQQLCDVT LQVKYEDIPA AQFMAHKWl
101ASSSPVFKAM FTNGLREQGM EWSIEGIHP KVM E RUEEft YTASISVGE K
151CVLHVMN6AV MYUIDSWRA CSOFLVQQLO PSNAIGIANF AEQIGCTELH 
201QRAREYTYMH FGEVAKQEEF FNLSHCQLAT LISRDDLNVR CESEVFHACI
251 DWVKYDCPQR RFYVQAllRA VRCHALTPRF LQTQLQKCEILQADARCKDV 
301LVQIFQELTL HKPTQAVPCR APKVGRUYT AGGYFRQSLS YlEAYNPSNG 
3515WLRLADLQV PRSGLAGCW GGLLYAVGGR NNSPDGNTDS SALDCYNPMT 
401NQWSPCASMS VPRNRK3VGV IDGHIYAVGG SHGC1HHSSV ERYEPERDEW 
451HLVAPMLTRR IGVGVAVLNR LLYAVGGFDG TNRLNSAECY YPERNEWRMI 
501TPMNT1RSGA GVCVLHNCIY AAGGYDGQDQ LNSVERYDVE TETWTFVAPM 
551 RHHRSALGIT VHQGKIYVLG GYDGHTFLDS VECYDPDSOT WSEVTRMTSG 
601RSGVGVAVTM EPCRKQIDQQ NCTC
Figure 4.6: MASCOT protein database search results for a peptide mass 
fingerprint obtained from the MALDI-TOF MS analysis of band 1. The
peptide mass fingerprint was applied to a MASCOT protein database 
search which identified the band 1 tryptic digest as mouse Keapl 
without any post-translational modification. The top five proteins 
identified with the highest score of confidence are shown. The amino 
acid sequence coverage for mouse Keapl was 57% and specific peptides 
covered by the MALDI-TOF MS analysis are underlined and in bold 
letters.
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Figure 4.7: MALDI-TOF mass spectrum of the trypsin digests from 
proteins present in band 2. Band 2 as depicted in Fig 4.4 was excised, 
digested with trypsin and analysed by MALDI-TOF. The resulting peptide 
mixture was visualised on a Voyager DE Pro MALDI-TOF Biospectrometry 
Workstation, in linear positive ion mode.
Accession Mass Score Description
1. KEAPl_MOU$E 69508 141 Kelch-like ECH-associated protein 1 - Mus musculus (Mouse)
2. KEAPl.RAT 69354 104 Kelch-like ECH-associated protein 1 - Rattus norvegicus (Rat)
3. KEAP1_PK3 69771 71 Kelch-like ECH-associated protein 1 - Sus scrofa (Pig)
4. KEAP1_HUMAN 69621 62 Kelch-like ECH-associated protein 1 - Homo sapiens (Human)
Match to: KEAP1_M0USE Kelch-like ECH-associated protein 1 • Mus mutcuiut (Mouse)
Sequence Coverage: 28%
1 MQPEPKLS6A PRSSOFLPLW SKCPEGAGDA VMYASTECKA EVTPSODGNR 
51 TFSYTUPHT kqafqvmnel RLSQQLCDVT LQVKYIPIPA AQFMAHKWL 
101ASSSPVFKAM FTNGLREQGM EWSIEGIHP KVMERLIEFA YTAS1SVGEK 
151CVLHVMNGAV MYQIDSWRA CSOFLVQQLD PSNAIGIANF AEQIGCTELH 
201QRAREYIYMH FGEVAKQEEF FNLSHCQLAT LISRDDLNVR CESEVFHACI 
251DWVKYDCPQR RFYVQALLRA VRCHALTPRF LQTQLQKCEILQADARCKDY 
301LVQIFQELTL HKPTQAVPCR APKVGRUYT AGGYFRQSLS YLEAYNPSNG 
351SWLRLADLQV PRSGLAGCW GGLLYAVGGR NNSPDGNTDS SALDCYNPMT 
401NQWSPCASMS VPRNRIGVGVIDGHIYAVGG SHGCIHHSSV ERYEPERDEW 
451 HLVAPMLTRR KjVGVAVLNR UYAVSGFPG TNRLNSAECY YPERNEWRMI 
501TPMNT1RSGA GVCVLHNCIY AAGGYDGQDQ LNSVERYDVE TETWTFVAPM 
551RHHRSALGU VHQGKIYVLG GYDGHTFLDS VECYDPDSDT WSEVTRMTSG 
601RSGVGVAVTM EPCRKQIDQQ NCTC
Figure 4.8: MASCOT protein database search results for a peptide mass 
fingerprint obtained from the MALDI-TOF MS analysis of band 2. The
peptide mass fingerprint was applied to a MASCOT protein database 
search which identified the band 2 tryptic digest as mouse Keapl 
without any post-translational modification. The top four proteins 
identified with the highest score of confidence are shown. The amino 
acid sequence coverage for mouse Keapl was 28% and specific peptides 
covered by the MALDI-TOF MS analysis are underlined and in bold 
letters.
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4.3.3 Alkylation of Keapl-V5 cysteine residues with a high 
concentration of alkylating agents, iodoacetamide and N- 
ethylmaleimide
The cell based model, previously described to investigate the 
formation of chemical adducts on Keapl-V5 cysteines (Copple et ah 
2008a), was used to study the basal thiol status of Keapl in the cellular 
environment. The common alkylating agents, IA and NEM were used to 
investigate the Keapl-A/5 cysteine status in HEK293T cells by LC-ESI- 
MS/MS. A high concentration of IA and NEM (50mM) was used to treat 
the cells for 2mins. This was used as a freezing technique to attempt to 
alkylate all available reduced cysteine residues. Successful cysteine 
alkylation would indicate that the alkylated cysteine exists in a reduced 
form under basal conditions. Following alkylation, Keapl-V5 was 
immunoprecipitated from whole cell lysates with anti-V5 agarose beads 
and DTT was used to reduce any potential by reversible oxidation. 
Afterwards, NEM or IA was added to alkylate the newly reduced 
cysteines to differentiate the modification of cysteines before and after 
DTT reduction.
IA could not adduct some of Keapl-V5 cysteine residues despite 
the high concentration used (Fig 4,9a) but conversely, NEM was able to 
adduct every cysteine on the recombinant Keapl-V5 (Fig 4.9b). This is 
with exception of cysteine 622 and 624, which might not be released 
from the V5-agarose beads after tryptic digest due to their close 
proximity to the V5 tag of Keapl-V5. Cysteines 395 and 406, for 
example, were not alkylated by IA but could be alkylated by NEM. NEM 
was therefore considered to be a more efficient alkylating agent 
compared to IA and was used in subsequent investigations. 
Furthermore, the ability of NEM to adduct all of the Keapl-V5 cysteines 
suggests that all of these residues are reduced basally and are available
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for alkylation in cells (Fig 4.10). To further confirm this observation, 
human serum albumin (HSA) was treated with NEM to determine 
whether or not NEM had the potential to break any disulphide bonds 
that form between cysteines. HSA contains 35 cysteines, 34 of which 
are involved in disulphide bond formation leaving one cysteine (Cys34) 
as a free thiol (Oettl et al. 2010). At a range of HSA to NEM ratios, NEM 
was only able to adduct the single reduced Cys34 (Table 4.1 and Fig 
4.11). This indicates that NEM is unable to break disulphide bonds in 
HSA.
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Figure 4.10: MS/MS spectrum indicating modification of Keapl-V5 (a) 
Cys-23/38 and (b) Cys-77 by NEM in HEK293T cells, y- and b-ions are 
labelled where present. * represents ions for which a mass shift of 
+126.ODa indicates modification by NEM.
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CVLHVMNGAVMYQIDSVVR
14\ 40524
Figure 4.10: MS/MS spectrum indicating modification of Keapl-V5 (c) 
Cys-151 and (d) Cys-171/196 by NEM in HEK293T cells, y- and b-ions are 
labelled where present. * represents ions for which a mass shift of 
+126.ODa indicates modification by NEM.
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Figure 4.10: MS/MS spectrum indicating modification of Keapl-V5 (e) 
Cys-226 and (f) Cys-241/229 by NEM in HEK293T cells, y- and b-ions are 
labelled where present. * represents ions for which a mass shift of 
+126.ODa indicates modification by NEM.
158
Chapter 4
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Figure 4.10: MS/MS spectrum indicating modification of Keapl-V5 (g) 
Cys-257 and (h) Cys-273 by NEM in HEK293T cells, y- and b-ions are 
labelled where present. * represents ions for which a mass shift of 
+126.ODa indicates modification by NEM.
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Figure 4.10: MS/MS spectrum indicating modification of Keapl-V5 (i) 
Cys-288 and (j) Cys-297/319 by NEM in HEK293T cells, y- and b-ions are 
labelled where present. * represents ions for which a mass shift of 
+126.ODa indicates modification by NEM.
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Figure 4.10: MS/MS spectrum indicating modification of Keapl-V5 (k) 
Cys-368 and (I) Cys-395/406 by NEM in HEK293T cells, y- and b-ions are 
labelled where present. * represents ions for which a mass shift of 
+126.ODa indicates modification by NEM.
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Figure 4.10: MS/MS spectrum indicating modification of Keapl-V5 (m) 
Cys-434 and (n) Cys-489 by NEM in HEK293T cells, y- and b-ions are 
labelled where present. * represents ions for which a mass shift of 
+126.ODa indicates modification by NEM. Immonium ions are labelled 
with C corresponding to cysteine.
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Figure 4.10: MS/MS spectrum indicating modification of Keapl-V5 (o) 
Cys-513/518 and (p) Cys-583 by NEM in HEK293T cells, y- and b-ions are
labelled where present. * represents ions for which a mass shift of 
+126.ODa indicates modification by NEM.
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Figure 4.10: MS/MS spectrum indicating modification of Keapl-V5 (q) 
Cys-613 by NEM in HEK293T cells, y- and b-ions are labelled where
present. * represents ions for which a mass shift of +126.ODa indicates 
modification by NEM.
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HSA;NEM 1:0 1:1 1:10 1:100 1:500
No Pos NEM IA NEM !A NEM IA NEM IA NEM IA
1 34 X X X X X X X X X
2 53 X X X X X
3 62 X X X X X
4 75 X X X X X
5 90 X X X X X
6 91 X X X X X
7 101 X X X X X
8 124 X X X X X
9 168 X X X X X
10 169 X X X X X
11 177 X X X X X
12 200
13 245 X X X X X
14 246 X X X X X
15 253 X X X X X
16 265 X X X X X
17 278 X X X X X
18 273 X X X X X
IS 283 X X X X X
20 316
21 360 X X X X X
22 361 X X X X X
23 369 X X X X X
24 392 X X X X X
25 437 X X X X X
26 438 X X X X X
27 448 X X X X X
28 461
23 476
30 477 X X X X X
31 487 X X X X X
32 514 X X X X X
33 558 X I x X X X
34 559 X I x X X X
35 567 X j x X X X
Table 4.1: HSA cysteine residue 34 is selectively modified by NEM. HSA
was incubated with NEM, or DMSO as a control at increasing molar 
ratios from 0 to 500 for 2mins under in vitro condition, HSA was washed 
several times and reduced with lOmM DTT. After further washes, 55mM 
of IA was added to adduct the newly reduced cysteines. HSA was 
digested with trypsin overnight and LC-ESI-MS/MS analysis was 
performed.
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Figure 4.11: MS/MS spectrum indicating modification of HSA Cys-34 by 
NEM in vitro, y- and b-ions are labelled where present. * represents ions 
for which a mass shift of +126.ODa indicates modification by NEM.
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4.3.4 Using deuterated-5-NEM as an alkylating agent
It has shown that, IA could not adduct Keapl-V5 cysteine 
residues as efficiently as NEM (Fig 4.9). Another alternative alkylating 
agent which has similar characteristics to NEM was therefore required to 
substitute IA. Dueterated-5-NEM (d5NEM) (Fig 4.12) was selected as an 
alternative alkylating agent to IA as it has the same structure as NEM, 
although it is 5Da heavier. This mass difference can be detected by LC- 
ESI-MS/MS (Niwayama et al. 2001). Hence, NEM and d5NEM were used 
as alkylating agents to investigate the basal thiol status of Keapl-V5. 
Here a lower concentration of NEM (ImM) was used to adduct Keapl- 
V5 cysteines for 5min. At this concentration of NEM, all of the Keap-V5 
cysteines were modified by NEM, suggesting that the cysteines were 
available for NEM adduction (Fig 4.13). After DTT reduction, d5NEM was 
able to adduct all of the remaining Keapl-V5 cysteines (Fig 4.14), except 
for cysteine 297 which must have been fully adducted by NEM (Fig 4.13). 
This is in line with what was observed previously; high concentrations of 
NEM were able to adduct virtually all of the Keapl-V5 cysteines.
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Molecular Weight:125.13 Molecular Weight: 130.16
Figure 4.12: Chemical structure of NEM and d5NEM. The d5NEM is 
heavier than NEM by SDa, due to the presence of deuterated hydrogen 
(D) instead of hydrogen on the ethyl group.
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Figure 4.14: MS/MS spectrum indicating modification of Keapl-V5 (a) 
Cys-77 and (b) Cys-257 by d5NEM in HEK293T cells, y- and b-ions are 
labelled where present. * represents ions for which a mass shift of 
+131.ODa indicates modification by dsNEM.
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Figure 4.14: MS/MS spectrum indicating modification of Keapl-V5 (c) 
Cys-288 and (d) Cys-613 by d5NEM in HEK293T cells, y- and b-ions are 
labelled where present. * represents ions for which a mass shift of
+131.ODa indicates modification by d5NEM. Immonium ions are labelled 
with C corresponding to cysteine.
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4.3.5 Identification of S-glutathionylation of cysteine residues in 
Keapl-V5 under basal conditions and after cellular stress
Cysteine residues can undergo reversible oxidation to form 
disulphide bridges, S-glutathionyiation or sulphenic acids. These 
oxidations are known as oxidative post-translational modifications 
(oxPTM). These oxPTM are known to control the activation or 
inactivation of proteins involved in many signalling pathways (Spickett et 
at. 2010). As previously shown, two forms of Keapl-V5 were identified 
on a CCB gel following immunoprecipitation with anti-V5 agarose beads 
from the cell lysates of HEK293T expressing Keapl-V5 (Fig 4.4). 
However, MALDI-TOF MS analysis did not identify any difference 
between the two forms. Figure 4.9 shows that alt Keapl-V5 cysteine 
residues are present in a reduced form basally and are available to be 
alkylated by NEM, which suggests the absence of disulphide bridges. 
Following this observation, investigations were carried out to determine 
if there were other forms of reversible cysteine oxidation, such as s- 
glutathionylation, occurring on Keapl-V5 cysteine residues basally or 
after cellular stress.
HEK293T cells were transfected with Keapl-V5 overnight and 
treated with lOOpM BSO or water as a control for 24hr. Following BSO 
treatment, cells were treated with high concentrations of IA, NEM or 
DMSO as a control for 2min. BSO, a known GSH depleting agent was 
employed (Griffith 1982) and has been shown in chapter 3 to activate 
Nrf2 when cellular GSH levels drop to 20% of the basal level. Under the 
current test conditions, BSO was found to deplete GSH to nearly 0% of 
control and this has also shown for IA and NEM treatment with or 
without prior BSO treatment in Keapl-V5 expressing HEK293T (Fig 4.15). 
Therefore, we attempted to determine if this GSH depletion was enough 
to induce S-glutathionylation on Keapl-V5 cysteine residues.
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S-giutathionylation was determined by MALDi-TOF and GSH 
blotting analysis. Keapl-V5 was immunoprecipitated from HEK293T after 
treatment, resolved using SDS-PAGE under reducing and non-reducing 
conditions. The blots were probed with Keapl and GSH antibodies. 
Immunoblotting showed the presence of S-glutathionylation on Keapl- 
V5 under non-reducing conditions (Fig 4.16a and c), which disappeared 
under reducing conditions (Fig 4.16b and d). From the immunoblotting 
analysis, S-giutathionylation was observed in the control, BSO, IA or 
NEM treated samples and in the BSO with IA or NEM treated samples 
(Fig 4.16).
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Figure 4.15: GSH depletion by BSO in HEK293T. HEK293T cells were 
transfected with Keapl-V5 overnight and treated with lOOpM BSO or 
water as control for 24hrs. Following BSO or water treatment, cells were 
treated with IA and NEM for 2min and lysed with lOmM HCL GSH was 
depleted by BSO with or without IA (a) and NEM (b). Total GSH was 
normalised to total protein content versus control. Error bars = average 
of two independent experiments of triplicate measurements, n=2.
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Non-reducing
IP:Keapl
b Reducing
IP:Keapl
IB:6SH IB:Keapl IB:GSH IB:Keapl
]^Keapl-V5
c
Keapl-V5 <Keapl-V5
Figure 4.16: S-glutathionylation of Keapl-V5 in control and treated 
cells. HEK293T were transfected with Keapl-V5 overnight and treated 
with lOOpM BSO and water as a control for 24hr. Cells were further 
treated with 50mM IA or NEM and DMSO as a control for 2min. Cells 
were lysed with RIPA buffer and Keapl-V5 was immunoprecipitated with 
anti-V5 agarose beads. Immunoprecipitated proteins were resolved by 
SDS-PAGE under non-reducing or reducing conditions, and probed with 
anti-Keapl and anti-GSH antibodies. S-glutathionylation of Keapl 
occurred in control and treated samples under non-reducing conditions
(see I-----I) (a and c). However, under reducing conditions S-
glutathionylation of Keapl is reversed the GSH immunoreactive signal 
disappeared from Keapl-V5 (see dD) (b and d). IP; 
immunoprecipitation. IB; immunoblotting. Representative gel shown 
from n=2.
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MALDI-TOF MS analysis was applied as a second method to look 
for GSH adduction of cysteine residues. Immunoprecipitated Keapl-V5 
from HEK293T cells following treatment was resolved by SDS-PAGE and 
was stained with CCB. CCB-stained protein bands on the gel were 
excised and tryptically digested overnight for MALDI-TOF MS analysis 
(Fig 4.17). Bands excised from the CON and IA samples were identified 
as Keapl-V5 by MALDI-TOF MS. Keapl-V5 could not be identified in 
BSO-treated samples, as there might not have been enough peptides 
detected to cover the full amino acid sequencing of Keapl by MALDi- 
TOF. The MALDI-TOF MS analysis identified S-glutathionylation on 
cysteine 273 in Keapl in the control sample but it was a miscleaved 
peptide (Fig 4.18-4.20). The protein band excised in the IA sample was 
identified as Keapl-V5 and s-glutathionylation could be detected on 
cysteine 77 by MALDI-TOF MS analysis (Fig 4.21-4.23).
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Figure 4.17: CCB staining of immunoprecipitated Keapl-V5 from over 
expressing HEK293T cells. HEK293T cells were transfected with Keapl- 
V5 and treated with lOOpM BSO or water as a control for 24hr. 
Following BSO treatment, cells were further treated with 50mM IA or 
DMSO as a control. Whole cell lysates were prepared and incubated 
with anti-V5 agarose beads for 2hr at 4°C. Protein bound to anti-V5 
agarose beads were loaded onto SDS-PAGE gels and CCB staining for 
protein was performed. Stained protein bands (cm) were excised, 
digested with trypsin and analysed by MALDI-TOF MS. The data obtained 
from MALDI-TOF MS spectra were used in a MASCOT protein database 
search to identify the major protein constituent(s) for each band, 
therefore giving protein identity with the highest degree of confidence 
for each band.
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Figure 4.18: Representative MALDI-TOF mass spectrum of the tryptic 
digests of the Keapl band from control samples. CCB staining of 
proteins bound anti-V5 agarose beads was performed. Stained protein 
bands were excised, digested with trypsin and analysed by MALDI-TOF. 
The resulting peptide mixture was visualised on a Voyager DE Pro 
MALDI-TOF Biospectrometry Workstation, in linear positive ion mode.
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AcccKion Mass Score Description
1. KEAPl_MOUSE 69508 176 Kelch-like ECH-associated protein 1 • Mus musculus (Mouse)
2. KEAP1_RAT 69354 137 Kelch-like ECH-associated protein 1 - Rattus norvegicus (Rat)
3. KEAP1_PIG 69771 86 Kelch-like ECH-associated protein 1 - Sus scrofa (Pig)
4. SG269_MOUSE 191006 79 Tyrosine-protein kinase-protein kinase SgK269 • Mus musculus (Mouse)
5. KEAP1_HUMAN 69621 79 Kelch-like ECH-associated protein 1 - Homo sapiens (Human)
Match to: KEAPl_MOUSE Kclch-lika ECH>auociit«d protein 1 - Muc mutculut (Moum)
Sequence Coverage: 46%
1 MQPEPKLSGA PRSSQFLPIW SKCPEGAGDA VMYASTECKA EVTPSQDGNR 
51 TPSmEPHT KQAFqVMNEL RLSQQICDVT LQVKYEDIPA AQFMAHKWL 
101ASSSPVFKAM FTNGLREQGM EVV5IEGIHP KVMERUEFA YTASISVGEK 
151CVLHVMNGAV MYQIDSWRA CSDFLVQQtD PSNA1GIANF AEQIGCTELH 
201QRAREYIYMH FGEVAKQEEF FNLSHCQLAT USRDOLNVR CESEVFHACI 
251DWVKYDCPQP RFlfyQAU.RA VRCHALTPRF LQTQLQKCEI LQADARCKDY 
301 LVQIFQEITI HKPTQAVPCR APKVGRLIYT AGGYFRQSLS YLEAYNPSNG 
351SWLRLAPLQV PRSGLAGCVVGGLLYAVGGR NNSPDGNTDSSAEDCYNPMT 
401 NQWSPCASMS VPRNRIGVGV IDGHIYAVGG SHGC1HHSSV FRYEPEROEW 
451 HLVAPMLTRR IGVGVAVLNR LLYAVGGFDG TNRLNSAECY YPERNEWRMI 
501TPMNTIRSGA GVCVLHNCfY AAGGYDGQDQ LNSVERYDVETETWTFVAPM 
551RHHRSALGIT VHQGK1YVIG GYDGHTFLDS VECYDPOSDT WSEVTRMTSG
Start - End Observed Mr (expt) Mr(calc) ppm Miss Sequence
13 22 1192.6670 1191.6597 1191.6288 26 0 R.SSQSXPLWSK.C
40 50 1173.6266 1172.6193 1172.5422 66 0 K.AEVTPSQDGNR.T
51 61 1341.6895 1340.6822 1340.6248 43 0 R.TFSYTLEDHTK.Q
62 - 71 1164.6172 1163.6099 1163.5757 29 0 K. QAFGVMNELR. L
85 97 1520.7686 1519.7613 1519.7129 32 0 K.YEDIPMQFMAHK.V
117 - 131 1652.8959 1651.8886 1651.8239 39 0 R. EQGMEWSIEGIHPK. V
136 - 150 1627.9120 1626.9048 1626.8505 33 0 R.LIEFAYTASISVGEK.C
205 216 1486.7467 1485.7394 1485.6962 29 0 R.EYIYMHFGEVAK.Q
261 - 269 1165.6384 1164.6311 1164.6767 -39 1 R.RFYVQA1LR.A
262 - 269 1009.6185 1008.6112 1008.5756 35 0 R.FYVQALLR.A
273 - 279 797.4431 796.4358 796.4014 43 0 R.CHA1TPR.F
280 - 287 1005.5999 1004.5926 1004.5655 27 0 R.FLQTQLQK.C
288 - 296 1018.5972 1017.5899 1017.4913 97 0 R. CEILQADAR. C
327 - 336 1160.6505 1159.6433 1159.6026 35 0 R.LIYTAGGYFR.Q
337 354 2085.0384 2084.0311 2083.9963 17 0 R. QSLS YLEAYNPSNGSWLR. L
355 362 911.5452 910.5379 910.5236 16 0 R.LADLQVPR.S
363 380 1648.9282 1647.9210 1647.8767 27 0 R. S GLAGCWGGLLYAVGGR. N
443 - 447 693.3642 692.3569 692.3129 64 0 R.YEPER.D
443 - 459 2142.1085 2141.1012 2141.0364 30 1 R. YE PERDEWHLVAPMLTR. R
448 459 1467.7947 1466.7874 1466.7340 36 0 R. DEWHLVAPMLTR. R
460 - 470 1153.7613 1152.7541 1152.7091 39 1 R.RIGVGVAVLNR.L
461 470 997.6531 996.6458 996.6080 38 0 R. IGVGVAVLNR. L
471 - 483 1382.7608 1381.7535 1381.6990 39 0 R. LLYAVGGFDGTNR. L
495 - 507 1661.8642 1660.8569 1660.8177 24 1 R.NEWRMITPMNTIR. S
499 - 507 1076.5830 1075.5758 1075.5518 22 0 R.MITPMNTIR.S
537 551 1844.9069 1843.8996 1843.8451 30 0 R. YDVETETWTFVAPMR. H
555 565 1110.6336 1109.6263 1109.6193 6 0 R.SALGITVHQGE.I
597 - 614 1838.0091 1837.0018 1836.8645 75 1 R. MTSGRSGVGVAVTMEPCR. K
615 624 1180.6035 1179.5962 1179.5012 80 1 R.KQIDQQNCTC.-
Figure 4.19: MASCOT protein database search results for a peptide 
mass fingerprint obtained from the MALDI-TOF MS analysis of the 
Keapl band from control samples. The peptide mass fingerprint shown 
was used in a MASCOT protein database search, which identified mouse 
Keapl without any post-translational modification from the tryptic 
digest. The top five proteins identified with the highest score of 
confidence are shown. The amino acid sequence coverage for mouse 
Keapl was 46% and specific peptides covered by the MALDI-TOF MS 
analysis are underlined and highlighted in bold.
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Accession Mass Score Description
1. KEAPi_MOUSE 69508 160 Kelch-like ECH-associated protein 1 - Mus musculus (Mouse)
2. KEAP1_RAT 69354 123 Kelch-like ECH-associated protein 1 - Rattus norvegicus (Rat)
3. KEAP1_PIG 69771 80 Kelch-like ECH-associeted protein 1 - Sue scrofa (Pig)
4. MRH4_LODEl 191006 77 ATP-dependent RNA helicase MRH4, mitochondrial - Lodderomyces 
elongisporus (Yeast)
3. KEAP1_HUMAN 69621 68 Kelch-like ECH-associated protein 1 • Homo sapiens (Human)
Match to: KEAPl_MOUSE Kelch-like ECH-associated protein 1 - Mu* musculus (Mouse)
Sequence Coverage: 47%
1 MQPEPKISGA PRSSQFLPLW SKCPEGAGDA VMYASTFCKA EVTPSOPSNR 
51 TFSYTLEDHT KQAfGVMNEL RLSQQLCDVT LQVKYEDIPA AQFMAHKWi 
101ASSSPVFKAM ^TNGLREQGM EWSlEGiHP KVMERLIEFA YTAS1SVGEK 
151CVLHVMNGAV MYQIDSWRA CSDFLVQQLD PSNAIGIANF AEQIGCTELH 
201 QRAR£Y1YMH ffiEVAKOEEF FNLSHCQLAT USRDOLNVR CESEVFHACI 
251 DWVKYDCPQR RFYVQALLRA VRCHALTPRF LQTQLQKCE1LQADARCKDY 
501 LVQIFQELTL HKPTQAVPCR APKVGRUYT AGGYFRQSLS YLEAYNPSNG 
351SWIRLADLQV PRSGLAGCVV GGLLYAVGGR NNSPDGNTDS SAIDCYNPMT 
401 NQWSPCASMS VPRNRIGVGV IDGHIYAVGG SHGCIHHSSV FRYEPERDFW 
451 HLVAPMLTRRIGVGVAVLNR LLYAVGGFDG TNRLNSAFCY YPERNEWRMI 
501 IPMNTiRSGA GVCVLHNCIY AAGGYDGQDQ LNSVFRYDVE TETWTFVAPM 
551 RHHRSALGiT VHQGKiYVi G GYDGHTFLDS VECYDPDSOT WSFVTRMTSG 
601 RSGVGVAVTM EPCRKQ1DQQ NCTC
13 - 22 
40 - 50 
51 - 61 
62 - 71 
85 - 97 
117 - 131 
136 - 150 
205 - 216
261 - 269
262 - 269 
270 - 279 
273 - 279 
280 - 287 
288 - 296 
327 - 336 
337 - 354 
355 - 362 
363 - 380 
443 - 447 
443 - 459 
448 - 459
460 - 470
461 - 470 
471 - 483 
495 - 507 
499 - 507 
537 - 551 
555 - 565 
597 - 614
Observed Mr (expt) Mr(calc)
1192.6670 1191
1173.6266 1172
1341.6895 1340
1164.6172 1163
1520.7686 1519
1652.8959 1651
1627.9120 1626
1486.7467 1485
1165.6384 1164
1009.6185 1008
1428.6727 1427
797.4431 796
1005.5999 1004
1018.5972 1017
1160.6505 1159
2085.0384 2084
911.5452 910
1648.9282 1647
693.3642 692
2142.1085 2141
1467.7947 1466
1153.7613 1152
997.6531 996
1382.7608 1381
1661.8642 1660
1076.5830 1075
1844.9069 1843
1110.6336 1109
1838.0091 1837
.6597 1191.6288 
6193 1172.5422 
.6822 1340.6248 
6099 1163.5757 
7613 1519.7129 
8886 1651.8239 
9048 1626.8505 
7394 1485.6962 
6311 1164.6767 
6112 1008.5756 
6654 1427.6762 
4358 796.4014 
5926 1004.5655 
5899 1017.4913 
6433 1159.6026 
0311 2083.9963 
5379 910.5236 
9210 1647.8767 
3569 692.3129 
1012 2141.0364 
7874 1466.7340 
7541 1152.7091 
6458 996.6080 
7535 1381.6990 
8569 1660.8177 
5758 1075.5518 
8996 1843.8451 
6263 1109.6193 
0018 1836.8645
26
66
43
29
32 
39
33
29 
-39
35
-8
43
27
97
35 
17 
16 
27 
64
30
36 
39
38
39 
24 
22 
30
6
75
Miss Sequence
0 R.SSQFLPLWSK.C 
0 K.AEVTPSQDGNR.T 
0 R.TFSYTLEDHTK.Q 
0 K.QAFGVMNELR.L 
0 K.YEDIPAAQFMAHK.V 
0 R. EQGMEWSIEGIHPK . V 
0 R.LIEFAYTASISVGEK.C 
0 R.EYIYMHFGEVAK.Q 
1 R.RFYVQAU-R. A 
0 R. FYVQALLR . A
1 R.AVRCHALTPR.F Glutathione (C)
0 R.CHALTPR.F 
0 R.FLQTQLQK.C 
0 K.CEILQADAR.C 
0 R.LIYTAGGYFR.Q 
0 R.QSLSYLEAYNPSNGSWLR.L 
0 R.LADLQVPR.S 
0 R. S GLAGCWGGLLYAVGGR . N 
0 R.YEPER.D
1 R. YE PERDEWHLVAPMLTR. R 
0 R.DEWHLVAPMLTR.R 
1 R.RIGVGVAVLNR.L 
0 R.IGVGVAVLNR.L 
0 R.LLYAVGGFDGTNR.L 
1 R.NEWRMITPMNTIR.S 
0 R.MITPMNTIR.S 
0 R.YDVETETWTFVAPMR.H 
0 R.SALGITVHQGK.I 
1 R.MTSGRSGVGVAVTMEPCR.K
Figure 4.20: MASCOT protein database search result for a peptide mass 
fingerprint obtained from the MALDI-TOF MS analysis of the Keapl 
band from control samples. The peptide mass fingerprint shown was
used in a MASCOT protein database search, which identified mouse
Keapl with S-glutathionylation on cysteine 273 but it was a miscleaved 
peptide. The top five proteins identified with the highest score of 
confidence are shown. The amino acid sequence coverage for mouse 
Keapl was 47% and specific peptides covered by the MALDI-TOF MS 
analysis are underlined and highlighted in bold.
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Figure 4.21: Representative MALDI-TOF mass spectrum of the trypsin 
digests of the Keapl from the IA treated samples. CCB staining for 
protein bound to anti-V5 agarose beads was performed. Stained protein 
bands were excised, digested with trypsin and analysed by MALDI-TOF 
MS. The resulting peptide mixture was visualised on a Voyager DE Pro 
MALDI-TOF Biospectrometry Workstation, in linear positive ion mode.
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Accession Mass Score Description
1. Mixture 1 196 KEAPl MOUSE + V010 FOWPV
2. KEAPIJYIOUSE 69508 126 Kelch-llke ECH-associated protein 1 • Mus musculus (Mouse)
3. KEAP1_RAT 69354 118 Kelch-like ECH-associated protein 1 • Rattus norvegicus (Rat)
4. MY61F_DROME 69771 64 Myosin-18 - Drosophila melanogaster (Fruit Fly)
5. UBIE_2YMMO 191006 64 Ubiquinone/menaquinone biosynthesis methy(transferase ubiE • Zymomonas 
mobilis (bacterium)
Match to: KEAPl_MOU$E K«lch-lik« ECH-ixsociatcd protein 1 - Mus mutcului (Mouse)
Sequence Coverage: 50%
1 MQPEPKLSGA PRSSQFLPLW SKCPEGAGPA VMYASTECKAEVTPSQOGNS
51 TFSYTLEPHT KQAPGVMNEL R15QQLCDVT LQVKYEDIPA AQFMAHKWL 
101ASSSPVFKAM FTNGIREQGM EWSIEGiHP KVMERUEFAYTASISVGEK 
151CVLHVMNGAV MVQIOSWRA CSDFLVQQlD PSNAIGSANF AEQIGCTELH 
201QRAREYIYMH FGEVAKQEEF FNLSHCQLAT LISRDDLNVR CESEVFHACI 
251 DWVKYPCPQR RFYVQALLRA VRCHALTPRFIQTQ1QKCEIIQADARCKDY
351 SWIRLADLQV PRSGLAGCVV GGUYAVGGR NNSPDGNTDS SALDCYNPMT 
401 NQWSPCASMS VPRNKIGVGV IDGHIYAVGG 5HGCIHHS5V ERYEPERDFW 
451 HLVAPMLTRR IGVGVAVLNR LLYAVGGFPG TNRLNSAECY YPERNEWRMI
501TPMNTIRSGA GVCVLHNCIY AAGGYDGQDQ LNSVERYDVE TETWTFVAPM 
551 BHHRSALGFr VHQGKIYVLG GYDGHTFIDS VECYDPDSDT WSEVTRMTSG
601RSGVGVAVTM EPCRKQIDQQ NCTC
Start - End Observed Mr(expt) Mr(calc) ppm Miss Sequence
13 - 22 1192.6834 1191.6761 1191.6288 40 0 R.SSQFLPLWSK.C
51 - 61 1341.7008 1340.6936 1340.6248 51 0 R.TFSYTLEDHTK.Q
72 - 84 1531.9168 1530.9095 1530.8076 67 0 R.LSQOLCDmoVK.T Carbairidoitethyl (C)
85 - 97 1520.8501 1519.8428 1519.7129 85 0 K.YEDIPAAQFMMK.V
151 - 169 2134.0169 2133.0097 2133.0533 -20 0 K. CVIHVMNGAVMYQIDSWR. A
217 - 234 2193.1625 2192.1552 2192.0684 40 0 K.SEElTOsacQIATLISR.D Carbamidonethyl (C)
241 - 254 1779.8743 1778.8670 1778.7756 51 0 R.CZSEVmciDWVK.T 2 Carbanudonsthyl (C)
255 - 260 836.4151 837.4078 837.3439 76 0 K.TDCPQR.R Carbatidonethyl (C)
261 - 269 1165.6774 1164.6701 1164.6767 -6 1 R.RFYVQALLR.A
262 - 269 1009.6477 1008.6404 1008.5756 64 0 R.PYVQALLR.A
270 - 279 1180.6352 1179.6279 1179.6295 -1 1 R.AVRCRA1IPR.F Carbaaidoaethyl (C)
273 - 279 797.4207 796.4135 796.4014 15 0 R.CHALTPR.F
273 - 279 854.3822 853.3749 853.4229 -56 0 R.CHALTPR.F Carbaaidoaethyl (C)
280 - 287 1005.6203 1004.6130 1004.5655 47 0 R.FLQTQLQK.C
288 - 296 1075.5885 1074.5812 1074.5128 64 0 k.ceilqadar.c Carbaaidoaethyl (C)
288 - 298 1363.7160 1362.7087 1362.6384 52 1 K.CEILQADARCK.D 2 Carbaaidoaethyl (C)
299 - 320 2656.5108 2655.5036 2655.3843 45 0 K.DTLVQIFQELTLHKPTQAVPCR.A Carbaaidoaethyl (C)
327 - 336 1160.6803 1159.6730 1159.6026 61 0 R.LIYTAGGYFR.Q
337 - 354 2085.0691 2084.0618 2083.9963 31 0 R.QSLSYLEAYNPSNGSWLR.L
355 - 362 911.5953 910.5880 910.5236 71 0 R. LADLQVPR.S
363 - 380 1648.9063 1647.8990 1647.8767 14 0 R.SGIAGCWGGLLTAVGGR.N
363 - 380 1706.0025 1704.9952 1704.8981 57 0 R. SGLAGCWGGLLYAVGGR. N Carbaaidoaethyl (C)
416 - 442 2813.5068 2812.4996 2812.3828 42 0 R.IGVGVIDGHIYAVGGSBGCIHHSSVER.T Carbaaidoaethyl (C)
443 - 447 693.3351 692.3278 692.3129 21 0 R.YEPER.D
461 - 470 997.6653 996.6580 996.6080 50 0 R.IGVGVAVUiR.L
471 - 483 1382.7813 1381.7740 1381.6990 54 0 R.LLTAVGGFDGTNR.L
484 - 494 1401.7074 1400.7001 1400.6030 69 0 R.LNSA1CTTPER.R Carbaaidoaethyl (0
537 - 551 1844.9609 1843.9536 1843.8451 59 0 R.TOVETETRTFVAPMR.H
597 - 614 1837.9836 1836.9764 1836.8645 61 1 R.MTSGRSGVGVAVTOEPCR.K
Figure 4.22: MASCOT protein database search results for a peptide 
mass fingerprint obtained from the MALDI-TOF MS analysis of the 
Keapl from the IA treated samples. The peptide mass fingerprint shown 
was used in a MASCOT protein database search, which identified mouse 
Keapl with cysteines adducted with carbamidomethy. The top five 
proteins identified with the highest score of confidence are shown. The 
amino acid sequence coverage for mouse Keapl was 50% and specific 
peptides covered by the MALDI-TOF MS are analysis are underlined and 
highlighted in bold.
182
Chapter 4
Accession Mass Score Description
1. MURI_CLONN 28542 73 Glutamate racemase - Clostridium novyi (strain NT) (Bacterium)
2. V010 FOWPV 40591 69 Uncharacterised serpin-like protein FPV010 - Fowlpox virus
3. AN R53_MOUSE 56702 65 Ankyrin repeat domain-containing protein 53 - Mus muscuius (Mouse)
«. GADX_SHIR 31432 62 HTH«typ« transcriptional regulator gadX - Shigella ftexnari (Bacterium)
5. KEAPl.MOUSE 69508 57 Kelch-like ECH-associated protein 1 - Mus muscuius (Mouse)
Match to: KEAPl_MOUSE Kalch-lika ECH-»ttoei»t«d protein 1 • Mu« muscuius (Moum)
Sequence Coverage: 32%
1 MQPEPKLSGA PRSSQFLPLW SKCPE6AGDA VMYASTECKA EVTPSQDGNR 
51 TFSYTLEDHT KQAPGVMNEl RLSQQi.CDVT LQVKYEDIPA AQFMAHKVVL 
101ASSSPVFKAM FTNGLREQGM EWSiEGIHP KVMERUEFAYTASISVGEK 
151CVLHVMNGAV MYQID5VVRA CSDFLVQQLO PSNAIGIANF AEQiGCTElH 
201QRAREYIYMH FGEVAKQEEF FNISHCQLAT LISRDOLNVR CESEVFHACI 
251DWVKYDCPQR RFYVQAURA VRCHALTPRF LQTQLQKCEI LQADARCKDY 
301 LVQIFQELTt HKPTQAVPCR APKVGRUYT A6GYFRQSLS YLEAYNPSNG 
351 SWLRLADLQV PRSGLAGCVV GGLLYAVGGR NNSPDGNTDS SALDCYNPMT 
401NQWSPCASMS VPRNRIGVGVIDGHIYAVGG SHGCIHHSSV ERYEPERDFW 
451HLVAPMLTRR K3V0VAVLNR LLYAVGSFDgTNRLNSAECY YPERNEWRMI 
501TPMNTIRSGA GVCVLHNCIY AAGGYDGQOQ LNSVFRYDVE TFTWTFVAPM 
551EHHRSAIGIT VHQGKIYVIG GYOGHTFLDS VECYDPOSDT WSEVTRMT5G 
601 RSGVGVAVTM EPCRKQIDQQ NCTC
Start - End Observed Mr(expt) Mr (calc) ppm Miss Sequence
13 - 22 1192.6834 1191.6761 1191.6288 40 0 R.SSQFLPLWSK.C
51 - 61 1341.7008 1340.6936 1340.6248 51 0 R.TFSYTLEDHTK.Q
72 - 84 1779.8743 1778.8670 1778.8543 7 0 R.LSQQLCDVTLQVK.Y Glutathione (C)
85 - 97 1520.8501 1519.8428 1519.7129 85 0 K.YEDIPAAQFMMK.V
151 - 169 2134.0169 2133.0097 2133.0533 -20 0 K.CVLHVMNGAVMYQIDSWR.A
261 - 269 1165.6774 1164.6701 1164.6767 -6 1 R.RFYVQALLR.A
262 - 269 1009.6477 1008.6404 1008.5756 64 0 R.FYVQALIfl.A
273 - 279 797.4207 796.4135 796.4014 15 0 R.CHALTPR.F
280 - 287 1005.6203 1004.6130 1004.5655 47 0 R.FLQTQLQK.C
327 - 336 1160.6803 1159.6730 1159.6026 61 0 R.LIYTAGGYFR.Q
337 - 354 2085.0691 2084.0618 2083.9963 31 0 R.QSLSYLEAYNPSNGSWLR.L
355 - 362 911.5953 910.5880 910.5236 71 0 R.LADLQVPR.S
363 - 380 1648.9063 1647.8990 1647.8767 14 0 R. SGLAGCWGGLLYAVGGR. N
443 - 447 693.3351 692.3278 692.3129 21 0 R.YEPER.D
461 - 470 997.6653 996.6580 996.6080 50 0 R.IGVGVAVLNR.L
471 - 483 1382.7813 1381.7740 1381.6990 54 0 R.LLYAVGGFDGTNR.L
537 - 551 1844.9609 1843.9536 1843.8451 59 0 R.YDVETETWTFVAPMR.H
Figure 4.23: MASCOT protein database search results for a peptide 
mass fingerprint obtained from the MALDI-TOF MS analysis of the 
Keapl from the IA treated samples. The peptide mass fingerprint shown 
was used in a MASCOT protein databased search, which identified 
mouse Keapl GSH binding to cysteine 77. The top five proteins 
identified with the highest score of confidence are shown. The amino 
acid sequence coverage for mouse Keapl was 50% and specific peptides 
covered by the MALDI-TOF MS analysis are underlined and highlighted in 
bold.
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4.3.6 Determination of cysteine oxidation on Keapl-V5 after BSO 
treatment using LC-ESi-MS/MS
S-glutathionylation has been shown here to occur on Keapl 
basaily and after GSH depletion or chemical stress through 
immunoblotting. However, MADLI-TOF MS analysis could only identify S- 
glutathionylation on cysteine 273 and on cysteine 77 in the control and 
lA-treated samples, respectively. Next, cysteine oxidation on Keapl-V5 
was investigated with LC ESI-MS/MS in order to determine if Keapl 
cysteine oxidation is a possible mechanism for Nrf2 activation. The 
ability of BSO to deplete GSH (Fig 4.15) was used to model the effect of 
redox perturbation without any concomitant cysteine modification. 
NEM, which was previously shown to alkylate all Keapl-V5 cysteine 
residues, was used to determine if BSO induced any form of cysteine 
oxidation that might render Keapl-V5 cysteines less available for NEM 
adduction. DNCB, which selectively adducts one Keapl-V5 cysteine 257 
(Copple et al. 2008a), was also used to determine if BSO induces 
oxidation of this residue and renders cysteine 257 unavailable for DNCB 
adduction. Therefore, HEK293T cells were pre-treated with lOOpM of 
BSO for 24hr and then exposed to 50mM of NEM for 2min or lOOpM of 
DNCB for Ihr. Keapl-V5 adduction by NEM and DNCB was then 
compared before and after BSO treatment.
Prior treatment of cells with BSO did not make any Keapl-V5 
cysteine residues less available for NEM adduction. Every cysteine 
residues of a proportion of Keapl-V5 were available to be adducted with 
NEM after BSO treatment. This included the three critical cysteines 
(CyslSl, Cys273 and Cys288) previously implicated in the role of Keapl 
function (Zhang et al. 2003; Levonen et al. 2004; Wakabayashi et al. 
2004; Kobayashi et al. 2006a; Yamamoto et al. 2008) (Fig 4.24a).
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Furthermore, in the samples treated alone with BSO, all Keapl-V5 
cysteines were available for IA adduction after DTT reduction (Fig 4.24b). 
This therefore, suggests that there was no cysteine oxidation (reversible 
or irreversible) detectable by LC ESI-MS/MS, caused by BSO. 
Nevertheless, BSO redox perturbation caused Keapl-V5 cysteine 257 to 
be less available for dinitrophenol (DNP) adduction on subsequent 
treatment with DNCB (Fig 4.25b and Fig 4.26b) when compared to DNCB 
treatment only (Fig 4.25a and 4.26a). DNP adduction on cysteine 257 
was only observed in two out of five experiments when samples were 
pre-treated with BSO, while DNP-modification of cysteine 257 was 
observed in five out of five experiments when BSO pre-treatment was 
omitted.
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Figure 4.26: MS/MS spectrum indicating modification of Keapl-V5 Cys- 
257 by (a) DNCB and (b) BSO and DNCB in HEK293T cells, y- and b-ions
are labelled where present. * represents ions for which a mass shift of 
+166.ODa indicates modification by DNCB.
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4.3.7 Using diamide as an alternative oxidising agent to BSD, to induce 
cysteine oxidation on Keapl-V5
Diamide (Fig 4.27) is a known thiol oxidising agent that converts 
reduced GSH to GSH disulphide (GSSG). Use of diamide is a common 
approach to induce S-glutathionylation on proteins thiols in the 
presence of GSH (Dalle-Donne et al. 2003b; Hansen et al. 2009). The 
mechanism of diamide-induced S-glutathionylation is through 
modification of reactive protein thiols to diamide-activated protein 
species (1). The diamide activating protein species can then react with 
GSH to form a protein-GSH mixed disulphide and a hydrazine product (2) 
(Kosower eta/. 1995).
(CH3)zNCON=NCON(CH3)z + Protein-SH-- - - - >(CH3)zNCON(S-Proteiii)NHCON(CH3)2 (1)
diamide diamide activated protein species
(CH3)2NCON(S-Protein)NHCON(CH3)2+ GSH —>Protein-SSG + (CH3)2NCONHNHCON(CH3)2 (2) 
diamide activated protein species hydrazine
Diamide
Figure 4.27: The chemical structure of diamide.
Diamide therefore was used as an alternative to BSO to model 
the effect of redox perturbation without any concomitant cysteine 
modification. Diamide was initially tested for Nrf2 activation and GSH 
depletion in Hepa-lclc7 cells. Diamide induced Nrf2 dose-dependently 
in Hepa-lclc7 cells after a 30min treatment (Fig 4.28a). No toxicity was 
observed during treatment after 30min (Fig 4.28b). The oxidation of GSH
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to GSSG by diamide in vitro and in Hepa-lclc7 ceils was also 
determined. For in vitro GSH oxidation, 100|iM diamide was added to 
500|aM of GSH in water and allowed to react for BOmin at room 
temperature. For cellular oxidation, Hepa-lclc7 cells were treated with 
diamide (BOOpM) for BOmin at room temperature. Samples were 
analysed by LC-MS/MS. GSH was oxidised to GSSG by diamide in vitro 
and the production of hydrazine and GSSG was identified by MS/MS 
spectra (Fig 4.29a - e). Hepa-lclc7 cells were treated with 300|JM of 
diamide and led to the formation of GSSG. However, the presence of 
GSSG was not quantitatively measured in the cells.
After treatment with diamide, immunoprecipitated Keapl-V5 
was resolved by SDS-PAGE under reducing and non-reducing conditions. 
Probing the blots with an anti-GSH antibody indicated that S- 
glutathionylation of Keapl-V5 had occurred (Fig 4.30). The observed 
formation of S-glutathionylation may have caused Keapl-V5 cysteines to 
be less available for cysteine modification, therefore, HEK293T cells 
were transfected with Keapl-V5 overnight and treated with 100|iM 
diamide for BOmin. Cells were then treated with ImM of NEM for Smins 
and Keapl-VS was immunoprecipitated with anti-V5 agarose beads. 
Following immunoprecipitation, Keapl-V5 was reduced with DTT and 
treated with d5NEM before tryptic digestion overnight for LC-ESI-MS/MS 
analysis. Prior treatment with diamide rendered NEM unable to alkylate 
cysteines 171 and 196, however the three critical cysteines 151, 273 and 
288 were not affected (Fig 4.31b). This suggests that diamide may have 
oxidised both cysteine 171 and 196. However, there was no evidence to 
suggest that oxidation occured on the three critical cysteines 151, 273 
and 288 within this investigation.
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Figure 4.28: The effect of diamide on Nrf2 activation and cell toxicity.
Hepa-lclc7 cells were treated for BOmin with diamide. Whole cell 
lysates were resolved by SDS-PAGE and probed for Nrf2. Diamide (a) 
activates Nrf2 dose-dependently. Actin is shown as a loading control. 
Recombinant mouse His-tagged Nrf2 was loaded as a positive control on 
the blot (+con). The bottom panel shows the densitometric anaylsis of 
Nrf2 positive bands normalised against actin. The LDH assay showed 
minimal leakage upon treatment with diamide which was not significant 
(b). Extracellular LDH release is expressed as a percentage of total 
(extracellular plus intracellular) LDH activity. In all experiments, the 
control cells were treated with water. Error bars = standard deviation of 
mean, n=3. Representative gel from n=3.
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a) Diamide
Parent ion m/z 173
Figure 4.29: Representative Ion chromatogram and LC-MS/MS 
spectrum of (a) diamide in vitro. lOOpM of diamide was reacted with 
500jjM of GSH in water at room temperature for 30min. Panel is a 
representative ion extracted chromatogram and MS/MS containing 
diamide, (M+H)+ m/z 173.
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b) Diamide+ GSH
Figure 4.29: Representative Ion chromatogram and LC-MS/MS 
spectrum of (b) diamide and GSH conjugate in vitro. lOOpM of diamide 
was reacted with SOOpM of GSH in water at room temperature for 
BOmin. Panel is a representative ion extracted chromatogram and 
MS/MS containing diamide and GSH, no conjugate formed.
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Parent ion m/z308
f\
Figure 4.29: Representative Ion chromatogram and LC-MS/MS 
spectrum of (c) GSH in vitro. lOOpM of diamide was reacted with 
500|JM of GSH in water at room temperature for 30min. Panel is a 
representative ion extracted chromatogram and MS/MS containing GSH, 
protonated molecular ion m/z 308.
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d) GSSG
Parent ion m/z 613
Figure 4.29: Representative Ion chromatogram and LC-MS/MS 
spectrum of (d) GSSG in vitro. lOOpM of diamide was reacted with 
500|JM of GSH in water at room temperature for BOmin. Panel is a 
representative ion extracted chromatogram and MS/MS containing 
GSSG, protonated molecular ion m/z 613.
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e) Hydrazine
Parent ion m/zlTS
Figure 4.29: Representative Ion chromatogram and LC-MS/MS 
spectrum of (e) hydrazine in vitro. lOOpM of diamide was reacted with 
SOOpM of GSH in water at room temperature for 30min. Panel is a 
representative ion extracted chromatogram and MS/MS containing 
hydrazine, protonated molecular ion m/z 175.
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Reducing Non-reducing
IP.Keapl IP:Keapl
Keapl-VS
IB.Keapl IB:GSH IB:Keapl IB:GSH
z o z O QJo </) ~o o CO ■Ou CO E u CO Ere re
o 5
z O re z o reou COCO
■o
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•o
Ere re
5 a
Keapl-V5
Figure 4.30: S-giutathionylation of Keapl-V5 in control and treated 
cells. HEK293T were transfected with Keapl-V5 overnight and treated 
with lOOpM BSO and diamide for 24hr and 30min respectively using 
water as a control for 24hr. Cells were further treated with 50mM IA or 
NEM and DMSO as a control. Cells were lysed with RIPA buffer and 
Keapl-V5 was immunoprecipitated with anti-V5 agarose beads. 
Immunoprecipitated proteins were resolved by SDS-PAGE under non­
reducing or reducing conditions, and probed with anti-Keapl and anti- 
GSH antibodies. S-glutathionylation of Keapl occurred in control, BSO
and diamide treated samples under non-reducing conditions (see I__ I).
However, under reducing conditions s-glutathionylation of Keapl was 
reversed and the GSH immunoreactive signal disappeared from Keapl-
VS (see I---- 1). Representative gel from n=l. IP; immunoprecipitation. IB;
immunoblotting. Representative gel shown from n=l.
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4.4 DISCUSSION
The Keapl/Nrf2 pathway plays an important role in cellular 
defence against endogenous and exogenous stress. The pathway 
controls the transcription of cytoprotective genes which enable the 
protection of cells against these stresses (Itoh etol. 1997). The currently 
accepted hypothesis is that Keapl, through covalent modification of its 
cysteine residues, mediates the up-regulation of cytoprotective genes by 
permitting Nrf2-dependent gene expression. Since cysteine is the most 
sensitive amino acid to covalent modification due to its chemical 
reactivity, it has been postulated to play a significant role as a 'sensor' to 
chemical and oxidative stress (Rudolph et al. 2009). Extensive studies 
have shown that three critical cysteines are involved in the functionality 
of Keapl. CyslSl maintains the binding of Cul3 ligase to Keapl. The 
adduction of CyslSl leads to the dissociation of Cul3 ligase from Keapl, 
which inhibits Nrf2 ubiquitination and subsequent degradation (Zhang et 
al. 2004; Gao et al. 2007; Rachakonda et al. 2008; Eggler et al. 2009; 
Kobayashi et al. 2009). The mutation of CyslSl to a larger partial molar 
volume of the amino acid side chain on Keapl also increases the 
activation of Nrf2. However, this assumes that the modification of 
cysteine 151 which also increases the molar volume at this position will 
also be enough for Nrf2 activation (Eggler et al. 2009). Cysteines 273 and 
288 maintain the ability of Keapl to repress basal Nrf2 activation (Zhang 
et al. 2003; Levonen et al. 2004; Wakabayashi et al. 2004; Kobayashi et 
al. 2006a; Yamamoto et al. 2008). Adduction to these two cysteines 
simultaneously may suggest to cause the disruption of Nrf2 binding to 
Keapl at the DLG motif (Tong et al. 2007) or the release of zinc 
(Dinkova-Kostova et al. 2005), leading to the disruption in Nrf2 
ubquitination and proteosomal degradation. Other studies which report 
cysteine modifications have shown that cysteine adduction by
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electrophiles or chemicals can lead to Nrf2 activation and induction of 
Nrf2-dependent proteins in vitro and in cell based assays (Dinkova- 
Kostova et a!. 2002; Dietz et al. 2005; Eggler et ol. 2005; Hong et al. 
2005a; Hong et al. 2005b; Liu et al. 2005; Luo et al. 2007; Copple et al. 
2008a; Dietz et al. 2008; Rachakonda et al. 2008; He et al. 2010). Hence, 
it is plausible that Keapl cysteine residues play a significant role as 
'sensors7 to cellular stress. However, little is known about the basal thiol 
status of Keapl in cells and how they actually serve as sensors to 
chemical and oxidative stress.
A cell based model system was previously described by us in the 
CDSS in which mouse Keapl-V5 was over-expressed in HEK293T cells 
(Copple et al. 2008a). Within this system, Keapl-V5 modifications on 
cysteine residues in a cellular context were detected. Initial 
investigations reported in this chapter were designed to transfect and 
over-express mouse Keapl-V5 in Hepa-lclc7 cells. This cell did not 
express sufficient levels of Keapl needed for experiments in this 
chapter. Thus, the HEK293T cell model was used for all subsequent 
experiments. The expression of Keapl-V5 in HEK293T cells as a model 
for the investigation of cellular modification of Keapl cysteines remains 
an accepted model, but clearly it would have been more advantageous 
to investigate cellular modification of Keapl in Hepa-lclc7 with respect 
to liver cells. Immunoprecipitation of endogenous Keapl from Hepa- 
lclc7 cells was attempted previously within the department (Dr Ian 
Copple, thesis 2008). It was not possible to immunoprecipitate sufficient 
Keapl for LC-ESI-MS/MS analysis within these investigations, probably 
because Keapl cellular levels are known to be very low (McMahon et al. 
2006). Therefore, a new method of transfection was tested to transfect 
Keapl-V5 into Hepa-lclc7 within this investigation. Lipofectamine-
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mediated transfection of Keapl-VS into Hepa-lclc7 was attempted 
previously in our department and showed a lower level of expression 
than HEK293T transfected cells by the same method. This is in line with 
the reported observations in this chapter, where expression of Keapl-V5 
in Hepa-lclc7 cells by Lipofectamine transfection and longer 
transfection did not improve Keapl-V5 expression (Fig 4.2a and 4.2b). A 
Nucieofection-mediated method was therefore attempted to improve 
expression of Keapl-V5 in the Hepa-lclc7 cells. Using Nucleofection, an 
improvement in expression of Keapl-V5 was seen (Fig 4.3a) compared 
to lipofectamine. However, optimising the transfections conditions by 
increasing the number of cells and using a longer incubation period did 
not further improve Keap-V5 protein over expression (Fig 4.3b and c). 
Moreover, transfection of Hepa-lclc7 using nucleofection gave an 
inconsistent level of Keapl expression across experiments. Hence, 
HEK293T cells remained the most suitable cell type to use to express 
Keapl-V5 for the subsequent cysteine covalent modification studies.
Two common alkylating agents, IA and NEM, were used for 
detection of cysteine modification by LC-ESI-MS/MS. High 
concentrations of IA and NEM (50mM) over 2min were used to alkylate 
Keapl-V5 cysteine residues intracellularly. This is to achieve the 
maximum coverage of Keapl~V5 cysteines intracellularly with the 
shortest time without resulting in permanent damage to the cells. 
However, the full adduction of Keapl-V5 cysteines by carbamidomethyl 
was not detected in five experiments using a high concentration of IA 
(Fig 4.9a). Surprisingly, when high concentrations of NEM were used, the 
maximum adduction of Keapl-V5 was detected in four experiments (Fig 
4.9b). Hence, the difference in Keapl-V5 cysteine modifications by IA 
and NEM suggested that there was a difference in the ability of these
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chemicals to adduct cysteine residues. Indeed, it has been suggested 
that NEM has a faster reactivity in alkylating thiol groups compared to IA 
(Rogers et al. 2006). Therefore, the advantage of NEM in being a better 
and more efficient alkylating agent, allowing this compound to adduct 
every Keapl-V5 cysteine residues, resulted in it being utilised in 
subsequent investigations. Interestingly, this does suggests that all the 
cysteine residues in of Keapl-V5 cysteine residues are virtually available 
for NEM alkylation and that a proportion of them are all in a reduced 
form under basal conditions. Keapl is a cysteine-rich protein, with highly 
reactive cysteine residues that can readily form intra- or inter- molecular 
disulphides bonds (Rudolph et al. 2009). Hence, to further confirm that 
Keapl cysteines are all in a reduced form under basal conditions, NEM 
was tested for its ability to break disulphide linkages and react with 
cysteines in such a bond. HSA was used as a model protein for this 
purpose. HSA contains thirty-five cysteines, all of these except for Cys34 
participate in disulphide linkage (Oettl et al. 2010). The MS/MS analysis 
showed that NEM was only able to bind to Cys34 even at increasing HSA 
to NEM molar ratios (Table 4.1). Therefore, this suggests that NEM was 
not able to break disulphide linkages. This further supports the 
observation that all Keapl~V5 cysteines are previously available for 
modification and that a proportion of them are reduced under basal 
conditions, without disulphide linkage.
NEM was found to be a more efficient alkylating agent compared 
to IA in the investigations described in this chapter. This was in line with 
what Rogers and colleagues have suggested previously (Rogers et al. 
2006). Hence, an alternative alkylating agent which has similar chemical 
characteristics to NEM was required to replace IA in order to carry out 
differential labelling experiments. A heavy hydrogen labelled NEM,
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dsNEM, was selected as the alternative alkylator (Fig 4.12). d5NEM has 
exactly the same structure as NEM but it is 5Da heavier than NEM, which 
can be easily identified on the LC ESI-MS/MS (Niwayama et al. 2001). It 
was shown within this chapter that d5NEM was able to adduct Keapl-V5 
cysteines (Fig 4.13). NEM (ImM) was able to adduct all Keapl-V5 
cysteines in HEK293T cells and d5NEM was able to adduct all Keapl-V5 
cysteines after DTT reduction, except for cysteine 297 which might have 
been fully adducted by NEM. Hence, after intense and overwhelming 
chemical exposure, virtually a proportion of all the cysteines in Keapl 
molecule in the cell are still in a reduced state.
Two bands which correspond to the molecular weight of Keapl- 
V5 were observed following the CCB staining of Keapl-V5 resolved by 
SDS-PAGE following VS-immunoprecipitation of from HEK293T cells (Fig 
4.4). MALDI-TOF MS analysis identified both forms as mouse Keapl but 
no forms of cysteine oxidation were detected within them (Fig 4.5-4.S). 
S-glutathionylation is one of the reversible forms of post-translational 
modification where cysteine is oxidised by GSH. The formation of S- 
glutathionylation on proteins can either be constitutive, serve as a 
storage mechanism of cellular GSH, serve to protect cysteine against 
irreversible oxidation, act in the regulation of protein function or be a 
form of cellular stress-induced oxidation (Dalle-Donne et ol. 2007). 
Currently, there are a range of proteins that have been shown to be S- 
glutathionylated and whose function is regulated by S-glutathionylation. 
Proteins which can be inhibited by S-glutathionylation are NF-kB 
(Pineda-Molina et al. 2001; Qanungo et al. 2007), IKK (Reynaert et al. 
2006; Chung et al. 2010), actin (Dalle-Donne et al. 2003a; Dalle-Donne et 
al. 2003b) and p53 (Velu et al. 2007; Yusuf et al. 2010). Examples of 
proteins which can be activated by S-glutathionylation include carbonic
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anhydrase 3 (Kim et al. 2005), matrix metalloproteinase (Okamoto et al. 
2001) and p21ras (Clavreul et al. 2006). Other than the regulation of 
protein function, S-glutathionylation has been shown to prevent the 
ubiquitination of IkB (Kil et al. 2008) and also to protect thiols from 
irreversible oxidation in metallothionein molecules (Casadei et al. 2008). 
Therefore, the oxidation of Keapl cysteines by GSH was further 
investigated by using immunoblotting and MALDI-TOF analysis to 
determine S-glutathionylation of Keapl-V5.
The immunoblotting method showed that under non-reducing 
conditions, S-glutathionylation of Keapl-V5 was detected with an anti- 
GSH antibody in control and treated cells (Fig 4.16a and c). However, 
under reducing conditions S-glutathionylation was reversed from Keapl- 
V5 as it was not detected with anti-GSH antisera (Fig 4.16b and d). This is 
in line with a recent report that describes S-glutathionylation on 
endogenous Keapl in Hepa-lclc7 cells treated with an electrophilic 
thiophene compound (Zhang et al. 2010). The authors, however, did not 
observe S-glutathionylation in untreated cells, which was observed on 
Keapl-V5 in control HEK293T samples within this study. This difference 
in observations could be explained through the model used here which 
utilised the overexpression of Keapl-V5 whereas Zhang and colleagues 
looked at endogenous Keapl.
The MALDI-TOF MS analysis of protein bands excised from CCB- 
stained gels (Fig 4.17) identified control samples (Fig 4.18-4.20) and IA 
treated (Fig 4.21-4.23) bands as mouse Keapl. S-glutathionylation was 
also detected on both Control and IA bands by MALDI-TOF. However, 
the S-glutathionylation which was detected on Cys273 was present in a 
miscleaved peptide from the control band (Fig 4.20). From the IA band, 
S-glutathionylation was detected on Cys77 (Fig 4.23). This observation
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on Cys77 has also been reported by Holland and colleagues who used 
recombinant Keapl (Holland et al. 2008). Therefore, S-glutathionylation 
on Keapl could have occurred from either constitutive or cellular stress 
oxidation.
The investigation of potential cysteine oxidation on Keapl that 
may lead to Nrf2 activation was furthered explored by the use of LC ESI- 
MS/MS analysis. The same HEK293T cell Keapl-V5 model was used to 
look for cysteine modification by LC ES1-MS/MS. The ability of BSO to 
deplete GSH was used to model the effect of redox perturbation without 
any concomitant cysteine modification. BSO was observed to induce 
oxidative stress by cellular GSH depletion (Ito et al. 2006). The 
investigation of whether BSO can induce oxidation of Keapl-V5 in our 
model was measured indirectly by assaying the availability of adduction 
on the Keapl-V5 cysteines following BSO treatment. Prior treatment of 
cells with BSO did not hinder the ability of a high concentration of NEM 
to alkylate Keapl-V5 cysteines (Fig 4.24). Therefore, this suggested that 
depletion of GSH in our model did not induce oxidation of a sufficient 
proportion of the Keapl-V5 cysteines to be detected by LC-ESI-MS/MS 
analysis. We have shown previously that DNCB selectively alkylates 
cysteine 257 in Keapl (Copple et al. 2008a) and that exposure to DNCB is 
associated with the induction of Nrf2 and GSH depletion (chapter 2). The 
treatment of cells with lOOpM DNCB for Ihr after GSH depletion with 
BSO allows the cells to undergo further chemical or oxidative stress, and 
potentially, sufficient/further oxidation to be detected by LC-ESI-MS/MS. 
Indeed, DNCB exposure with BSO treatment did reduce the frequency of 
DNP adduction of cysteine 257 in comparison to DNCB treatment only 
(Fig 4.25). This suggests that cysteine oxidation of Keapl may occur in a 
cellular context.
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Diamide, a known oxidising agent, was used as an alternative to 
BSO to induce cysteine oxidation on Keapl-V5. It is commonly applied to 
induce s-glutathionylation on protein thiols (Dalle-Donne et al. 2003b; 
Casadei etal. 2008; Hansen et al. 2009; Yusuf eta/. 2010). In Hepa-lclc7 
cells, diamide was able to induce Nrf2 activation from 30pM to 300pM 
after 30min exposure (Fig 4.28a) and cellular toxicity was not apparent 
(Fig 4.28b). Diamide, in the presence of 6SH, could oxidise GSH to GSSG 
but did not form a GSH-conjugate. Using LC-MS/MS, GSSG was detected 
after treatment with diamide under in vitro conditions (Fig 4.29d) and 
also in Hepa-lclc7 cells, where GSSG was formed in the presence of 
diamide but not in untreated cells. Using, immunoblotting of Keapl-V5 
with anti-GSH antibodies, the data presented in this chapter show that 
S-glutathionylation can occur on Keapl-V5 following diamide treatment 
under non-reducing conditions, which is reversible under reducing 
conditions (Fig 4.30). Cysteine oxidation by diamide was further 
investigated using LC-ESI-MS/MS analysis. Keapl-V5 expressing HEK293T 
cells were treated with lOOpM diamide, followed by ImM of NEM. 
Immunoprecipitated Keapl-V5 was tryptically digested and analysed by 
MS/MS. Diamide treatment resulted in the Keapl-V5 cysteines, 171 and 
196, to be unavailable for NEM alkylation. However the three critical 
cysteines (CyslSl, Cys273 and Cys288) were not affected (Fig 4.31a). 
Therefore, this suggested that diamide may have caused the oxidation of 
Cysl71 and Cysl96 which could be adducted by dsNEM after DTT 
reduction (Fig 4.31a).
Oxidising agents such as BSO and diamide, have been shown 
here to induce Nrf2 activation and deplete GSH through separate 
mechanisms. Both compounds induce cysteine oxidation of Keapl-V5 
containing cysteines. Cysteine oxidation on Keapl-V5 was indirectly
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measured through the modification of reduced cysteines by 
electrophiles after BSO or diamide treatment. S-glutathionylation couid 
not be detected directly, due to the detection limits of LC-ESI-MS/MS. 
Reversible oxidation was difficult to detect on peptides which are not 
reduced as they do not ionise on the mass spectrometry; the amount of 
oxidised cysteine peptides may have been below the limit of MS/MS 
detection. Regardless of these limitations, using BSO and diamide and 
electrophiles to indirectly determine cellular Keapl cysteine oxidation 
remains a novel method. Currently, the investigation of cellular Keapl 
cysteine oxidation is restricted to 2D immunoblotting (Wakabayashi et 
al. 2004), non-reducing ID immunoblotting (Fourquet et al. 2010) and 
biotinylated cysteines (Takagi etal. 2009). To date, LC-MS/MS analysis of 
Keapl oxidation was only successfully carried out in vitro using bacteria 
expressing recombinant Keapl (Holland etal. 2008).
Currently, there is no reported evidence that all Keapl cysteine 
residues can all exist in the reduced form in living cells and are not 
involved in any disulphide linkage. The crystal structure of the Keapl 
DGR domain indicates eight cysteines that are not involved in a 
disulphide linkage (Li et al. 2004). However, the data presented here 
show for the first time that the Keapl-V5 thiol status of all cysteine 
residues can exist in a reduced form under basal conditions in a cell, 
under conditions where the protein is functionally active in targeting 
Nrf2 (Ms Rym Megherbi thesis) and therefore that a proportion of all 
Keapl cysteines are available for covalent modification. This represents 
an important finding considering that Keapl is a very cysteine-rich 
protein (4.3% and 4% of the total amino acid content in human and 
mouse Keapl protein are cysteine residues, which is above the average 
of 2.3% across human and mouse proteins). Other cysteine-rich protein
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such as metallothionein, an antioxidant protein (30% of 61 amino acids 
are cysteines) (Messerle et al. 1990; Zangger et ol. 1999), do contain 
disulphide bonds in vivo under physiological conditions unlike Keapl 
(Feng et ai. 2006). Furthermore, the detection of S-glutathiony!ation of 
Keapl-V5 in the HEK293T cell model used here suggests that S- 
glutathionylation can be found in Keapl-V5 basally and after cellular 
stress. This suggests that Keapl can either be constitutively oxidised 
under basal conditions or oxidised under conditions of oxidative stress 
to prevent irreversible oxidation of Keapl free thiols during cell stress. 
Therefore, the hypothesis that Keapl cysteines play a significant role as 
"key sensors" that sense exogenous and endogenous stress is further 
supported by the observations made within this chapter, i.e. that all 
Keapl cysteines are reduced and available.
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Use of click chemistry for the investigation of Nrf2
activation
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5.1 INTRODUCTION
The Keapl/Nrf2 pathway protects the cells against endogenous 
and exogenous stress. The nuclear accumulation and activation of Nrf2 
leads to the transcription of many cytoprotective proteins, i.e. phase II 
enzymes, antioxidants, molecular chaperones and transport proteins 
(Prestera et al. 1995; Hayes et at. 1999; Itoh et al. 1999b; Kwak et al. 
2003; Hu et al. 2006; Adachi et al. 2007; Aleksunes et al. 2009; Xu et al. 
2010). The widely accepted model of Nrf2 activation centres on the 
covalent modification of Keapl cysteines that could lead to the de­
repression of Nrf2, through the abrogation of Nrf2 ubiquitination and 
subsequent proteosomal degradation. The investigation of the 
relationship between Nrf2 activation and Keapl cysteine modification 
has been extensively investigated. Different classes of reactive 
compounds that covalently modify cysteines in both bacterially- 
expressed recombinant Keapl and ectopically-expressed Keapl cells 
have been found to induce Nrf2 activation (Dinkova-Kostova et al. 2002; 
Zhang et al. 2003; Levonen et al. 2004; Dietz et al. 2005; Dinkova- 
Kostova et al. 2005; Eggler et al. 2005; Hong et al. 2005a; Sakurai et al. 
2006; Luo et al. 2007; Copple et al. 2008a; Rachakonda et al. 2008). 
These classes of reactive compounds can target cysteines found on 
different domains of Keapl based on their chemistry with the targeted 
cysteines (Holland et al. 2008; Kobayashi et al. 2009; Holland et al. 
2010). This combined with previous work further supports the 
hypothesis that Keapl cysteine modification leads to activation of Nrf2, 
although this does not rule out the potential involvement of other 
triggers for activation
Click-Chemistry (CC) was first introduced into the field of activity- 
based protein profiling (ABPP) to determine the functional state of
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proteins in their endogenous cellular environment (Cravatt et al. 2000; 
Adam et al. 2002; Speers et al. 2005). Until recently, ABPP experiments 
have been conducted only with cell or tissue homogenates. However, 
CC-ABPP enables profiling of living cells and organisms through CC 
probes which comprise two elements; a reactive group, which enables 
the binding and covalent labelling of the protein under investigation and 
secondly one or more reporter tags for detection and isolation of probe- 
labelled proteins (Speers et al. 2004; Speers et al. 2005). CC is a 
copper(l)-catalysed [3+2] cycloaddition reaction between alkyne and 
azide groups (Fig 5.1) (Kolb et al. 2001; Speers et al. 2004). The azide 
group can be labelled with either rhodamine (Speers et al. 2004) or 
biotin reporter tags (Speers et al. 2005) (Fig 5.1) for in-gel fluorescence 
screening or protein purification for proteomics analysis (Speers et al. 
2004; Evans et al. 2005). Alkyne groups are rarely found in vivo, 
therefore CC can be used to monitor covalent modification of proteins in 
cells (Evans et al. 2005). A number of electrophiles can have an alkyne 
group incorporated and then utilised as CC probes for proteomics 
profiling and analysis of cysteine modifications (Macpherson et al. 2007; 
Vila et al. 2008; Weerapana et al. 2008). lodoacetamide (IA) and 
maleimide reactive groups are common cysteine alkylating agents and 
have been extensively studied in proteomic investigations (Rogers et al. 
2006; Shin et al. 2007; Zabet-Moghaddam et al. 2008). In addition, IA 
and N-ethylmaleimide (NEM) are also known to modify Keapl cysteines 
and activate Nrf2 (Dinkova-Kostova et al. 2002; Eggler eta/. 2005; Eggler 
et al. 2007; Copple et al. 2008a). Consequently, these compounds were 
utilised in CC experiments, incorporating an alkyne group in both to 
form the novel structures: iA-click and NEM-click for cysteine 
modification profiling during Nrf2 activation (Fig 5.2).
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Investigations into the relationship between Keapl cysteine 
modifications and Nrf2 activation have relied significantly on proteomic 
analysis. These investigations are commonly based on Keapl cysteine 
modification by reactive compounds, detected on tandem liquid 
chromatography-mass spectrometry/mass spectrometry (LC-MS/MS) 
(Dinkova-Kostova et al. 2002; Hong et a!. 2005a; Copple et al. 2008a; 
Rachakonda et al. 2008). This enables the identification of the site of 
cysteine modifications by reactive compounds. In this chapter, I have 
aimed to use these click compounds as novel alkylating agents in the 
investigation of Keapl covalent modification and Nrf2 activation. The 
initial aim was to assess these novel click compounds in comparison with 
their parent compounds with regard to their ability to deplete GSH, 
activate Nrf2 by alkylating cysteines on Keapl and their effect on cell 
viability. Ultimately, the goal of this work is to determine which novel 
click compound is suitable as a novel probe and for future investigations 
of Keapl cysteine modification and Nrf2 activation.
alkyne
+
azide Click-chemistry
<^j: Rhodamine or Biotin Tagged
Figure 5.1: Schematic diagram of Click Chemistry. Cycloadditon reaction 
between alkyne and azide group.
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0
I
a) lodoacetamide (IA)
o
b) N*ethylmaleimide (NEM)
Figure 5.2 Chemical structure of parent compounds and their click 
derivatives, lodoacetamide (a) and lodoacetamide-click (c) and; N- 
ethylmaleimide (b) and N-ethylmaleimide-click (d).
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5.2 MATERIALS AND METHODS
5.2.1 Materials
The lodoacetamide-click and N-ethylmaleimide-click molecules 
were kind gifts of Professor Paul O'Neill (Department of Chemistry, 
University of Liverpool, UK), lodoacetamide and N-ethylmaleimide were 
from Sigma-Aldrich (Poole, UK). All other reagents were of analytical or 
molecular grade and were purchased from Sigma-Aldrich.
5.2.2 Cell Culture and Cell Count
Hepa-lclc7 cells were maintained and counted as detailed in 
section 2.2.2.
5.2.3 Cell Treatment
Hepa-lclc7 cells were seeded onto 96-well plates and 24-well 
plates at 2 x 104 cells/well and 2 x 105 cells/well respectively on the 
previous day. IA, lA-ciick, NEM and NEM-clicks were dissolved in 
dimethyl sulfoxide (DMSO). Cells treatment was prepared as detailed in 
section 2.2.3.
5.2.4 Preparation of whole cell lysates
For whole cell lysate preparation was detailed as in section 2.2.4.
5.2.5 Measurement of protein content
The total protein content was determined as detailed in section
2.2.5.
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5.2.6 Western immunoblotting
Nrf2 western immunoblotting was prepared as detailed in 
section 2.2.6.
5.2.7 Measurement of Lactate Dehydrogenase Leakage
Cellular cytotoxicity was determined by LDH measurements as 
detailed in section 2.2.10.
5.2.8 Measurement of Glutathione
Total GSH content was quantified as detailed in section 2.2.11.
5.2.9 LC-MS/MS method
Samples were prepared by adding together the following in a 
ratio of 1:1, NEM-Click:GSH, followed by a 1 in 25 dilution in phosphate 
buffered saline (PBS) (pH 7.4). The formation of conjugates was 
measured as described in 4.2.12. The gradient solvent system used to 
elute the sample was 95% H20 + 0.1% formic acid (A) and 5% methanol 
(B) held for 4min, then increased to 95% (B) linearly over 15min. The 
flow rate was 0.2mL/min, and column temperature was set to 30°C. A 
total ion current chromatogram was acquired using the following 
conditions: positive ionisation mode, ionisation voltage 5500V, ion 
source temperature 350°C, selected mass range 100 to 550Da. Collision 
activated dissociation of parent ions was performed using nitrogen gas 
in the Q2 collision cell. Collision energy was 25V, and collision gas was 
maintained at a setting of 8. LC-MS/MS scans were operated in MRM 
mode and product ion mode. The mass transitions monitored were 
485.5/356.5 (conjugated molecule) and 308.3/179.3 (GSH) [[M+H]-129]+. 
The dwell time per transition was 100ms.
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5.2.10 Data Analysis
Data are expressed as mean ± standard deviation of the mean. 
Normality was assessed by the Shapiro-Wilk Test. The significance of 
differences within the data was assessed by a one-way ANOVA for 
normally distributed data, and Kruskal-Wallis analysis of variance 
(ANOVA) for non-parametric data. A difference was considered 
significant at p<0.05.
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5.3 RESULTS
5.3.1 A comparison of Nrf2 activation by lA-click and its parent 
compound, IA
Hepa-lclc7 cells were exposed to IA and lA-click with the first 
aim to determine whether lA-click can activate Nrf2 and then to 
compare its Nrf2-inducing efficacy to its parent compound, IA. IA and lA- 
click both induce Nrf2 accumulation (Fig 5.3). lA-click can activate Nrf2 
despite the addition of the alkyne group. In contrast, the potency of IA 
and lA-click at inducing Nrf2 activation varies between them. IA induced 
Nrf2 at lOpM and reached the highest induction at lOOpM (Fig 5.3a). lA- 
click induced Nrf2 at 30pM, which was the highest level of induction for 
this compound (Fig 5.3b). Both compounds caused depletion of total 
GSH content dose-dependently (Fig 5.4a and b). Similar to Nrf2 
activation, lA-click has a weaker potency in depletion of GSH (Fig 5.4b) 
compared to IA (Fig 5.4a). lA-click resulted in GSH depletion to 40% of 
the control (Fig 5.4b), whereas IA caused GSH depletion to undetectable 
levels (Fig 5.4a). Cytotoxicity was determined by LDH leakage and this 
indicated no clear toxicity after Ihr incubation with either compound up 
to the high concentration of lOOOpM of lA-click (Fig 5.4c). However, 
after 24hr, toxicity was seen for IA and lA-click (lOpM to lOOOpM) (Fig 
5.4d). Due to the difficulty in synthesising lA-click with consequent low 
yields, only a single sample test was carried out, therefore statistical 
analysis was not appropriate for this experiment.
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Figure 5.3: The effect of IA and IA*click on Nrf2 activation. Hepa-lclc? 
cells were treated for Ihr with IA (a) and lA-click (b) and RIPA whole cell 
lysates resolved using SDS-page gels and probed for Nrf2. Exposure to IA 
(a) and lA-click (b) results in Nrf2 accumulation. Actin is shown as a 
loading control. The bottom panel shows the densitometric analysis of 
Nrf2 positive bands normalised against actin. The control cells were 
treated with 0.1% DMSO. A representative gel for IA and lA-click n=l is 
shown. Densitometric values shown for IA and lA-click, n=l.
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Figure 5.4: The effect of IA and lA-click on GSH and cell toxicity. Hepa- 
lclc7 cells were treated for Ihr with IA (a) or lA-click (b) and lysed with 
lOmM HCI. GSH depletion reaches 100% of control with a high dose of 
IA (a) and 40% of control with lOOpM of lA-click (b). Total GSH was 
normalised against total protein content. Cells were treated with IA or 
lA-click for Ihr (c) and 24hr (d). LDH assay shows minimal leakage upon 
treatment with IA or lA-click for Ihr, except for lA-click at 1000pM 
where substantial leakage was seen (c). The LDH assay shows substantial 
leakage upon treatment with IA or lA-click (d) after 24 hrs. Extracellular 
LDH activity is expressed as a percentage of total (extracellular plus 
intracellular) LDH activity. In all experiments, the control cells were 
treated with 0.1% DMSO. GSH percentage from triplicate 
measurements, n=l. Percentage leakage of total LDH from triplicate 
measurements, n=l.
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5.3.2 Nrf2 activation by N-ethylmaleimide and N-ethylmaleimide-click
Hepa-lclc7 cells were exposed to NEM and NEM-click with the 
aim to determine whether NEM-click resulted in Nrf2 activation, and 
then to compare this with NEM, the parent compound. NEM and NEM- 
click both induce Nrf2 accumulation (Fig 5.5), NEM-click can activate 
Nrf2 with similar potency as NEM, despite the addition of the alkyne 
group. Nrf2 activation by NEM and NEM-click is evident at 3jiM (Fig 5.5). 
NEM-click induced the highest level of Nrf2 at 30p.M (Fig 5.5a) and NEM 
(Fig 5.5b) induced the highest Nrf2 level at 100nM. Both compounds 
caused depletion of total GSH content dose-dependently (Fig 5.6a and 
b). Both NEM and NEM-click caused the depletion of GSH to 
undetectable levels at the highest dose of 100|iM (Fig 5.6a and b). 
Following a Ihr exposure to both NEM and NEM-click, no cytotoxicity 
was seen (Fig 5.6c). However, after 24hr, neither NEM nor NEM-click 
resulted in toxicity at 100|iM (Fig 5.6d), as determined by LDH leakage.
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Figure 5.5: NEM and NEM-click activation of Nrf2. Hepa-lclc? cells 
were treated for Ihr with NEM (a) or NEM-click (b) and RIPA whole cell 
lysates were resolved using SDS-PAGE gel and probed for Nrf2. NEM (a) 
and NEM-click (b) activates Nrf2 accumulation. Actin is shown as loading 
control. The bottom panel shows the densitometric analysis of Nrf2 
positive bands normalised against actin. Kruskal-Wallis, *p<0.05. The 
control cells were treated with 0.1% DMSO. A representative gel from 
n=3 is shown. Error bars = standard deviation of mean, n=3.
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Fig 5.6: The effect of NEM and NEM-click on GSH and cell toxicity.
Hepa-lclc7 cells were treated for Ihr with NEM (a) or NEM-click (b) and 
lysed with lOmM HCL. GSH depletion reaches to 100% of control with 
high dose of NEM (a) and NEM-click (b). Total GSH normalised against 
total protein content. Cells were treated with NEM or NEM-click for Ihr 
(c) and 24hr (d). Kruskal-Wallis, *p<0.05, **p<0.01. LDH assay shows 
minimal leakage upon treatment with NEM or NEM-click for Ihr (c). The 
LDH assay shows substantial leakage upon treatment with NEM or NEM- 
click (d) after 24hr. Extracellular LDH activity is expressed as a 
percentage of total (extracellular plus intracellular) LDH activity. One­
way ANOVA, *p<0.05, **p<0.01, ***p<0.001; +p<0.05, +++p<0.001. In 
all experiments, the control cells were treated with 0.1% DMSO. Error 
bars = standard deviation of mean, n=3.
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5.3.3 Identification of a NEM-click-glutathione conjugate on LC-MS/MS
NEM-click was then assessed for its ability to bind to GSH and to 
form a GSH conjugate, using 100nM of NEM-click which was mixed with 
an eqimolar concentration of GSH in PBS. This mixture was allowed to 
react for BOmin at room temperature. Samples were identified by LC- 
MS/MS analysis. A NEM-click-GSH conjugate was detected with a 
protonated molecular ion of m/z 485.52 (Fig 5.7a). Its identity was 
confirmed by a product ion scan (MS/MS) which produced fragment ions 
that corresponded to m/z 339.4, m/z 356.3 and m/z 410.28 (Fig 5.7b).
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Figure 5.7: LC-MS/MS spectra of a NEM-click-GSH conjugate. An
equimolar concentration of NEM-click (100|JM) was reacted with GSH in 
PBS at room temperature for BOmin. Samples were diluted for LC- 
MS/MS. A NEM-click-GSH conjugate was detected with a protonated 
molecular ion of 485.52Da (a). A product ion scan (MS/MS) which 
produced fragment ions that tentatively corresponded to the NEM-click- 
GSH conjugate is shown [M-X]+ (b).
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5.3.4 Comparison of Nrf2 activation and GSH depletion between the 
lA-click and NEM-click compounds
The effect of lA-click and NEM-click treatment on Nrf2 activity 
and GSH depletion can be seen clearly in double-y graphs (Fig 5.8). 
NEM-click had a more pronounced effect on both GSH and Nrf2 levels, 
resulting in greater GSH depletion and increased Nrf2 activation in 
comparison with lA-click. Consequently, it appears that NEM-click is a 
more potent Nrf2 inducer and cysteine alkylator.
180 i r 0.45
0 10 30 100
[pM]
Figure 5.8: Effect on Nrf2 and GSH by treatment of cells with lA-click 
and NEM-click. NEM-click increased Nrf2 nuclear accumulation with GSH 
depletion more potently than lA-click. Error bars have been omitted 
from the graphs for clarity.
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5.4 DISCUSSION
The hypothesis that Keapl cysteine covalent modifications are 
key to the mechanism of Nrf2 activation is well described with 
compelling evidence to support it. Three cysteines, CyslSl, Cys273 and 
Cys288 have been suggested to be critical in Keapl ability to repress 
Nrf2 basally. The association of Cul3 ligase to Keapl is disrupted when 
CyslSl is covalently modified by electrophiles, that could lead to the 
abrogation of Nrf2 ubquitination and proteasomal degradation (Zhang et 
al. 2003; Zhang et al. 2004; Gao et al. 2007; Rachakonda et al, 2008). 
The mutation of Cys273 and Cys288 render Keapl unable to repress 
Nrf2 via the abrogation of Nrf2 ubiquitination and subsequent 
degradation (Zhang et al. 2003; Levonen et al. 2004; Wakabayashi et al. 
2004; Kobayashi et al. 2006a) and also Nrf2 activation by Nrf2 inducers is 
attenuated or aboragated (Zhang et al. 2003; Levonen et al. 2004). 
However, it is not clear that the cysteines that are most important in 
covalent modifications in Nrf2 activation have been uncovered, despite 
the fact that many chemical compounds target cysteines on different 
domains of Keapl [for a review, see (Holland et al. 2010) ]. Since the 
Keapl/Nrf2 pathway can be activated concurrently with the covalent 
modification of Keapl cysteines, the use of activity-based protein 
profiling to profile cysteines may be a useful tool to aid in improved 
understanding of the Keapl/Nrf2 pathway. Recently, ABPP has been 
applied to investigate the relation between covalent modifications of 
cysteine and the functionality of the proteins, such as the Transient 
Receptor Potential (TRP) Al ion channel and the chloride intracellular 
channel (CLIC) family (Macpherson et al. 2007; Weerapana et al. 2008). 
Rhodamine labelling with click compounds by CC was used to show that 
TRPA1 ion channel can be activated by cysteine modification and also 
the cysteine modifications by click compound was investigated by mass
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spectrometry analysis (Macpherson et al. 2007). The CLIC family 
members conserved cysteine residue has been shown to be bound by 
click compounds via fluorescent imaging (Weerapana et al. 2008). 
Hence, the application of electrophilic compounds coupled with an 
alkyne group (Fig 5.1) has been used to target those proteins. For that 
reason, the use of two novel cysteine alkylating compounds, lA-click (Fig 
5.2c) and NEM-click (Fig 5.2d) in the Keapl/Nrf2 pathway were 
investigated in this chapter.
IA and NEM are common alkylating agents that were used to 
investigate Keapl cysteine modification by proteomic analysis. Both IA 
and NEM were incorporated with an alkyne group to form the click 
compounds. The click compounds were used in comparison with their 
parent compounds, IA and NEM, to look at their Nrf2 induction efficacy. 
lA-click and NEM-click both activated Nrf2 and depleted GSH similar to 
their parent compounds. In addition, the Nrf2 responses to both click 
molecules and their parent compounds occur at concentrations where 
toxicity is not or has not yet become apparent, hence these factors 
appear to be able to sense and respond before toxicity emerges. 
Nevertheless, lA-ciick activates Nrf2 but it did not induce Nrf2 as 
effectively as IA (Fig 5.3). As shown in the results, lA-click did not induce 
Nrf2 or deplete GSH, and consequently toxicity emerges within Ihr after 
treatment with the highest dose of lOOOpM. The addition of the alkyne 
group to IA was shown to reduce the effectiveness in cysteine 
modification seen from the decreased Nrf2 activation and GSH 
depletion. Macpherson et al noted the opposite effect on lA-click's 
cysteine-modifying properties; they reported that lA-click had a lower 
ECso compared to IA (Macpherson et al. 2007). However, this difference 
can be explained through the investigation and the use of different
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methods for determination of cysteine modification. In contrast, NEM- 
click was as efficient as NEM in activating Nrf2 (Fig. 5.5). In fact, the 
profiles of Nrf2 activation and GSH depletion by both compounds were 
very similar. NEM-click also reacted with GSH in vitro, to form a NEM- 
click-GSH adduct shown by LC-MS/MS (Fig 5.7). Unlike lA-click, the 
addition of the alkyne group to NEM did not reduce Nrf2 activation 
properties. Comparing both click compounds, NEM-click was shown to 
be a more efficient Nrf2 activator and depletes GSH, forming GSH 
adduct (Fig 5.8). Furthermore, NEM and NEM-click were less toxic 
compared to IA and lA-click at 10 and 30pM over 24hr. Therefore, NEM- 
click is clearly a more suitable alkylating agent than lA-click to use in 
Keapl/Nrf2 pathway experiments.
A novel proteomic analysis method using click compounds to 
investigate the role of cysteine modification on protein functions have 
been shown here. The used of CC to label cysteine residues of TRAP1 
and CLIC protein with reactive compounds incorporated with an aikyne 
group have been shown (Macpherson et al. 2007; Vila et al. 2008; 
Weerapana et al, 2008). The role of cysteines in these proteins was 
measured by rhodamine fluorescence gel visualisation or identification 
of cysteine peptide adduction by mass spectrometry after protein 
purification from cells (Macpherson et al. 2007; Weerapana et al. 2008). 
The cysteine reactive compounds used against TRPA1; isothiocyanate, 
NEM and IA, not only binds to TRPA1 but can also bind to Keapl 
(Wakabayashi et al. 2004; Eggler et al. 2005; Hong et al. 2005a; 
Macpherson et al. 2007; Salazar et al. 2008). Recently, 4- 
hydroxylnonenal (HNE), a known lipid oxidation product which can also 
modify Keapl, was reported to be incorporated with an alkyne group. 
The HNE-alkyne was used to modify cellular proteins and HNE-alkyne
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modified proteins were reacted with an azide-biotin tag using CC. All 
HIME-alkyne modified biotin tagged proteins were isolated and purified 
using streptavidin beads and identified by mass spectrometry (Vila et al. 
2008). Currently, all Keapl cysteine modification experiments have been 
conducted through the purification of epitope-tagged Keapl, expressed 
either in bacteria or in over-expressed cell lines, utilising mass 
spectrometry for the identification of the isolated epitope-tag Keapl 
(Dinkova-Kostova et al. 2002; Levonen et al. 2004; Copple et al. 2008a; 
Rachakonda et al. 2008). Based on the studies of Vila et al, 
overexpressed Keapl, without any epitope tag, or endogenous Keapl, 
can be modified by NEM-click for isolation and purification. This can 
serve as a novel method in the immunoprecipitation of Keapl 
overexpressed as wild type or at endogenous levels in cells. 
Furthermore, this method can be used to isolate and purify endogenous 
Keapl for mass spectrometry if the abundance of Keapl is enough. 
NEM-click can also be used as an alternative alkylating agent to NEM for 
cysteine modification for mass spectrometry. This will help in 
differentiating from standard NEM modification during in cell treatment 
and should help to quantify the amount of Keapl cysteines that are 
available to be modified by either NEM or NEM-click. NEM-click can 
provide a better understanding on how endogenous Keapl senses 
chemical stress and how the role of cysteines residues plays in Nrf2 
activation. Therefore, the novel compound NEM-click, which has similar 
properties as NEM shown here can be used as a novel method in the 
investigation of Keapl cysteine modification and Nrf2 activation.
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6.1 INTRODUCTION
One of main contributors to patient morbidity and mortality 
during drug therapy are adverse drug reactions (ADRs). The liver is a 
major target organ for the occurrence of ADRs due to its physiological 
role in drug metabolism and clearance. Drug induced liver injury (DILI) is 
one of the most common causes of drug withdrawal and 
acetaminophen-induced liver injury accounts for nearly 50% of acute 
liver failure cases seen in the United States (Lee 2003). The critical 
protein hypothesis suggests that the binding of chemically reactive 
metabolites (CRMs) to cellular proteins caused impairment to their 
functionality and will elicit cellular toxicity. Hence, during the initiation 
of an ADR, the formation of CRMs from parent compounds may play a 
major part. Although the liver functions as a detoxification organ, it can 
also generate CRMs through the activity of the CYP450 enzymes. These 
enzymes can bioactivate parent drug compounds to CRMs which are 
rapidly quenched by glutathione (GSH). However, the binding and 
alteration of hepatic proteins by CRMs after the depletion of GSH may 
also induce a hepatocellular defence response. The various proteins 
involved in the hepatocellular defence response that were described in 
chapter 1 can trigger different tiers of defence, drug metabolism and an 
adaptive response, to achieve cellular defence responses to counter the 
toxic insults (Fig 1.3). The redox sensitive transcription factors namely, 
Nrf2 and NF-kB, play an important role in the cellular defence system. 
This is attributed to their ability to induce the transcription of 
cytoprotective proteins such as phase II enzymes, antioxidant and GSH 
synthesising proteins. Hence, the understanding of the molecular 
mechanisms behind the regulation and activation of these transcription 
factors will provide valuable insight on the events that occur during 
progression and consequence of drug induced liver injury (DILI).
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Therefore, the main aims of this thesis were to further the 
understanding of how these transcription factors can regulate cellular 
defence responses to cellular stress, especially by the involvement of the 
Keapl/Nrf2 pathway.
6.2 THE SIMULTANEOUS REGULATION OF THE KEAP1/NRF2 AND NF-KB 
PATHWAYS UNDER CELLULAR STRESS
Paracetamol (APAP), a commonly used analgesic and antipyretic 
drug, is associated with DILI following overdose. In fact, DILI caused by 
an overdose of APAP is the main cause of acute liver failure in both the 
UK (Davern et al. 2006) and USA (Larson et al. 2005). The APAP induced 
toxicity is associated with the formation of its reactive metabolite, 
NAPQ.I, which is able to bind to cellular proteins and also elicits cellular 
adaptive response (Zhou et al, 2005 and Copple et al, 2008). Hence, 
NAPQI along with two other molecules, DNCB and BSO have been used 
to investigate the cellular adaptive response to cellular stress. The 
results presented in chapter 2 suggested that NAPQI, DNCB and BSO can 
induced a differential cellular response, by triggering different cellular 
stresses, chemical or oxidative, that can bring about a different response 
from both transcription factors (Nrf2 and NF-kB). Chemical stress from 
NAPQI and DNCB activates Nrf2 but inhibits NF-kB, while oxidative stress 
from GSH depletion mediated by BSO activates both Nrf2 and NF-kB 
simultaneously in the cell based model. These findings are in line with 
what the laboratory here has previously published regarding the 
induction of Nrf2 by NAPQI (Goldring et at. 2004; Copple et al. 2008a) 
and BSO (Copple et al. 2008a), and also the inhibition of NF-kB by NAPQI 
(Blazka et al. 1995) or induction of NF-kB by BSO (D'Alessio et al. 2004; 
Filomeni et al. 2005) shown by others. However, it should be 
emphasised that the Nrf2 and NF-kB mediated cellular stress responses
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observed previously were based on the investigation of individual 
proteins. The observations made in chapter 2 were based on the 
simultaneous response of both Nrf2 and NF-kB towards cellular stress, 
as such co-regulation has not been shown before in the published 
literature.
Based on the difference in response by Nrf2 and NF-kB to 
chemical and oxidative stress, RIMAi modulation of the transcription 
factors was used to mimic activation and inhibition of Nrf2 and NF-kB by 
cellular stress. Using with RNAi modulation and DNCB as a model 
electrophile, the results suggested that there is crosstalk between the 
Nrf2 and NF-kB pathways. From the observations seen in chapter 2, the 
RNAi modulation of p65 attenuates Nrf2 protein expression and the 
induction of GSH by Keapl RNAi modulation suggests a possible 
crosstalk mechanism between the Nrf2 and NF-kB pathways. However, 
the mechanism remains unknown and further investigations are 
required but this is consistent with evidence shown by others that 
crosstalk between Nrf2 and NF-kB may occur. Nrf2 has been shown to 
regulate GCLC indirectly via NF-kB in rat (Yang et al. 2005a; Yang et al. 
2005b). The transcriptional role of Nrf2 can be repressed directly by the 
activity of NF-kB competing for the transcription co-activator CREB 
binding protein (CBP) (Liu et al. 2008). Recently, evidence suggests that 
NF-kB activity can be regulated by the Keapl/Nrf2 pathway and this is 
thought to occur via the direct regulation of IKK(3 by Keapl (Lee et al. 
2009; Kim et al. 2010a). This evidence further suggests that the presence 
of co-regulation between Nrf2 and NF-kB exists. Furthermore, the 
Keapl/Nrf2 and NF-kB pathways have been shown to be involved in 
crosstalk with other transcription factors and proteins. Evidence has 
shown that both pathways are involved in crosstalk with the p53
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pathway. The NF-kB pathway has been shown to negatively regulate p53 
by either controlling the expression of the p53 inhibitory E3 ubiquitin 
ligase Mdm2 (Tergaonkar et al. 2002), or competing for the binding of 
CBP with p53 by phosphorylated p65 in stimulated cells (Huang et al. 
2007). The Keapl/IMrf2 pathway has been shown to be positively 
regulated by the cyclin-dependent kinase (CDK) inhibitor p21, a p53 
dependent protein, via the binding of p21 to Keapl which results in the 
accumulation of Nrf2 during cellular stress (Chen et al. 2009). In 
addition, Keapl/Nrf2 and NF-kB pathways have been reported to 
interact with sequestosome l/p62 protein. In recent reports, it has been 
observed that p62 regulates the Keapl/Nrf2 pathway by directly binding 
to Keapl (Lau et al. 2010), this direct interaction has been postulated to 
target Keapl for degradation via autophagy which can inhibit the 
ubiquitination and degradation of Nrf2 by Keapl during Nrf2 activation 
(Copple et al. 2010b). Crosstalk interaction between p62 and NF-kB 
pathway has also been observed, whereby p62 has been suggested to 
serve as a scaffolding protein to facilitate the activation of NF-kB 
pathway. This is through the ubiquitination of tumor necrosis factor 
receptor-associated factor 6 (TRAF6) which leads to the phosphorylation 
of IKK(3 and initiation of NF-kB activating pathway (Wooten et al. 2005; 
Nakamura et al. 2010). Therefore, these crosstalk interactions amongst 
transcription factors and proteins may suggest the complexity of cell 
defence and survival response during cellular stress, and are 
schematically represented in figure 6.1. This demonstrates the 
complexity of how a cell initiates its defence response against the 
progression and onset of cellular damaged. Nevertheless, in order to 
improve the understanding of the role of Nrf2 and NF-kB in cellular 
stress, further work is required to fully elucidate these crosstalk 
mechanisms.
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Fig 6.1: Schematic overview of crosstalk interactions between 
Keapl/Nrf2 and NF-kB pathways, and their interactions with p53 and 
other proteins, (a) Keapl negatively regulate NF-kB pathway via 
promoting IKK3 ubiquitination and proteosomal or autophagic 
degradations (Lee et al. 2009; Kim et al. 2010a). (b) NF-kB represses Nrf2 
transcriptional role by competing for CBP (Liu et al. 2008). (c) NF-kB can 
negatively regulate p53 by competing for CBP (Huang et al. 2007) or 
increasing p53 inhibitory protein Mdm2 (Tergaonkar et al. 2002). (d) p53 
can positively regulate Keapl/Nrf2 pathway by the direct binding of p21, 
p53 dependent protein, to Keapl (Chen et al. 2009). (e) p62 interacts 
with Keapl/Nrf2 and NF-kB pathways by regulating Keapl degradation 
via autophagy (Copple et al. 2010b) and facilitating the activation of NF- 
kB pathway (Wooten etal. 2005; Nakamura et ai 2010), respectively.
6.3 THE ROLE OF KEAP1 CYSTEINE MODIFICATION IN THE MECHANISM 
OF NRF2 ACTIVATION
The mechanism behind the role of Keapl in sensing cellular 
stress and allowing Nrf2 nuclear accumulation remains unclear. 
However, mutagenesis studies from cultured cells overexpressing
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mutant Keapl and transgenic mouse models have identified three 
critical cysteines (CyslBl, Cys273 and Cys288) that play an important 
role in the ability of Keapl to repress Nrf2. These three critical cysteines, 
which serve as key sensors, are originally suggested from previous 
reports highlighting four highly sensitive cysteines (Cys257, Cys273, 
Cys288 and Cys297) found within the IVR domain (Dinkova-Kostova etal. 
2002). Therefore, the consequence of the modification of these critical 
cysteines has been postulated to result in the conformational change of 
Keapl, which will in turn result in the abrogation of Nrf2 ubiquitination 
and degradation. This is supported by the observations from circular 
dichroism spectroscopy experiments which show that the covalent 
modification of CyslBl leads to a structural change in Keapl, which 
results in the dissociation of Cul3 ligase from Keapl (Gao et o/. 2007; 
Rachakonda et al. 2008). However, it has yet to be demonstrated 
conclusively that the modification of Keapl can antagonises the 
interaction between Keapl and Nrf2 via the DIG and ETGE motifs.
Despite the focus on the three critical cysteines of Keapl 
(CyslBl, Cys273 and Cys288), a large range of Nrf2 inducing molecules 
still target Keapl cysteines randomly (Fig 4.1). In addition, recent work 
by Hayes and colleagues proposed that endogenous molecules, nitric 
oxide (NO), zinc and alkenals target Keapl cysteines too and these 
molecules modify Keapl cysteines during cellular stress leading to Nrf2 
activation (McMahon et al. 2010). This is attributed to the fact that 
Keapl is a cysteine-rich protein and that the other Keapl cysteine 
residues can also play a role in the Keapl mediation of Nrf2 activation 
and control of cellular defence. Therefore, the molecular mechanisms of 
how Keapl senses cellular stress which can lead to the activation of Nrf2 
is further investigated in this thesis.
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6.3.1 Role of cysteine modification and GSH depletion in Nrf2 
activation
The mechanism of Nrf2 activation by cysteine modification and 
GSH depletion was addressed in chapter 3. The chemical modification of 
Keapl cysteines with or without GSH depletion has been shown to 
induce Nrf2 nuclear accumulation (chapter 3). Alkylating agents such as 
dinitrochlorobenzene (DNCB) and iodoacetamide (IA) can activate Nrf2 
by covalently modifying Keapl cysteine residues and depleting GSH. On 
the other hand, alkylating agents such as 15d-PGJ2 and dexamethasone 
21—mesylate (Dex-mes) that only covalently modify Keapl cysteine 
residues but does not deplete GSH can also activate Nrf2. This is in 
agreement with the hypothesis thst chemical modification of key Keapl 
cysteines can initiate Nrf2 activation (Dinkova-Kostova et al. 2002). 
However, GSH depletion without concomitant chemical modification by 
buthionine sulfoximine (BSO), a known GSH depleting agent, can also 
instigate the nuclear accumulation of Nrf2. The GSH depletion 
mechanism of BSO, which can cause redox perturbation in the cell 
(Hansen et al. 2004; Ito et al. 2006), results in an increase in the 
susceptibility of Keapl cysteines to oxidation. This may then lead to Nrf2 
activation. The oxidation of Keapl was first observed following the 
formation of intermolecular disulphide bonds between Keapl subunits 
after treatment with an Nrf2 inducing agent (Wakabayashi et al. 2004). 
Moreover, others have also observed that Nrf2 activation can be 
initiated by the formation of disulphide bonds between Keapl cysteines 
and by other forms of cysteine oxidations (Fig 1.5), which will now be 
highlighted. Hydrogen peroxide, hypochlorous acid and NO have all been 
shown to oxidise Keapl by the formation of disulphide bonds (Fourquet 
et al. 2010). A similar response is seen by increasing the amount of GSSG 
to GSH ratio (Holland et al. 2008). The cysteines on Keapl have also
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been found to be s-oxidised by a proton pump inhibitor, Lansoprazole 
(Takagi et al. 2009). S-glutathionylation was also observed on Keapl 
cysteine residues in the presence of high GSSG concentrations (Holland 
et al. 2008) and also after treatment with a thiophene compound (Zhang 
et al. 2010). NO and NO donating compounds such as spermine 
NONOate and s-nitrosocysteine have been suggested to induce 
nitrosylation on Keapl cysteines (Buckley et al. 2008; Li et al. 2009). 
Therefore, these observations strongly support the postulation that Nrf2 
activation can occur through Keapl cysteine oxidation. Furthermore, S- 
glutathionylation was also observed on Keapl-V5 proteins after 
treatment with BSO, IA or NEM in chapter 4. To further support this 
postulation, an investigation into the potential of BSO treatment to 
induce cysteine oxidation was carried out by MS analysis in chapter 4. 
Following prior treatment with BSO, the ability of DNCB to alkylate 
cysteine 257 on Keapl was reduced compared to treatment without 
BSO. This suggests that the oxidation of cysteine 257 can inhibit DNCB 
modification. Therefore, the evidence presented in chapters 3 and 4 
supports the mechanism of Nrf2 activation by Keapl cysteine 
modification, either by covalent modification directly with chemicals or 
via oxidation through the indirect mechanism of GSH depletion.
6.3.2 An investigation into the basal thiol status of Keapl
Despite the weight of evidence that supports the role played by 
the sensing of chemical and oxidative stress by Keapl which can lead to 
the activation of Nrf2, little is known about the basal status of the 
cysteines in Keapl within living cells. To date, only the DGR domain of 
mouse and human Keapl has been structurally classified by 
crystallisation (Li et al. 2004; Padmanabhan et al. 2006). In addition, the 
eight cysteine residues in the DGR domain have been observed to be
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basally reduced {Li et al. 2004). Therefore, by establishing the basal thiol 
status of Keapl, a greater understanding of the molecular basis of how 
Keapl cysteines serve as sensor to chemical and oxidative stress can be 
gained. In chapter 4, using a cell-based method, all of the cysteine 
residues in Keapl were found to be potentially available to be alkylated 
or oxidised and a proportion of them are all in a reduced form under 
basal conditions. This observation supports the hypothesis that Keapl 
cysteine modification is a key mechanism for Nrf2 activation in cell 
defence. The modification of a single cysteine can lead to 
conformational changes in the Keapl structure. This therefore disrupts 
the binding between Keapl and Nrf2 and/or Cul3 ligase, resulting 
ultimately in the abrogation of Nrf2 ubquitination. Hence, the presence 
of reduced and available cysteine residues may allow Keapl to serve as 
the universal 'sensor' for chemical and oxidative stress.
Recently, the structure of Keapl was reconstructed by electron 
microscopy (Ogura et al. 2010). The authors suggested that Keapl is a 
forked-stern structure connecting to two linkers made up of the BTB 
domain, which is further connected to the IVR and DGR domains which 
are enclosed in a large globular structure. Based on the reconstructed 
Keapl structure, the following suggestions are made on the role of 
Keapl as a sensor for Nrf2 activation; 1) the modification of the IVR 
cysteines can affect the structural integrity of the DGR domain leading to 
the disruption of Nrf2 DIG binding to the DGR domain (hinge and latch 
model); 2) the modification of the BTB cysteines, especially cysteine 151, 
can disrupt the association of the Cul3 ligase and Keapl (Ogura et al. 
2010). However, there is no concrete evidence that confirms that 
covalent modification of IVR domain can disrupt Nrf2 through the 'hinge 
and latch model', but there is some evidence that suggest the covalent
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modification of cysteine 151 on BIB domain can lead to the 
disassociation of CulB ligase from Keapl (Gao etal. 2007; Rachakonda et 
ai 2008). Moreover, increasing the molar volume of cysteine 151 by 
substituting it for a larger residue can also affect the interaction 
between CulB ligase and Keapl (Eggler et al. 2009). Nevertheless, it is 
the first time that Keapl cysteine residues have been suggested to be 
available and reduced basally. This clearly suggests that all cysteines are 
partially important in sensing cellular stress and implies the importance 
of the role of Keapl in activating cellular protection.
6.4 FUTURE DIRECTIONS
Since the discovery of NF-kB (Sen et al. 1986) and Nrf2 (Moi et al. 
1994), huge advances have been made with regards to the 
understanding of the chemical, biochemical and molecular events that 
regulate the NF-kB and Keapl/Nrf2 pathways. This thesis has sought to 
address the importance of the co-regulation or crosstalk between the 
NF-kB and Keapl/Nrf2 pathways. The availability of both pathways to be 
activated or inhibited by cysteine modification, via chemical stress, can 
lead to a perturbation balance between cell protection and cell death. 
Therefore, the identification of cysteine modifications on NF-kB should 
be considered for future investigations. This is to determine whether or 
not the potential of a chemical to modify cysteine residues within Keapl 
which results in Nrf2 activation can also inhibit NF-kB. As well as key 
cysteines within IKK, the p65 and p50 subunits have been shown to be 
covalently modified; the position of covalent cysteine modifications 
should be identified to verify which part of the NF-kB pathway is being 
inhibited, and this should be done in cells which overexpressed the Nrf2 
and NF-kB pathways to look for dose-response relationships, before
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attempting to examine them at endogenous level with the technology 
allowing this to be done.
Cells are also constantly exposed to redox perturbation under 
physiological conditions and this perturbation can cause GSH depletion, 
which results in the activation of both Nrf2 and NF-kB. Hence, the use of 
GSH modulators should also be considered for future research to 
determine exactly how GSH depletion can induce the activation of both 
Nrf2 and NF-kB. The use of BSO and phorone to deplete GSH and a 
measurement of oxidative stress using chemical probes such as 2'-7'- 
dichlorofluorescene diacetate (DCF-DA) may be performed. This would 
provide an indication as to the level of oxidative stress from GSH 
depletion that is require for the induction of Nrf2 and NF-kB. This in turn 
will further support the notion that oxidative stress without concomitant 
modification can also activate the cellular defence response. 
Antioxidants such as N-acetylcysteine (NAC) and GSH ester can be used 
to replenish the depleted GSH. The use of these agents will determine if 
the presence of NAC or the GSH ester can attenuate the activation of 
Nrf2 and the inhibition of NF-kB in cells undergoing chemical stress. 
Furthermore, the attenuation of the activation of Nrf2 and NF-kB in cells 
undergoing oxidative stress can also be investigated in this system.
Thus, these future investigations will provide a better 
understanding about how chemical or oxidative stresses can lead to the 
activation of cellular protection via Nrf2 or NF-kB activation or cell death 
via NF-kB inhibition. In addition, both the Keapl/Nrf2 and NF-kB 
pathways have been suggested to be in crosstalk with other 
transcription factor, p53 (Tergaonkar et al. 2002; Huang et al. 2007; 
Chen et al. 2009) or p62 protein (Wooten et al. 2005; Copple et al. 
2010b; Lau et al. 2010; Nakamura et al. 2010). Hence, the effect of direct
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chemical cysteine modification or modification via oxidation as a 
consequence of GSH depletion on Nrf2 and NF-kB with regards to their 
interaction with p53 or p62 needs to be further examined. This will 
provide a higher level of understanding of how the cells respond to 
different forms of cellular stresses by the adaptive response from the co­
regulation of different transcription pathways; 1) cellular protection via 
Keapl/Nrf2; and 2) cell survival via NF-kB.
Despite having strong evidence to suggest that the direct 
cysteine modification of Keapl (Dinkova-Kostova et al. 2002; Hong et al. 
2005a; Copple et al. 2008a; Kobayashi et al. 2009) by Nrf2-inducing 
molecules results in the activation of Nrf2, it has yet to be defined how 
GSH depletion, without direct cysteine modification, by BSO and 
diamide, can trigger Nrf2 activation. However, both BSO and diamide 
can alter the GSH:GSSG ratio or the GSH:GSSG redox potential in cells 
(Hansen et al. 2004; Hansen et al. 2009). In fact, the alteration of the 
GSH:GSSG ratio or the redox potential by BSO have been suggested to 
induce Nrf2 nuclear translocation (Hansen et al. 2004). A recent report 
by Holland and colleagues, has shown that by altering the GSH:GSSG 
ratio In vitro, this can induce cysteine oxidation in bacterially-expressed 
recombinant Keapl (Holland et al. 2008). Therefore, the use of BSO and 
particularly diamide, which can increase the intracellular GSSG 
concentration (Hansen et al. 2009), to alter the GSH:GSSG ratio in living 
cells is a worthwhile experiment. This will allow the investigation of 
cysteine oxidation on Keapl in a more physiologically relevant 
environment. The constraint that further hampers the investigation of 
protein oxidation is that oxidation of Keapl cysteine might occur only on 
a small proportion of the total sum of Keapl proteins, which is beyond 
the limit of detection of the current mass spectrometry method (MS)
244
Chapter 6
used within this investigation. This is despite the use of a cell model 
which overexpresses Keapl at relatively high levels. Therefore, future 
investigations should be considered to improve the methods used to 
determine the oxidation status of Keapl cysteines. A more sensitive MS 
analysis system such as the QTRAP™, which is a combination of a triple 
quadrupole scan mode and ion-trap mass spectrometer, can be used. 
The QTRAP triple quadrupole scan modes such as precursor ion and 
constant neutral loss scans which are not available on other types of 
mass spectrometer makes QTRAP more efficient in detecting peptides 
with posttranslational modifications and the QTRAP ion-trap mass 
spectrometer which can trap more fragment ions yielding higher 
sensitivity, may contribute to a lower limit of detection during MS 
scanning (Hager 2004).
The investigations carried out in chapter 4 revealed that the MS- 
based method used was not sensitive enough to detect potential 
oxidation modifications by BSO. However, with regards to DNCB 
treatment, the availability of cysteine 257 to be modified by DNCB is 
hindered by the pre-treatment with BSO. Hence, this suggests that the 
treatment with BSO coupled with DNCB further increased the redox 
perturbation of the cell which may have caused the oxidation of cysteine 
257. In this regard, the investigation of cysteine oxidation by an indirect 
measurement of cysteine modification by NEM should be considered for 
future research. These proposals are based on the observations from 
previous work from within this laboratory which has shown that cysteine 
257 is selectively modified by other dinitrophenyl (DNP) compounds 
such as DNCB (Coppie et al. 2008a), dinitrobromobenzene, 
dinitroiodobenzene and dinitrofluorobenzene (Megherbi Thesis 2010). 
This suggests that Cys257 may be important for the sensing of chemical
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insults from DNP compounds via direct DNP modification or oxidation 
from DNP-induced cellular stress. Therefore, for future research, the use 
of the differential chemical approach developed in section 4.3.4 of 
chapter 4 to identify indirectly which cysteines are oxidised should be 
employed (Fig 6.2). Hence, this method may also facilitate the 
investigation into Keapl cysteines, especially CyslSl, Cys273 and 
Cys288, and the role of oxidation during Nrf2 activation.
With regards to the investigation of cysteine modification within 
Keapl, experiments conducted currently rely on using cell-based models 
that can express proteins from transfected genes at high levels that are 
incorporated with an epitope tag. This methodology is useful for gaining 
a chemical insight into the modification of intracellular Keapl. However, 
the overexpression of the protein and the incorporation of the epitope 
tag do not reflect the expression of endogenous proteins in cells in 
cultured or in vivo. Therefore, the enrichment of endogenous Keapl or 
the overexpression of Keapl without an epitope tag is required in order 
to facilitate the true analysis of cysteines modification in cells. The 
enrichment of endogenous Keapl can be assisted with the use of the 
NEM-click methodologies described in chapter 5. NEM-click can be used 
to target Keapl via cysteine modification and NEM-click modified Keapl 
can be immunoprecipitated by click chemistry. This can allow the 
enrichment of endogenous Keapl to be sufficient for MS analysis. 
Furthermore, Keapl without an epitope tag can be expressed in cells 
and immunoprecipitated using NEM-click. Therefore, Keapl expression 
can be maintained in cells similarly to the endogenous protein. This 
would facilitate a more accurate analysis of the role of Keapl in cellular 
stress and protection. Therefore, for future investigation the use of click 
chemistry described in chapter 5 should be considered.
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Figure 6.2: Schematic overview covering the use of a differential 
chemical approach to identify cysteine oxidation. Following the 
treatment of Keapl which is overexpressed in HEK293T cells with Nrf2 
inducing molecules, modified Keapl is immunoprecipitated by agarose 
V5 beads and treated with NEM. DTT is used to reduce Keapl oxidised 
cysteines to free cysteines and dSNEM is added to modify all the free 
cysteines. Keapl is then tryptically disgested overnight prior to MS 
analysis. The purple circles represent oxidised cysteines induced by Nrf2 
inducing molecules. Blue circles represent cysteines modified by NEM 
which are not oxidised. Red circles represent cysteines modified by 
dSNEM after DTT reduction.
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6.5 CONCLUDING DISCUSSION
The studies presented in this thesis were designed to further 
address our understanding of how redox transcription factors are 
regulated and to elucidate their role in cellular protection against 
chemical-induced damage. In particular, the aims of the investigations 
have been carried out to elucidate the simultaneous regulation of the 
Keapl/Nrf2 and NF-kB pathways in response to chemical or oxidative 
stresses, and to explore how these two forms of stresses can trigger the 
mechanism of Nrf2 activation. The results presented from these 
investigations have demonstrated that Keapl/Nrf2 and NF-kB respond 
differently to these stresses. Chemical stress can activate Keapl/Nrf2 
but inhibit IMF-kB, whereas GSH depletion can activate both pathways. In 
addition, chemical stress involving molecules that can alkylate cysteine 
residues can initiate the Nrf2 activation regardless of GSH depletion. 
Also, oxidative stress from molecules that deplete GSH without 
modifying cysteine residues can also initiate Nrf2 activation. Based on 
these findings, an investigation into the basal status of Keapl thiols was 
undertaken with regards to investigating the role of Keapl cysteine 
residues serving as a site for chemical or oxidative modification in the 
molecular mechanism during the activation of Nrf2 (Dinkova-Kostova et 
ol. 2002; Wakabayashi et al. 2004; Copple et ol. 2008a}. The observation 
that a proportion of the Keapl cysteine residues are all present in the 
thiol reduced state and available for modification under basal conditions 
further supports the hypothesis that Keapl cysteines are perhaps the 
universal sensor for Nrf2 activation. Hence, the better understanding of 
co-regulation of transcription factors involved in cellular defence and 
the molecular mechanisms of activating Nrf2 can further improve on the 
understanding of how cells adapt to cellular environmental stress and 
perturbation, and also determine the baseline or threshold level of
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chemical defence. Moreover, this new knowledge may improve pre- 
ciinical screens for novel therapeutic drugs against diseases such as 
cancer, where resistance to treatments are on the rise.
The roles of the Nrf2 and NF-kB pathways in regulating cellular 
defence and survival may also play an important role not only in DILI but 
also in cancer. In this thesis, my work has shown that exogenous 
molecules can have a differential effect on the regulation of both Nrf2 
and NF-kB pathways. The Keapl/Nrf2 (Lau et al. 2008) and NF-kB (Li et 
al. 2010) pathways have been shown to play an important roles in 
chemoresistance during cancer treatment. Increases in Nrf2 levels, the 
loss of Keapl (Singh et al. 2008; Wang et al. 2008; Zhang et al. 2010) and 
increased levels of NF-kB (Zatelli et al. 2009; Cherfils-Vicini et al. 2010; 
Kong et al. 2010) all confer chemoresistance in cancer cells. Therefore, it 
wilt be important to determine if a chemotherapeutic agent used in the 
treatment of cancer does have a differential effect on both pathways. 
This understanding is important as chemotherapeutic drugs which target 
components of the NF-kB pathway may also activate Nrf2 which could 
ultimately confer the induction of resistance to treatment in cancer 
cells. Hence, future research focussed on the design of safe and effective 
therapeutic agents and anti-cancer therapeutics is dependent on a 
comprehensive understanding of the biochemical and molecular 
mechanisms that result in the simultaneous regulation of transcription 
factors during adaptive response in cellular defence.
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